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In a chemist research, three convictions perch. 
First: the absolute certainty of doing it. 
Second: it is a kind of fight between the man and his own despair. Even not knowing the names 
of those ancient wise masters, we will always follow them right after.  
Third: the columns of his work are the table of elements and much of human empowerment. 
Together with these three certainties, what remains is dark obscurity: brave discoverers plunge 
not knowing how far the ocean borders are going.  
We are definitely some water alchemy and lots of fantasy! 
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defensa y evaluación de la Tesis Doctoral, del Real Decreto 1393/2007, de 29 de Octubre, 
(BOE 30 de Octubre de 2007) por el que se establece la ordenación de las enseñanzas 
universitarias oficiales de la Universidad Complutense de Madrid, y de acuerdo a lo dispuesto 
en sus artículos 4.1 y 4.2, la presente Tesis Doctoral se ha redactado en inglés previo visto 
bueno de los directores, autorización del Departamento así como autorización de la Comisión 
de Doctorado. Conforme a esta normativa se incluye adicionalmente un amplio resumen en 
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 1. General Introduction  
Cancer is the generic term used to describe a group of more than a hundred different 
diseases with one common defining feature: the rapid generation of abnormal cells that grow 
beyond their usual boundaries and can then invade adjoining tissues or, in many cases, migrate 
to other parts of the body. The final outcome is mostly the same in all situations: progressive 
multiple organ dysfunction and death. 
Recent studies conducted by the World Health Organization1 have identified cancer as a 
leading cause of death worldwide. The disease accounted for 7.9 million demises (or around 
13% of all deaths worldwide) in 2008, with estimations to continue rising with a projected 13.1 
million deaths in 2030. 
Cancer is a multistage process. In its most classical view, the transformation of a normal 
cell into a tumour cell starts when a specific damage to its DNA occurs as a consequence of 
mutations in one or many different genes due to the action of external agents, including physical 
carcinogens (such as X rays or ultraviolet and ionizing radiation); chemical carcinogens (such 
as asbestos, components of tobacco smoke; aflatoxin, a food contaminant; or arsenic, a 
drinking water contaminant); and biological carcinogens (such as some viral, bacterial, or 
parasitic infections). 
Important processes such as cell proliferation, growth, differentiation and apoptosis can 
be severely altered by these mutations. When the outcome of such modifications is the start of 
a carcinogenic progression, those genes involved are called proto-oncogenes. Their mutation 
unleashes a rapid and abnormally permanent clonal expansion independent of external 
stimulation (i.e. growth factors, hormones, etc), carrying built-in proliferative advantages that will 
help them prevail over their normal peers. This unnaturally sped up process, together with an 
accumulated genetic instability and the consequent selective pressure from the surroundings 
upon this group of cells, increases the chances for future mutations possibly affecting a second 
group of genes called tumour suppressor genes. These are in charge of controlling the 
progression of the cell cycle whenever a repairable damage to the DNA is found, and also 
responsible for the initiation of the apoptotic signal as far as the damage is reckoned 
irreversible. The loss of function of these genes follows a recessive pattern, meaning it only 
happens after the two alleles are damaged. This is a gradual process during which an individual 
can perfectly live for many years without presenting any symptom, as the amount and efficacy 
of the protein encoded by the healthy allele can entirely suffice for its requirements in the 
specific cell. Complete loss of function of these genes happens via a degenerative process 
known as loss of heterozygosity, an event immediately followed by the appearance of the 
disease phenotype.2 
                                                     
1 http://www.who.int/mediacentre/factsheets/fs297/en/index.html. 
2 (a) Fukasawa, K. Nat. Rev. Cancer 2007, 7, 911-924. (b) Haber, D. A.; Gray, N. S.; Baselga, J. Cell 2011, 145, 19-24. 
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Up to this stage the cellular mass has become a malignant neoplasm growing even more 
but in a less differentiated fashion and out of control. At a certain point, survival signals override 
the cell own apoptotic mechanisms and the tumour is then able to elicit the generation of new 
blood vessels to its periphery (angiogenesis), to help supply for the shortage of nutrients and 
oxygen of its ever-growing cell population. To reach the maximum level of propagation, this 
primary tumour has yet to start a spreading process, but as soon as it kicks off the proteolytic 
digestion of the cell lining or endothelium that deters it from overtaking the blood flow, 
colonization of new tissues (metastasis)3 takes no long. 
Upon mutation, a proto-oncogene (or its product) can become a tumour-inducing agent, 
an oncogene. Among these are found many genes coding for membrane receptors comprised 
in processes like cell division and growth. Therefore, if it were possible to ascertain which of 
these components are entangled in most tumour processes, as well as their activation 
mechanisms, developing new therapeutic strategies would seem straightforward.  
Cell division takes place when certain membrane receptors are activated by their 
endogenous ligands. These can be released by neighbouring cells (paracrine signalling), or by 
the target cell on its own (autocrine signalling). Most receptors implicated in processes like cell 
division and differentiation are tyrosine kinase receptors (TKRs), namely those capable of 
transferring phosphate groups from the donor molecule adenosine triphosphate (ATP), to 
serine, threonine or tyrosine residues on the substrate protein.4 Protein phosphorylation has two 
fundamental goals: (i) to change a temporary conformation of a protein, modifying its enzymatic 
activity, and (ii) to generate recognition sites for other proteins intervening in the same signalling 
pathway. In general, it is assumed that protein phosphorylation controls the transmission and 
amplification of the mitogenic signal. Usually, these two complex processes result in the 
sequential activation of the Ras protein and the mitogen-activated protein kinases (MAPKs) 
pathway.5 These latter are ultimately responsible of activating those genes involved in cell 
division.6 
1.1. Tyrosine kinase receptors (TKRs) 
TKRs are classified into four main families according to their structural similarity. In 
particular, subclass I, absolutely vital in tumour processes, comprises all sorts of epidermal 
growth factor receptors (EGFRs). This group is further divided into four well differentiated 
                                                     
3 (a) McSherry, E. A.; Donatello, S.; Hopkins, A. M.; McDonnell, S. Cell. Mol. Life Sci. 2007, 64, 3201-3218. (b) Brennan, 
K.; Offiah, G.; McSherry, E. A.; Hopkins, A. M. J. Biomed. Biotechnol., Hindawi Publishing Corporation, 
doi:10.1155/2010/460607 2010. (c) Arteaga, C. L.; Baselga, J. Clin. Cancer Res. 2012, 18, 612-618. 
4 (a) Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K.; Walter, P. Molecular Biology of the Cell, Taylor & Francis 
Inc., 5th Ed., 2007. (b) DeVita Jr., V. T.; Lawrence T. S.; Rosenberg, S. A.; DePinho, R. A.; Weinberg, R. A. Cancer: 
Principles and Practice of Oncology, Wolters Kluwer - Lippincott Williams & Wilkins, 9th Ed., 2011. 
5 (a) Sebolt-Leopold, J. S. Oncogene 2000, 19, 6594-6599. (b) Chapman, M. S.; Miner, J. N. Expert Opin. Investig. 
Drugs 2011, 20, 209-220. 
6 (a) Barbacid, M. Ann. Rev. Biochem. 1987, 56, 779-827. (b) Young, A.; Lyons, J.; Miller, A. L.; Phan, V. T.; Alarcón, I. 
R.; McCormick, F. Adv. Cancer Res. 2009, 102, 1-17. 
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members: HER1 (also called EGFR or ErbB1), HER2 (neu or ErbB2), HER3 (ErbB3) and HER4 
(ErbB4).7 All HERs are expressed in many tissue types, though primarily found in epithelial, 
mesenchymal, and neuronal tissues. The four receptors consist of an extracellular domain, 
further composed of four (I-IV) regions or sub-domains, at which the ligand binding occurs, a 
hydrophobic α-helical transmembrane segment, and an intracellular tyrosine kinase domain that 




Figure 1. a. Details on the structural features of the four members of the ErbB family (ErbB1-4). b. 
Schematic analysis of ligand-mediated receptor rearrangement to gain extended conformation necessary 
for receptor dimerization. (Source: See citation 7) 
The intracellular tyrosine kinase domain of these HERs is highly conserved among the 
family excepting HER3 which apparently lacks kinase activity (Figure 1a). On the other hand, 
extracellular domains do not have the same degree of structural conservation, which suggests 
high level of specialization in ligand recognition,9 except for HER2, whose endogenous ligand 
has not yet been identified. This receptor exists in the extended (open) ‘active’ conformation 
state, being constitutively available for dimerization. There are two main reasons for this. The 
                                                     
7 Baselga, J.; Swain, S. M. Nat. Rev. Cancer 2009, 9, 463-475. 
8 (a) Olayioye, M. A.; Neve, R. M.; Lane, H. A.; Hynes, N. E. EMBO J. 2000, 19, 3159-3167. (b) Ferguson, K. M.; 
Berger, M. B.; Mendrola, J. M.; Cho, H. S.; Leahy, D. J.; Lemmon, M. A. Mol. Cell  2003, 11, 507-517. (c) Lurje, G.; 
Lenz, H. J. Oncology 2009, 77, 400-410. 
9 (a) Yarden, Y.; Sliwkowski, M. X. Nat. Rev. Mol. Cell Biol. 2001, 2, 127-137. (b) Burgess, A. W. Growth Factors 2008, 
26, 263-274. 
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first one has do to with the absolute absence of interaction, the so-called ‘tether’, between sub-
domains II and IV; a normal situation in any inactive (not ligand-bound) representative of the 
HER family of receptors. The second reason deals with sub-domains I and III, those involved in 
ligand recognition by HER1, 3, and 4. When a ligand recognizes its receptor, these two sub-
domains are bridged together (Figure 2b) by the ligand. This induces a dramatic conformational 
change that leaves their dimerization arm (located in region II) exposed and ready to interact 
with a second, same or different, receptor (Figure 1b). The extensive and highly complementary 
nature of the I-III interface on HER2 buries much of this receptor’s surface that corresponds to 
the equivalent EGFR ligand binding sites, keeping the receptor extracellular domain in 
continuous ‘autoactivated’ conformation ready to dimerize (Figure 2a).10 This might explain the 
unique ability of HER2 to transform cells (and to cause cancer) when overexpressed. 
 
 
Figure 2. a. Ribbon representation of the human extracellular domain of the HER2 receptor (PDB code 
1n8z). Individual sub-domains are labelled, same as other structures (red for sub-domains I and III, green 
for sub-domains II and IV). The close proximity of domains I and III is notable, as discussed in the text. 
The HER2 dimerization loop is also clearly exposed. b. One-half of the EGFR dimer model is shown for 
comparison. (Source: See citation 9) 
Under physiological conditions, HER activation is mostly controlled by both spatial and 
temporal expression of their endogenous ligands. These are proteins that belong to the 
epidermal growth factors (EGFs) family, which upon binding to their target receptors, cause 
them to stabilize in a conformation that allows dimerization with another vicinal receptor of the 
same (homodimerization) or different class (heterodimerization), and thus setting off the 
                                                     
10 (a) Burgess, A. W.; Cho, H. S.; Eigenbrot, C; Ferguson, K. M.; Garrett, T. P. J.; Leahy, D. J.; Lemmon M. A.; 
Sliwkowski, M. X.; Ward, C. W.; Yokoyama, S. Mol. Cell 2003, 12, 541-552. (b) Lemmon, M. A. Exp. Cell Res. 2009, 
315, 638-648. 
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complete signalling pathway.11 The EGF family of ligands consists of thirteen members sharing 
in many cases structural features which bias them to overlap their action on the same 
receptor.12 They are generally assorted into three main subgroups. The first one comprises the 
actual EGF, transforming growth factor-α (TGF-α), and amphiregulin (AR), all of which show 
exclusive preference for the HER1. The second group contains betacellulin (BTC), heparin-
binding EGF (HB-EGF) and epiregulin (EPR), which show dual specificity, binding both HER1 
and HER4. The third group is composed of neuregulins (NRGs), which further subdivide into 
NRG1 and NRG2 showing dual capacity to bind HER3 and HER4, plus NRG3 and NRG4 which 
only bind HER4. In such a way, each receptor can be activated by more than one ligand, except 
for HER2, which, as previously explained, has been found not to bind any endogenous ligand. 
In spite of this, it is the most appealing receptor in today’s molecular and clinical oncology, as it 
has demonstrated to be the preferred heterodimerization partner within the members of the 
HER family (Figure 3a).13 
 
 
Figure 3. a. Members of the EGF family and their respective receptors. b. Schematic representation of the 
main autophosphorylation sites on HER1-3, as well as their corresponding associated adapter proteins. 
(Source: See citation 13a) 
                                                     
11 Wieduwilt, M. J.; Moasser, M. M. Cell. Mol. Life Sci. 2008, 65, 1566-1584. 
12 (a) Citri, A.; Yarden, Y. Nat. Rev. Mol. Cell Biol. 2006, 7, 505-516. (b) Avraham, R.; Yarden, Y. Nat. Rev. Mol. Cell 
Biol. 2011, 12, 104-117. 
13 (a) Hynes, N. E.; Lane, H. A. Nat. Rev. Cancer 2005, 5, 341-354. (b) Zhang, H.; Berezov, A.; Wang, Q.; Zhang, G.; 
Drebin, J.; Murali, R.; Greene, M. I. J. Clin. Invest. 2007, 117, 2051-2058. (c) Hynes, N. E.; MacDonald, G. Curr. Opin. 
Cell Biol. 2009, 21,177-184. 
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The specific binding of one ligand to its receptor brings about the formation of homo 
and/or heterodimers over the cell surface, which immediately entails the activation of the 
tyrosine kinase portion of them. This results in a series of trans and autophosphorylations of 
many tyrosine residues all along the receptor intracellular domain.14 The phosphorylated 
residues serve as recognition sites for a great variety of adapter proteins (e.g. Shc, Grb7, Grb2, 
Nck, PLCγ, Figure 3b) which once bound initiate a cascade of sequential phosphorylations 
involving the proteins intervening in the transmission of the mitogenic signal, typically those of 
the MAPKs.15 The activation of the MAPKs16,17  takes place mainly through the adapter protein 
Grb2,18 which is capable of recognizing phosphorylated tyrosine residues on HER2 by means of 
its Src homology 2 domain (SH2). Once bound to HER2, it couples with the proline-rich C-
terminus of the Sos protein, via its two SH3 domains (Figure 4). Sos belongs to a broad family 
of molecules generically known as guanine nucleotide exchange factors (GEFs), components of 
intracellular signalling networks. They function as activators of small GTPases like Ras, 
exchanging guanosine diphosphate (GDP) for guanosine triphosphate (GTP). This single step 
promotes the recruitment of downstream-to-Ras signalling molecules to the cell membrane.19 
 
Figure 4. Schematic representation of ligand-mediated Ras-MAPKs activation via Grb2. 
GEF-dependent signalling is antagonized by GTPase activating proteins (GAPs), which 
promote hydrolysis of GTP to GDP on Ras, rendering it inactive. Therefore, the normal activity 
of Ras is controlled by a delicate equilibrium of its GTP- over its GDP-bound state (Figure 5).20  
                                                     
14 (a) Zhang, X.; Gureasko, J.; Shen, K.; Cole, P. A.; Kuriyan, J. Cell 2006, 125, 1137-1149. (b) Bose, R.; Zhang, X. 
Exp. Cell Res. 2009, 315, 649-658. 
15 (a) Mendelsohn, J.; Baselga, J. J. Clin. Oncol. 2003, 21, 2787-2799. (b) Cargnello, M.; Roux, P. P. Microbiol. Mol. 
Biol. Rev. 2011, 75, 50-83. 
16 Kolch, W. Biochem. J. 2000, 351, 289-305. 
17 Sebolt-Leopold, J. S.; Herrera, R. Nat. Rev. Cancer 2004, 4, 937-947. 
18 (a) Gale, N. W.; Kaplan, S.; Lowenstein, E. J.; Schlessinger, J.; Bar-Sagi, D. Nature 1993, 363, 88-92. (b) Tari, A. M.; 
Lopez-Berestein, G. Semin. Oncol. 2001, 28, 142-147. (c) Giubellino, A.; Burke, T. R. Jr.; Bottaro, D. P. Expert Opin. 
Ther. Targets  2008, 12, 1021-1033. 
19 McCormick, F. Nature 1993, 363, 15-16. 
20 (a) Downward, J. Nat. Rev. Cancer 2003, 3, 11-22. (b) Matallanas, D.; Crespo, P. Curr. Opin. Mol. Ther. 2010, 12, 
674-683. 
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Figure 5. The active – inactive Ras state is controlled by a cycle of hydrolyses: Ras-GDP to Ras-GTP 
catalysed by GEFs (Sos) and from Ras-GTP to Ras-GDP catalysed by GAPs. (Source: See citation 20) 
The MAPK signalling cascade consists of a network of messenger proteins, with the Ras 
family as the upstream elements (Figure 6). This is formed by three members: HRas, KRas, and 
NRas, generically called Ras. Once activated, Ras phosphorylates the next downstream 
enzyme Raf, which is actually a family of three serine/threonine kinases: c-Raf1, A-Raf and B-
Raf, generically known as Raf or MAPKKK, a very important crossroad of complex interactions 
with other proteins besides MAPKs themselves. Raf amplifies the signal transmission by 
phosphorylating the third level down kinases MEK1 and MEK2 (MAPK/ERK Kinase), also 
named MAPKK. The signal travels further down to a fourth level with phosphorylation of ERK1 
and ERK2 (extracellular signal regulated kinase), or simply MAPK. Translocation of ERK to the 
nucleus is followed by phosphorylation and activation of a variety of families of transcription 
factors such as: Ets-1, AP-1, c-Myc, NF-кB, or CREB. They promote translation of many genes 
(proto-oncogenes) that code for proteins involved in cell vital processes,21 including cell cycle 
progression, cell growth, inflammation, proliferation, migration, cell repair mechanisms, and 
angiogenesis. Figure 6 shows a summary of the entire signalling pathway mediated by ligand-
induced formation of the HER2-HER3 dimer.  
                                                     
21 Chang, F.; Steelman, L. S.; Lee, J. T.; Shelton, J. G.; Navalonic, P. M.; Blalock, W. L.; Franklin, R. A.; McCubrey, J. 
A. Leukemia 2003, 17, 1263-1293. 
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Figure 6. Schematic representation of ligand-induced HER2-HER3 dimerization and its downstream 
signalling pathway which entails the activation of genes coding for proteins involved in cell vital processes. 
(Source: See citation 7)  
1.2. The HER2 receptor 
All this complex network of events can be blocked by inhibition of HER2 signalling 
pathway. Therefore, the development of such inhibitors may constitute a new alternative 
therapeutic approach to the treatment of cancer,22 mainly those types of tumours characterized 
by HER2 overexpression. Approximately 30% of all known invasive breast cancers overexpress 
this receptor, a situation also shown in other types of neoplasms like ovary,23 lung, pancreas, 
colon, stomach, oesophagus, endometrium, cervix, and salivary glands.24 Tumours presenting 
high levels of HER2 are, in general, extremely invasive over nearby tissues and the lymphatic 
                                                     
22 (a) Schubbert, S.; Shannon, K.; Bollag, G. Nat. Rev. Cancer 2007, 7, 295-308. (b) Lee-Hoeflich, S. T.; Crocker, L.; 
Yao, E.; Pham, T.; Munroe, X.; Hoeflich, K. P.; Sliwkowski, M. X.; Stern, H. M. Cancer Res. 2008, 68, 5878-5887. (c) 
Baselga, J. Ann. Oncol. 2010, 21, Suppl. 7:vii36-40. 
23 Vermeij, J.; Teugels, E.; Bourgain, C.; Xiangming, J.; in 't Veld, P.; Ghislain, V.; Neyns, B.; De Grève, J. BMC Cancer 
2008, 8, 1-9. 
24 (a) Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Science 1987, 235, 177-182. (b) 
Holbro, T.; Hynes, N. E. Annu. Rev. Pharmacol. Toxicol. 2004, 44, 195-217. (c) Higgins, M. J.; Baselga, J. J. Clin. 
Invest. 2011, 121, 3797-3803. 
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system (Figure 7). Its presence is associated with poor disease-free survival and resistance to 
chemotherapeutic drugs, especially in breast cancer where it is used as a tumour marker.25  
 
Figure 7. Overexpression and special structural characteristics of HER2 favour its presence in 
heterodimers with HER1, 3, and 4. Causes for the potent signalling capacity of the dimers are summarized 
in the green square, while its consequences, in the yellow one. (Source: See citation 9a) 
Supported by the current wealth of information on the mechanisms of activation involved 
in the HER family of receptors, some therapeutic approaches have seen light successfully. 
Drugs targeting these receptors, and in particular HER2, have two major sites of action: (i) the 
extracellular and (ii) the intracellular kinase domains of the HER receptors. As implicated in the 
recognition of activating ligands and subsequent dimerization with a partner, the extracellular 
domain of these proteins constitute the first line of treatment and an excellent target accessible 
to monoclonal antibodies (mAbs). One humanized mAb targeting the HER2 has been approved 
for clinical use, and many others are under advanced phase clinical trials. The first mAb to enter 
clinical use was the HER2-targeting mAb trastuzumab (Herceptin®; Roche Registration Ltd.) 
derived from the first ever murine monoclonal antibody, 4D5, which inhibited the growth of 
human tumour xenografts overexpressing the receptor in athymic mice.26 Trastuzumab binds to 
the extracellular juxtamembrane portion of HER2 (sub-domain IV, shown in Figure 8a). By doing 
so, it is not just able of disrupting the further intracellular modifications necessary for the internal 
kinase to become phosphorylated, but actually elicits an immune response (antibody-dependent 
                                                     
25 (a) Nahta, R.; Yu, D.; Hung, M. C.; Hortobagyi, G. N.; Esteva, F. J. Nat. Clin. Pract. Oncol. 2006, 3, 269-280. (b) Di 
Cosimo, S.; Baselga, J. Nat. Rev. Clin. Oncol. 2010, 7, 139-147. 
26 Hudziak, R. M.; Lewis, G. D.; Winget, M.; Fendly, B. M.; Shepard, H. M.; Ullrich, A. Mol. Cell. Biol. 1989, 9, 1165-
1172. 
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cell-mediated cytoxicity, ADCC)27 and prevents cleavage of the HER2 extracellular domain, 
which is an additional mechanism for HER2 activation. It is the current standard of care for the 
treatment of HER2-amplified breast cancer where it causes tumour regression in 11-26% of 
patients with metastatic disease and increases disease-free survival (33-52%) and overall 
survival (34-41%) despite tumour size, nodal or hormone receptor status, and age when used 
with traditional chemotherapy in early stage disease.28  
 
 
Figure 8. Current methodologies used to block signalling through HER2. a. mAb trastuzumab binds 
directly to domain IV of the extracellular region of HER2 suppressing its signalling and inducing ADCC. b. 
mAb pertuzumab binds directly to domain II of the extracellular region of HER2 preventing its dimerization 
with another ErbB receptor. c. The antibody–drug conjugate trastuzumab–DM1. d. HER2-specific binding 
by antibodies with bispecific or trispecific selectivity for cytotoxic effector cells can mark tumour cells that 
overexpress HER2 for immunological destruction. e. Inhibition of the activity of the HER2 tyrosine kinase 
domain with TKIs such as lapatinib. f. Inhibition of HSP90 activity results in ubiquitylation and proteasomal 
degradation of both HER2 and its downstream signalling partners. (Source: See citation 7)  
                                                     
27 Musolino, A.; Naldi, N.; Bortesi, B.; Pezzuolo, D.; Capelletti, M.; Missale, G.; Laccabue, D.; Zerbini, A.; Camisa, R.; 
Bisagni, G.; Neri, T. M.; Ardizzoni, A. J. Clin. Oncol. 2008, 26, 1789–1796. 
28 (a) Hudis, C. A. N. Engl. J. Med. 2007, 357, 39-51. (b) Garnock-Jones, K. P.; Keating, G. M.; Scott, L. J. Drugs 2010, 
70, 215-239. (c) Brufsky, A. Am. J. Clin. Oncol. 2010, 33, 186-195. 
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Since the structural basis for the HERs dimerization have been elucidated, a second 
HER2-targeting mAb, pertuzumab (Genentech/Hoffman-La Roche) has been developed and is 
currently under phase III clinical trials in combination with other mAbs and/or chemotherapeutic 
agents.29 This antibody binds to the dimerization interface (domain II)30 of HER2 extracellular 
region (Figure 8b). Pertuzumab potentially interferes with the formation of HER2 heterodimers 
interrupting MAPK and PI3K-Akt oncogenic pathways. The activation of immune effector 
functions such as ADCC might also contribute to the efficacy of pertuzumab. In combination 
with trastuzumab and no chemotherapy, clinical results show an efficacy of around 50% in 
clinical benefit, and an overall response rate of 24%.31 
A variant to the use of “naked” antibody could be its association with a potent 
chemotherapeutic bullet. In this sense, trastuzumab-DM1 (T-DM1; Genentech/Hoffman-La 
Roche), consisting of the mAb conjugated to the potent anti-microtubule agent DM1, works as 
an excellent vehicle to deliver the drug inside the cell once trastuzumab has recognized and 
bound to HER2 (Figure 8c). Encouraging preclinical and early clinical anti-tumour activity with 
limited toxicity has been observed.32 
One last approach in the field of HER2-targeting mAbs includes the investigation on 
bispecific and trispecific antibodies that contain within their structure, recognition sites for HER2 
extracellular domain and for antigens on the surface of killer mature T cells. This dual capacity 
brings the two cells in close proximity, maximizing the immunological destruction of the tumour 
cell. This is the action mechanism of ertumaxomab (Fresenius Biotech GmbH), as shown in 
Figure 8d.33  
The tyrosine kinase function of the HER members is essential for intracellular signalling 
and cell transformation. As such, inhibition of this enzymatic function provides a rational basis 
for another class of targeted therapies based on the development of tyrosine kinase inhibitors 
(TKIs). The only currently commercialized reversible anti-HER2 TKI is lapatinib 
(Tyverb®/Tykerb®; Glaxo Group Ltd.), a compound based on the quinazoline scaffold which is 
equally active against HER1 and HER2 (Figure 9). It binds to the ATP binding region of the 
                                                     
29 (a) Agus, D. B.; Akita, R. W.; Fox, W. D.; Lewis, G. D.; Higgins, B.; Pisacane, P. I.; Lofgren, J. A.; Tindell, C.; Evans, 
D. P.; Maiese, K.; Scher, H. I.; Sliwkowski, M. X. Cancer Cell 2002, 2, 127-137. (b) Franklin, M. C.; Carey, K. D.; Vajdos, 
F. F.; Leahy, D. J.; de Vos, A. M.; Sliwkowski, M. X. Cancer Cell 2004, 5, 317-328. (c) Baselga, J.; Swain, S. M. Clin. 
Breast Cancer 2010, 10, 489-491. 
30 Spiridon, C. I.; Ghetie, M. A.; Uhr, J.; Marches, R.; Li, J. L.; Shen, G. L.; Vitetta, E. S. Clin. Cancer Res. 2002, 8, 
1720-1730.  
31 Baselga, J.; Gelmon, K. A.; Verma, S.; Wardley, A.; Conte, P.; Miles, D.; Bianchi, G.; Cortes, J.; McNally, V. A.; Ross, 
G. A.; Fumoleau, P.; Gianni, L. J. Clin. Oncol. 2010, 28, 1138-1144. 
32 (a) Lewis Phillips, G. D.; Li, G.; Dugger, D. L.; Crocker, L. M.; Parsons, K. L.; Mai, E; Blättler, W. A.; Lambert, J. M.; 
Chari, R. V.; Lutz, R. J.; Wong, W. L.; Jacobson, F. S.; Koeppen, H.; Schwall, R. H.; Kenkare-Mitra, S. R.; Spencer, S. 
D.; Sliwkowski, M. X. Cancer Res. 2008, 68, 9280-9290. (b) Lorusso, P. M.; Weiss, D.; Guardino, E.; Girish, S.; 
Sliwkowski, M. X. Clin. Cancer Res. 2011, 17, 6437-6447. 
33 (a) Kiewe, P.; Hasmüller, S.; Kahlert, S.; Heinrigs, M.; Rack, B.; Marmé, A.; Korfel, A.; Jäger, M.; Lindhofer, H.; 
Sommer, H.; Thiel, E.; Untch, M. Clin. Cancer Res. 2006, 12, 3085-3091. (b) Jäger, M.; Schoberth, A.; Ruf, P.; Hess, J.; 
Lindhofer, H. Cancer Res. 2009, 69, 4270-4276. 
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kinase domain of these receptors blocking their downstream signalling (Figure 8e).34 Though it 
has been trialled for other types of neoplasias, in a pivotal phase III study, lapatinib increased 
progression-free survival in patients with advanced HER2-positive breast cancer when given in 
combination with the DNA-synthesis inhibitor capecitabine (Xeloda®; Roche Registration Ltd.) 
(Figure 9). In patients who had failed therapy or become resistant to standard anthracyclines 
and taxanes chemotherapy even those including trastuzumab, lapatinib has turned out a 
promising alternative, therefrom it was granted marketing authorization in combination with 
capecitabine for second line treatment of refractory HER2-positive breast cancer. In addition to 
its ability to disrupt phosphorylation of wild-type HER2, this TKI is apparently capable of 
inhibiting the truncated form of HER2 (p95-HER2, whose extracellular domain has been lost), 
which is present in approximately 20% of all human breast cancers and could be held 
accountable for most of the observed resistance to trastuzumab. Lapatinib also induces 
accumulation of inactive HER2 dimers on the cell surface, resulting in increased trastuzumab 
binding and rendering the cell susceptible to its immune-mediated action. All the above has 
made this pair a neat synergistic team in preclinical models, suggesting that these agents could 
be combined in the clinic with impressive results.35 
Among the last generation of irreversible TKIs, those that permanently modify the ATP 
binding region of HER receptors, is neratinib (Pfizer Ltd.) (Figure 9). This drug, slightly similar in 
structure to lapatinib, is highly selective against HER1 and HER2, and in recent phase II trials 
showed responses in 24% patients previously treated with trastuzumab and in 56% of those not 
pretreated.36  
The most recent approach in the therapeutics of HER2-driven cancer is based on 
targeting heat-shock proteins (HSPs). These proteins facilitate the correct conformational 
maturation and folding of a range of signalling proteins like HER2. In particular, HSP90 controls 
the stability of nascent and mature HER2 and various components of the MAPKs. The 
disruption of HSP90 function results in ubiquitylation and proteasomal degradation of both 
HER2 and its downstream signalling partners, thereby abrogating their oncogenic activity 
(Figure 8f). Among a few promising candidates, tanespimycin (Bristol-Myers Squibb Pharma) 
(Figure 9) has shown important activity in combination with trastuzumab during phase II clinical 
trials.37  
                                                     
34 Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, 
E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. Cancer Res. 2004, 64, 6652-6659. 
35 (a) Brandes, A. A.; Franceschi, E.; Tosoni, A.; Degli-Esposti, R. Expert Rev. Anticancer Ther. 2010, 10, 179-184. (b) 
Cameron, D.; Casey, M.; Press, M.; Lindquist, D.; Pienkowski, T.; Romieu, C. G.; Chan, S.; Jagiello-Gruszfeld, A.; 
Kaufman, B.; Crown, J.; Chan, A.; Campone, M.; Viens, P.; Davidson, N.; Gorbounova, V.; Raats, J. I.; Skarlos, D.; 
Newstat, B.; Roychowdhury, D.; Paoletti, P.; Oliva, C.; Rubin, S.; Stein, S.; Geyer, C. E. Breast Cancer Res. Treat. 
2008, 112, 533-543. 
36 Burstein, H. J.; Sun, Y.; Dirix, L. Y.; Jiang, Z.; Paridaens, R.; Tan, A. R.; Awada, A.; Ranade, A.; Jiao, S.; Schwartz, 
G.; Abbas, R.; Powell, C.; Turnbull, K.; Vermette, J.; Zacharchuk, C.; Badwe, R. J. Clin. Oncol. 2010, 28, 1301-1307. 
37 Erlichman, C. Expert Opin. Investig. Drugs 2009,18, 861-868. 










































Tanespimycin (Bristol-Myers Squibb Pharma)  
Figure 9. HER2-targeting chemotherapeutic agents. 
1.3. HER2-Grb2 interaction 
Besides the well understood interaction between HER2 and Grb2, this latter has also 
been found to recognize phosphorylated residues on HER138 and HER439 though with an 
overall different outcome. Mutations in HER1 lead up to its constitutive activation in numerous 
human cancers (including gliomas,40 oesophagus carcinomas,41 lung,42 colorectal43 and breast 
cancers44). This transformation makes them resistant to certain approved mAbs and TKIs. The 
role of HER4 in tumorigenesis is less known and sometimes contradictory. There is, for 
instance, evidence suggesting that HER4 signalling promotes differentiation and growth 
inhibition of breast cancer cells, consistent with a more favourable prognosis for this disease.45  
Taken into account all these considerations, it turns out clear that hindering the 
interaction of Grb2 with HER1 and HER2 can offer a suitable pharmacological approach to the 
                                                     
38 Voldborg, B. R.; Damstrup, L.; Spang-Thomsen, M.; Poulsen, H. S. Ann. Oncol. 1997, 8, 1197-1206. 
39 Schulze, W. X.; Deng, L.; Mann, M. Mol. Syst. Biol. 2005, 1, 1-13. 
40 (a) Moscatello, D. K.; Holgado-Madruga, M.; Godwin, A. K.; Ramirez, G.; Gunn, G.; Zoltick, P. W.; Biegel, J. A.; 
Hayes, R. L.; Wong, A. J. Cancer Res. 1995, 55, 5536-5539. (b) Lo, H. W. Curr. Mol. Pharmacol. 2010, 3, 37-52. 
41 Sunpaweravong, P.; Sunpaweravong, S.; Puttawibul, P.; Mitarnun, W.; Zeng, C.; Barón, A. E.; Franklin, W.; Said, S.; 
Varella-García, M. J. Cancer Res. Clin. Oncol. 2005, 131, 111-119. 
42 (a) Rosell, R.; Morán, T.; Carcereny, E.; Quiroga, V.; Molina, M. A.; Costa, C.; Benlloch, S.; Tarón, M. Clin. Transl. 
Oncol. 2010, 12, 75-80. (b) Burns, T. F.; Rudin, C. M. Oncology (Williston Park) 2010, 24, 48-49. 
43 Saif, M. W. Expert Opin. Investig. Drugs 2010, 19, 357-369. 
44 (a) Corzo, C.; Tusquets, I.; Salido, M.; Corominas, J. M.; Bellet, M.; Suarez, M.; Baró, T.; Fabregat, X.; Serrano, S.; 
Solé, F. Tumour Biol. 2005, 26, 25-30. (b) Guiu, S.; Coudert, B.; Favier, L.; Arnould, L.; Fumoleau, P. Bull. Cancer 2010, 
97, 365-383. 
45 Koutras, A. K.; Fountzilas, G.; Kalogeras, K. T.; Starakis, I.; Iconomou, G.; Kalofonos, H. P. Crit. Rev. Oncol. Hematol. 
2010, 74, 73-78. 
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treatment of many tumour processes characterized by the overexpression and/or kinase 
hyperactivity of these receptors.46 In addition, it could represent an alternative strategy to 
overcome acquired resistance to mAbs or TKIs targeting HER2. The development of 
compounds capable of inhibiting the interaction between the HER2 receptor and its adapter 
protein Grb2 by binding its SH2 domain has received a great deal of attention in the late times.47 
Such molecules will aid to validate the applicability of this therapeutic approach for cancer 
treatment. This goal has been favoured by the elucidation of the tridimensional (3D) structure of 
many SH2 domains found in different proteins, and in particular, the Grb2-SH2 domain.  
1.4. The Grb2-SH2 domain 
The SH2 domain is an adapter module that recognizes peptide sequences containing one 
residue of phosphotyrosine (pTyr). It has been widely studied because of its frequent 
occurrence in a large number of physiologically relevant proteins (Figure 10). Nowadays more 
than 100 SH2 domains, belonging to 110 different proteins coded in the human genome, are 
known.48 
The SH2 domain is made up of approximately 100 amino acids distributed all along a 
central region of β sheets flanked by two α helices. Peptides carrying a pTyr residue bind this 
domain perpendicularly to one of the sides of the β sheets. The most conserved residues are 
found in the pTyr recognizing pocket. Additionally, the invariable presence of an arginine 
residue (Arg 86) imposes the known great affinity for these phosphopeptides.49 
In order to effectively design inhibitors of the SH2-pTyr interaction, it is key to know the 
SH2 domain as well as the SH2 domain-ligand complex X ray structures.  
                                                     
46 Dharmawardana, P. G.; Peruzzi, B.; Giubellino, A.; Burke, T. R. Jr.; Bottaro, D. P. Anticancer Drugs 2006, 17, 13-20. 
47 See citation 18c. 
48 (a) Kasembeli, M. M.; Xu, X.; Tweardy, D. J. Front. Biosci. 2009,14,1010-1022. (b) Pawson, T.; Kofler, M. Curr. Opin. 
Cell. Biol. 2009, 21, 147-153. 
49 Eck, M. J.; Shoelson, S. E.; Harrison, S. C. Nature 1993, 362, 87-91. 
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Figure 10. Representative protein families that contain at least one SH2  domain. The specific 
recognition function of this domain is constant, whereas the overall biological function of the protein may 
vary greatly according to the presence of other effector modules. (Source: Liu, B. A. et al. Mol. Cell 2006, 22, 
851-868.) 
Grb2 is a 25 KDa protein made up of one SH2 domain and two SH3 domains (Figure 
11).50 The SH3 domains specifically bind proline-rich regions on other proteins,51 whereas the 
Grb2-SH2 domain recognizes pTyr-containing peptide sequences (such as Glu-pTyr-Ile-Asn-
Gln).52 The 3D structure of the Grb2-SH2 domain was firstly elucidated in 1996 by means of 
heteronuclear multidimensional NMR, being very similar to other known SH2 domains.53  
                                                     
50 Maignan, S.; Guilloteau, J. P.; Fromage, N.; Arnoux, B.; Becquart, J.; Ducruix, A. Science 1995, 268, 291-293.  
51 See citation 18a. 
52 Rahuel, J.; García-Echeverría, C.; Furet, P.; Strauss, A.; Caravatti, G.; Fretz, H.; Schoepfer, J.; Gay, B. J. Mol. Biol. 
1998, 279, 1013-1022. 
53 Thornton, K. H.; Mueller, W. T.; McConnell, P.; Zhu, G.; Saltiel, A. R.; Thanabal, V. Biochemistry 1996, 35, 11852-
11864. 
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Figure 11. X ray structure of the human Grb2 protein obtained at a resolution of 3.1 Ǻ (PDB code: 1gri). 
Grb2-SH2 is composed of two α helices and eight β strands. According to Eck54 notation, 
the whole structure can be described as a short fragment of a β strand (βA) followed by an α 
helix (αA) to which three antiparallel β strands (βB-βD) are directly connected. These are 
continued into another set of three shorter antiparallel β strands (βD’-βF), which finally coils in 
the second α helix (αB), leaving this latter perfectly opposite to the αA (Figure 12). 
 
 
Figure 12. X ray structure of the SH2 domain of the human Grb2 protein obtained at a resolution of 1.8 Ǻ 
(PDB code: 1zfp). 
                                                     
54 See citation 49. 
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In general, SH2 domains possess two important regions devoted to the substrate 
docking. The first one specifically binds the pTyr residue, while the second one recognizes the 
peptide sequence surrounding the pTyr residue. Actually, pTyr alone does not confer specificity 
to the interaction of these compounds with the protein.55 
The structural elucidation of the Grb2-SH2-ligand complex carried out through X ray 
crystallography56 and NMR57 indicates that the ligand adopts a U shape when bound to Grb2-
SH2; contrary to what has been found in other SH2-containing proteins, in which the peptide 
bearing the pTyr residue lies perfectly extended along the domain. 
1.5. Peptide inhibitors of the Grb2-SH2 domain 
To start off the rational design of inhibitors to the HER2-Grb2 interaction, many peptide 
libraries containing pTyr were assayed in order to determine the minimal amino acid sequence 
necessary to selectively dock onto this domain. These studies have led to determine pTyr-X+1-
Asn-X+3 as the minimal peptide necessary for selective recognition of the SH2 domain, being 
the Asn absolutely required for affinity.58 At the beginning, it was proposed the tetrapeptide 
pTyr-Val-Asn-Val as the minimal sequence capable of binding the SH2 domain of Grb2; but 
soon after, further studies revealed that the former tetrapeptide could be reduced in one amino 
acid to the tripeptide pTyr-X+1-Asn, and still maintained its affinity for the SH2 domain. Its 
docking enabled confirmation of two important binding pockets in Grb2-SH2, as it has been 
observed in other SH2-bearing proteins. The first one, being of polar nature, accommodates the 
phosphate group; whereas the second one, mostly non-polar in nature, hosts the X+2 
hydrophobic residue (Figure 13). 
Once the structure of the SH2 domain was elucidated, and the requirements of ligands 
important for interaction were identified, all synthetic efforts were aimed at optimizing these 
compounds in order to obtain potent inhibitors able to block HER2-Grb2 interaction. 
The most relevant modifications made on the structure of the tripeptide pTyr-X+1-Asn-NH2 
are summarized in the following sections.  
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Figure 13. X ray structure of the SH2 domain of the human Grb2 protein obtained at a resolution of 1.8 Ǻ 
(PDB code: 1zfp) in which the polar (blue) and the non-polar (orange) pockets are highlighted by the side 
chains of the amino acids comprised in them.  
1.5.1. Modifications of the N-terminus (Nt) 
The N-terminus, Nt, is the pTyr residue in the pTyr-Ile-Asn-NH2 sequence. Different 
modifications, like N-alkylation of the pTyr or the formation of another peptide bond on this 
position, have been proposed. Results have shown a direct relationship between the increase in 
the substituent volume and the affinity for the SH2 domain, being the incorporation of an N-(2-
aminobenzoyl)-α-glutamyl (2-Abz-Glu, Figure 14) the modification yielding the best affinity 























Figure 14. Tetrapeptide Abz-Glu-pTyr-Ile-Asn-NH2. 
Subsequent X ray studies of the complex formed by the peptide Abz-Glu-pTyr-Ile-Asn-
Gln-NH2 (IC50 = 26 nM), analogous to the former one, and the Grb2-SH2 domain, have 
confirmed the existence of stabilizing interactions between the pTyr phosphate group and the 
amino substituent of the Abz moiety. These interactions altogether with an extra overlapping 
                                                     
59 Fretz, H.; Furet, P.; García-Echeverría, C.; Schoepfer, J.; Rahuel, J. Curr. Pharm. Des. 2000, 6, 1777-1796. 
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increase between the Abz aromatic ring and the Arg 67 guanidinium group are responsible for 
the high affinities observed.60 
1.5.2. Modifications of the X+1 position 
Variations of the X+1 position were examined on the (3-amino)-Z-pTyr-X+1-Asn-NH2 
tripeptide (Z = bencyloxycarbonyl) studying the influence of different side chains. For instance, 
gem-dimethyl, cyclopropyl, indanyl, sec-butyl, and cyclohexyl substituents were introduced. 
Among them, the derivative (3-amino)-Z-pTyr-Ac6c-Asn-NH2, bearing the non-natural amino 
acid 1-aminocyclohexanecarboxylic acid (Ac6c), showed the highest affinity (IC50 = 1 nM,61 



















Figure 15. Tripeptide (3-amino)-Z-pTyr-X+1-Asn-NH2 (X+1 = 1-aminocyclohexanecarboxylic acid, Ac6c).  
1.5.3. Modifications of the X+2 position 
It has been previously indicated the importance of the amino acid Asn for the specific 
binding to the Grb2-SH2 domain. The X ray structure of the SH2 domain complexed with the 
peptide H-Lys-Pro-Phe-pTyr-Val-Asn-Val-NH2 reveals the presence of two H bonds between the 
side chain of the Asn and the peptide backbone of Lys 109 (located in the βD sheet), and a third 
one with the carbonyl group of Leu 120 of the βE sheet.62 
Using the peptide (3-amino)-Z-pTyr-Ac6c-X+2-NH2 with its optimized Ac6c and 3-amino-Z 
subunits as the trial scaffold, several Asn surrogates (2-pentanone and the (1S,2R) and (1R,2S) 
enantiomers of the cis-2-amino-3-cyclohexenecarboxylic acid, cis-Achec) were tested. Among 
them, the derivative with X+2 = (1S,2R)-Achec (Figure 16) showed almost the same affinity for 
the protein (IC50 = 1.6 nM) as the original Asn-containing peptide (IC50 = 1 nM). The new amino 
acid perfectly mimics the three H bonds formed by the Asn. It is worth pointing out the 
                                                     
60 See citation 52. 
61 García-Echeverría, C.; Furet, P.; Gay, B.; Fretz, H.; Rahuel, J.; Schoepfer, J.; Caravatti, G. J. Med. Chem. 1998, 41, 
1741-1744. 
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significance of the peptide stereochemistry for its effective interaction with the SH2 domain, as 

















Figure 16. Tripeptide (3-amino)-Z-pTyr-Ac6c-X+2-NH2 (X+2 = (1S,2R)-Achec).  
1.5.4. Modifications of the C-terminus (Ct) 
X ray studies64 have demonstrated the existence of a hydrophobic region in Grb2-SH2 
close to the Ct bound phosphopeptide. This region comprises the side chains of the residues 
Lys 109 (βD6), Leu 111 (βD’1) and Phe 119 (βE3). Employing the peptide Ac-pTyr-Ile-Asn-NH-
R (R = H, IC50 = 890 nM) as the trial scaffold, a variety of substituents were attached to the Ct in 
order to increase the interactions in this hydrophobic pocket. The best two compounds 
contained the (naphth-1-yl)propyl and (2-hydroxynaphth-1-yl)propyl groups (Figure 17), which 
improved the affinity of the initial tripeptide in two orders of magnitude (IC50 values of 4765 and 






































Figure 17. Tripeptides Ac-pTyr-Ac6c-Asn-NH-X a. X = (naphth-1-yl)propyl. b. X = (2-hydroxynaphth-1-
yl)propyl. 
                                                     
63 See citation 62a. 
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3442-3449. 
66 See citation 59. 
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1.5.5. Replacement of the pTyr 
Although the X ray data set clear that the presence of a phosphate group is key for 
binding, phosphate-containing inhibitors may have bioavailability and stability problems under 
physiological conditions. Therefore, several phosphotyrosyl mimetics (Table 1)67,68 were tested, 
resulting in some cases in excellent affinities, although none of the variants reached the potency 
of the parent peptide.   
 






















1.5.6. Conformational restrictions 
Given the intrinsic flexibility of the Grb2-SH2 ligands described so far, it was 
hypothesized that affinity could be increased by introducing conformational restrictions in the 
molecule that would decrease the entropic penalization associated to the acquisition of the 
bioactive conformation. Conformational restrictions can be sorted out into two main groups: 
local (on the pTyr residue) or global.69 
1.5.6.1. Local restrictions affecting the pTyr residue 
The incorporation of rigid rings on the pTyr residue in peptides known for their high 
affinity for the Grb2-SH2 domain, like Ac-pTyr-Ac6c-Asn-NH-X [X = (naphth-1-yl)propyl, IC50 = 
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47 nM, Figure 17a], led to a new generation of cyclic systems (Figure 18a,b) with low ability to 

































Figure 18. Local restrictions on the pTyr residue.  
1.5.6.2. Global conformational restrictions 
Global conformational restrictions are those affecting the entire peptide structure. These 
have been accomplished by means of ring-closing disulfide or thioether bridges in a head-to-tail 
fashion. In several examples, pTyr has been replaced by phosphomimetics72 like 
(phosphonomethyl)phenylalanine (Figure 19a),73 resulting in a very good IC50 value (2.4 nM). 
Notwithstanding, substitution of pTyr for Tyr together with a glutamic acid in position X+2 (Figure 
19b), originally introduced to compensate for the lack of the phosphate group interactions with 
the Arg 86, carried along a significant affinity loss (IC50 = 20 μM).74   
Application of metathesis reactions to close the ring75 has brought a new family of 
macrocyclic inhibitors with very good affinity values, although with limited bioavailability 
indicators as main drawback. Among the best derivatives of this family,76 Figure 19c shows the 
most active one with an IC50 value of 2 nM.77 
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71 (a) Liu, D. G.; Wang, X. Z.; Gao, Y.; Li, B.; Yang, D.; Burke, T. R. Jr. Tetrahedron 2002, 58, 10423–10428. (b) Oishi, 
S.; Kang, S. U.; Liu, H.; Zhang, M.; Yang, D.; Deschamps, J. R.; Burke, T. R. Jr. Tetrahedron 2004, 60, 2971-2977. 
72 Song, Y. L.; Peach, M. L.; Roller, P. P.; Qiu, S.; Wang, S.; Long, Y. Q. J. Med. Chem. 2006, 49, 1585-1596. 
73 Song, Y. L.; Roller, P. P.; Long, Y. Q. Bioorg. Med. Chem. Lett. 2004, 14, 3205-3208. 
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Chem. 2005, 48, 764-772. (c) Liu, F.; Worthy, K. M.; Bindu, L. K.; Fisher, R. J.; Burke, T. R. Jr. J. Org. Chem. 2007, 72, 
9635-9642. 
76 (a) Schoepfer, J.; Gay, B.; End, N.; Muller, E.; Scheffel, G.; Caravatti, G.; Furet, P. Bioorg. Med. Chem. Lett. 2001, 11, 
1201-1203. (b) Shi, Z. D.; Liu, H.; Zhang, M.; Worthy, K. M.; Bindu, L.; Yang, D.; Fisher, R. J.; Burke, T. R. Jr. Bioorg. 
Med. Chem. 2005, 13, 4200-4208. (c) Kang, S. U.; Shi, Z. D.; Worthy, K. M.; Bindu, L. K.; Dharmawardana, P. G.; 
Choyke, S. J.; Bottaro, D. P.; Fisher, R. J.; Burke, T. R. Jr. J. Med. Chem. 2005, 48, 3945-3948. (d) Phan, J.; Shi, Z. D.; 
Burke, T. R. Jr.; Waugh, D. S. J. Mol. Biol. 2005, 353, 104-115. 
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Figure 19. Global conformational restrictions: development of oligopeptide macrocycles. 
Finally, a second generation of phosphotyrosine-containing cyclic pentapeptides, all 
reduced versions of the macrocycle of Figure 19b, have been prepared. In these structures, 
unnecessary amino acids have been removed, while the thioether linkage has been maintained 
and a β-turn inducing residue has been intentionally incorporated in order to gain affinity. Out of 
this new series, the derivative carrying 3-aminopiperidine-3-carboxylic acid as the β-turn inducer 
came out the best inhibitor with an IC50 of 0.4 µM (Figure 19d).78 
1.6. Non-peptide inhibitors of the Grb2-SH2 domain 
In spite of the high affinity values exhibited by many of the peptide inhibitors developed 
up to date, their validation as suitable drug-like agents for the treatment of cancer is still lacking 
mainly due to bioavailability drawbacks. In this context, there is need for a transition into new 
small non-peptide structures of lower molecular weight. 
In the very first instance, the aim was to suppress the greatest possible number of 
peptide bonds within the molecule, while keeping with pTyr as the only amino acid and 
mimicking the rest of the original tripeptide employing non-amino acid structures. Compounds 
                                                     
78 Jian, S.; Liao, C.; Bindu, L.; Yin, B.; Worthy, K. W.; Fisher, R. J.; Burke, T. R. Jr.; Nicklaus, M. C.; Roller, P. P. Bioorg. 
Med. Chem. Lett. 2009, 19, 2693-2698. 
26                                                                                                                                     General Introduction 
which incorporate a (3-aminomethylphenyl)urea were found to suit this requirement (Figure 20). 
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Figure 20. Small-molecule Grb2 ligands containing pTyr. 
With regard to non-peptide compounds in which the pTyr residue is completely removed, 
there are just a few examples in the current literature. The only known structures came out of 
high-throughput screening (HTS) assays fed with huge libraries of exceptionally diverse entities. 
Among the most interesting outcomes are the molecules depicted in Figure 21, with IC50 values 























Figure 21. Grb2-SH2 non-peptide ligands devoid of pTyr in their structure. 
In view of these facts, rational design of small molecules capable of efficiently interrupting 
HER2 downstream signalling by blocking its interaction with the adapter protein Grb2 seems a 
promising approach to definitely validate this protein as a target of interest in oncology. 
However, most ligands of the SH2 domain of Grb2 (Grb2-SH2) that inhibit the HER2-
Grb2 interaction described so far are of peptide nature and show important bioavailability 
limitations that preclude their development as drugs. In this regard, and in terms of finding non-
peptide molecules as Grb2-SH2 ligands, very little progress has been reported. Therefore, the 
development of small molecules capable of disrupting binding between HER2 and Grb2 might 
bolster research in this field. These assumptions have led us to start a project aimed at 
                                                     
79 Schoepfer, J.; Gay, B.; Caravatti, G.; García-Echeverría, C.; Fretz, H.; Rahuel, J.; Furet, P. Bioorg. Med. Chem. Lett. 
1998, 8, 2865-2870. 
80 (a) Nam, J. Y.; Kim, H. K.; Kwon, J. Y.; Han, M. Y.; Son, K. H.; Lee, U. C.; Choi, J. D.; Kwon, B. M. J. Nat. Prod. 2000, 
63, 1303-1305. (b) Harris, G. D.; Nguyen, A.; App, H.; Hirth, P.; McMahon, G.; Tang, C. Org. Lett. 1999, 1, 431-433. (c) 
Caravatti, G.; Rahuel, J.; Gay, B.; Furet, P. Bioorg. Med. Chem. Lett. 1999, 9, 1973-1978. 
General Introduction                                                                                                                        27 
developing small-molecule inhibitors that bind Grb2-SH2 and so block its signalling pathway. 
Such molecules could overcome the limitations of the above mentioned peptides and thus be 
useful to validate this therapeutic approach. 
 



























Objectives and Work Plan 
  
 2. Objectives and work plan 
The main goal of this project is to develop non-peptide small molecules capable of 
selectively binding the Grb2-SH2 domain. This overall objective will be addressed through the 
following steps:  
1. Computer-assisted design of compounds based on the crystal structure of the Grb2-SH2 






























2. Synthesis and determination of the capacity of all compounds to bind the Grb2-SH2 domain. 
3. Optimization process. 
4. Validation of the biological potential of the optimized compound(s). 
 



























 Results and Discussion  
  
 3. Results and Discussion  
3.1. Design of Grb2-SH2 ligands 
In search of Grb2-SH2 ligands with a structural novel core, we first identified the residues 
involved in key interactions with the protein from the crystal structure of the Grb2-SH2 domain in 
complex with the high-affinity 2-Abz-Glu-pTyr-Ile-Asn-Gln-NH2 pentapeptide.81 This structure 
reveals the pivotal roles of two protein sites in the interaction with the inhibitor. The first site is a 
highly conserved hydrophilic pocket among SH2 domains, which is responsible for pTyr binding 
and is defined by a cluster of serine residues, Ser88 (βB7), Ser90 (βC2) and Ser96 (βC3) (the 
positions in parentheses indicate the topology of the Grb2–SH2 domain, following the 
commonly used notation of Eck and collaborators82), and the positively charged amino acids 
Arg67 (αA2) and Arg86 (αB5) (Figure 22). Residue Arg67 (αA2) is especially important since it 
is involved in the interactions with the N-terminal domain of the peptide and forms a hydrogen 
bond with the backbone carbonyl group of the pY-1 amino acid (NH2R67···O=CpY-1). The second 
site includes the backbone atoms of the amino acids His107 (βD4), Lys109 (βD6), Leu120 
(βE4), and the side chain of Trp121 (EF1). The backbone carbonyl group of His107 (βD4) 
interacts with the backbone N–H group of the pY+1 amino acid (C=OH107···H–NpY+1) of the 
inhibitor, while both the backbone N–H (N–HK109···O=CpY+2) and carbonyl (C=OK109···H2NpY+2) 
groups of Lys109 (βD6) form hydrogen bonds with the side chain of Asn at the position pY+2 
(Figure 22).83 In addition, the NH2 group of this Asn side chain forms a hydrogen bond with the 
backbone carbonyl group of Leu120 (βE4) (C=OL120···H2NpY+2, Figure 22).  
                                                     
81 See citation 52. 
82 See citation 49. 
83 See citations 52 and 57. 
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 a        b 
           
Figure 22. a. Representative structures obtained in the MD simulations of Grb2-SH2 in complex with the 
2-Abz-Glu-pTyr-Ile-Asn-Gln-NH2 pentapeptide (PDB code:1zfp). a. Entire SH2 domain shown b. Zoom-in 
detail of interacting amino acids.  
According to these observations, we have designed two series of compounds with novel 
structural cores (Figure 23) that maintain all (series I) or some (series II) of the key interactions 
with the Grb2-SH2 domain. These compounds should shed light on the identification of the 
minimal key interactions needed for binding the Grb2-SH2 domain.84 This work was carried out 
in collaboration with Prof. Leonardo Pardo group at Laboratori de Medicina Computacional, 
Unitat de Bioestadistica, Universitat Autonoma de Barcelona. 
In series I, interactions with the hydrophilic pocket (responsible for the pTyr binding) and 
residues Arg67, His107, and Lys109 are kept. The W substituent mimics the backbone carbonyl 
group of the amino acid in position pY-1 that interacts with Arg67 (αA2) resembling the 
NH2R67···O=CpY-1 hydrogen bond with the pentapeptide 2-Abz-Glu-pTyr-Ile-Asn-Gln-NH2; the 
pTyr is linked to the spacer by an amide group, which preserves the hydrogen bond with the 
backbone carbonyl group of His107 (βD4) observed for the N–H group of the pY+1 residue 
(C=OH107···H–NpY+1). The terminal group is designed to contact both the backbone carbonyl and 
the N–H groups of Lys109 (βD6), mimicking the role of Asn in position pY+2 (N–HK109···O=CpY+2 
and C=OK109···H2NpY+2); and spacers of two and three methylene units were chosen to provide 
enough distance and flexibility to enable concerted interactions with the two binding sites of the 
protein domain (Figure 23). 
 
                                                     
84 Orcajo-Rincón, Á. L.; Ortega-Gutiérrez, S.; Serrano, P.; Torrecillas, I. R.; Wüthrich, K.; Campillo, M.; Pardo, L.; Viso, 
















































































































Figure 23. Design of general structures I. 
The interactions of one of the designed compounds ((S)-1k) relative to the 2-Abz-Glu-
pTyr-Ile-Asn-Gln-NH2 pentapeptide were evaluated by comparing MD simulations for the two 
complexes performed with the Molecular Mechanics - Generalized Born Surface Area (MM-
GBSA) methodology85 (Figure 24). In both cases equilibration was achieved during the first 5 ns 
of simulation, as monitored by the all-atoms root-mean square deviation (rmsd) and from key 
interatomic ionic and hydrogen bond distances between Grb2-SH2 and either 2-Abz-Glu-pTyr-
Ile-Asn-Gln-NH2 or (S)-1k as a function of time. It is worth mentioning that for (S)-1k the key 
interactions with Arg67 (αA2), His107 (βD4), and Lys109 (βD6) were maintained during the full 
simulation time, similar to what was observed for 2-Abz-Glu-pTyr-Ile-Asn-Gln-NH2 (Figure 22). 
  
                                                     
85 Kollman, P. A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W.; Donini, 
O.; Cieplak, P.; Srinivasan, J.; Case, D. A.; Cheatham, T. E. Acc. Chem. Res. 2000, 33, 889-897. 
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a        b 
           
Figure 24. a. Representative structures obtained in the MD simulations of Grb2-SH2 in complex with one 
of the designed compounds of series I ((S)-1k). a. Entire SH2 domain shown. b. Zoom-in detail of 
interacting amino acids.  
With respect to series II, it was designed without any amino acid in its structure and a 
reduced number of interactions with Grb2-SH2. The interactions with Arg67 (NH2R67···O=CpY-1) 
and His107 (C=OH107···H–NpY+1) were eliminated. Compounds of series II contain an acidic 
phosphate group attached to a phenyl ring mimicking the pTyr residue of the pentapeptide, and 
an amide bond designed to interact with the backbone N–H group of Lys109 resembling the N-
HK109···O=CpY+2 interaction. The spacer between the phenylphosphate and amide groups is 
formed by an alkoxymethylene chain with the appropriate distance and flexibility so that the 
terminal group can fit into a hydrophobic pocket observed in the crystal structure. The aliphatic 


















































































Figure 25. Design of general structures II. 
Figure 26 shows the docking structures for two compounds of series II (2f and 3a, 
respectively) in complex with the Grb2-SH2 domain obtained using the same MD simulations 
technique as for (S)-1k. The images show both compounds maintain the key interaction with 
Lys109 (βD6) and Leu120 (βE4) (only present in compound 2f), but have lost those with Arg67 
(αA2) and His107 (βD4), as such observed in the pentapeptide 2-Abz-Glu-pTyr-Ile-Asn-Gln-NH2 
(Figure 22).  
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a 
           
b 
           
Figure 26. Representative structures obtained in the MD simulations of Grb2-SH2 in complex with 
compounds 3a (panel a) and 2f (panel b). Both images show the entire SH2 domain (left panels) as well 
as their corresponding zoom-in detail (right panels). 
3.2. Synthesis and biological evaluation of compounds of series I and II 
Considering that our objective was to design different structural cores that helped us to 
outline the key interactions at the Grb2-SH2 domain and, optimally, could led to the 
identification of one (or several) initial hit compound(s) for each series, synthesis and biological 
evaluation of the compounds were carried out in parallel and in an iterative manner. 
3.2.1. Series I 
The synthesis of compounds 1a-j was accomplished by phosphorylation of commercial 
N-acetyl- or N-benzoyl-L-tyrosine, or of synthesized N-butyryl-L-tyrosine 4,86 which was followed 
by condensation with the appropriate amine and subsequent deprotection of the phosphate 
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group (Scheme 1). Intermediates 5a-c were prepared by a one-pot procedure, which involved 
the temporary protection of the carboxyl group of N-acyl-L-tyrosine as a silyl ester followed by in 
situ phosphitylation of the tyrosyl hydroxyl group and oxidation of the resultant phosphite 
triester. Derivatives 6a-j were obtained by condensation of 5a-c with the corresponding amine in 
the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) as a coupling reagent 
and 1-hydroxybenzotriazole (HOBt) as an additive to minimize racemization.87 Final removal of 























Reagents: (a) (i) NMM, tBuMe2SiCl, CH3CN, rt; (ii) 1H-tetrazole, iPr2NP(OBn)2, rt; (iii) tBuOOH aq., -20 ºC; (b) EDC, 
HOBt, CH2Cl2, R-NH2, rt; (c) H2/Pd(C)/ethanol, rt.
W = MeCO, PhCO, 
        n-PrCO (4)
5a: W = MeCO
5b: W = n-PrCO
5c: W = PhCO
6a-d: W = MeCO
6e-g: W = n-PrCO










1a-d: W = MeCO
1e-g: W = n-PrCO
1h-j:  W = PhCO












Scheme 1. Synthesis of compounds 1a-j.  
Non-commercial 1-(3-aminopropyl)tetrahydropyrimidin-2(1H)-one (7a) and 1-(2-
aminoethyl)imidazolin-2-one (7b) were obtained by treatment of N-(3-aminopropyl)propane-1,3-
diamine or N-(2-aminoethyl)ethane-1,2-diamine, respectively, with urea (Scheme 2) in a 








7a: n = 2
Δ
n n n n
7b: n = 1  
Scheme 2. Synthesis of amines 7a,b. 
 
                                                     
87 McNamara, J. F.; Lombardo, H.; Pillai, S. K.; Jensen, I.; Albericio, F.; Kates, S. A. J. Pept. Sci. 2000, 6, 512-518. 
88 Hurwitz, M. D.; Auten, J. P. US2613212, 1952. 
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Although the conditions of the condensation to obtain the intermediates 6a-j were chosen 
to avoid racemization of the chiral centre, we determined whether this was indeed the case. The 
extent of racemization associated to this synthetic procedure was estimated by coupling acid 
(S)-5a with (1S)-1-phenylethylamine and determination of the area of the peaks of methyl 
groups in the 1H-NMR spectrum (Figures 27 and 28). The difference in the chemical shifts of 
both methyl groups was confirmed in the spectrum of the 1:1 diastereomeric mixture resulting 
from the coupling of (S)-5a with racemic 1-phenylethylamine (Figure 27). The ratio between the 
two diastereomers [S,S (1.38 ppm) and S,R (1.49 ppm)] was 5:1 (Figure 28). This result 
indicates a 20% of racemization and means that in the cases where the two enantiomers have 
different biological activities, we could be under-estimating the affinity, making it necessary to 




































































Figure 27. Evaluation of the racemization extent associated to the synthesis of derivatives 1a-j. 
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Figure 28. 1H-NMR spectrum of the diasteriomeric mixture resulting from the condensation of acid (S)-5a 
with (1S)-1-phenylethylamine. 
Considering this maximum grade of racemization was not too high for a preliminary 
screening of series I of compounds, their capacity to bind Grb2-SH2 was evaluated by means of 
an enzyme-linked immunosorbent assay (ELISA) procedure using a glutathione S-transferase 
(GST) -Grb2-SH2 conjugate and the phosphopeptide biotin-Ahx-PSpYVNVQN89 as its partner 
ligand. Then, the extent of the Grb2-SH2-phosphopeptide interaction still observable in the 
presence of the compound could be measured by sequentially incubating with a mouse anti-
GST and a horseradish peroxidase (HRP) -conjugated goat anti-mouse antibodies. Finally, 
addition of 3,3′,5,5′-tetramethylbenzidine (TMB), substrate of HRP, yielded a blue-coloured 
solution that becomes yellow after acidification to stop the reaction. Determination of the 
absorbance at 450 nm at different concentrations of the compound under study gave a 
sigmoidal dose-response curve, from which IC50 values were calculated. The results obtained 
for compounds 1a-j are shown in Table 2. 
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(S,S) methyl group 
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Compound W Spacer Terminal G. IC50 (μM)a,b 
1a Me-CO- -(CH2)3- N NH
O
190±25 














1e nPr-CO- -(CH2)3- N NH
O
314±5 








1h Ph-CO- -(CH2)3- N NH
O
Inactivec 









aCompetition binding assays with the recombinant SH2 domain of Grb2 expressed as a GST fusion protein and the 
phosphopeptide biotin-Ahx-PSpYVNVQN were conducted as detailed in the Experimental Section. Dose-response 
relationships were generated by nonlinear regression fits of the competition curves with the software Prism. Data are 
expressed as mean±SEM of at least three independent experiments carried out in duplicate. bFor the compound 1224-
130, kindly donated by Prof. T. R. Burke, which was used as a control of the ELISA test, we obtained comparable IC50 
values to those previously reported.90 cInactive compounds displace less than 10% of the phosphopeptide at the 
maximal concentration used (5 mM).  
 
                                                     
90 Wei, C.-Q.; Li, B.; Guo, R.; Yang, D.; Burke, T. R. Jr. Bioorg. Med. Chem. Lett. 2002, 12, 2781-2784. 
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A structure-affinity relationship (SAR) study of the obtained data for this series of 
compounds enabled us to rationalize the influence of the different parts of the molecules, i.e., 
the terminal group, the spacer and the tyrosine N-acyl group (W substituent). Compound 1a 
exhibits the highest affinity for the Grb2-SH2 domain, with an IC50 value of 190 μM. 
Modifications in 1a, such as replacement of the six-membered ring of the terminal group for a 
five-membered ring, or shortening the spacer to two methylene units resulted, in all cases, in 
complete loss of affinity for the Grb2-SH2 domain (compounds 1b to 1d). In general, 
substitution of the W acetyl group with a longer butyryl chain led to inactive compounds. 
Increase of the volume of the W group by replacement of the acetyl N-terminal tyrosine-capping 
group with the bulkier benzoyl group also led in all cases to inactive compounds (1h to 1j).  
Given the partial racemization implicated in the synthesis of 1a, the most potent 
compound within the series (IC50 = 190 ± 25 μM), we prepared its enantiopure isomers (R)-1k 
and (S)-1k. These were obtained using the 9-fluorenylmethyloxycarbonyl (Fmoc) protecting 
group in order to prevent racemization (Scheme 3). After phosphorylation, Fmoc derivatives 8a 
and 8b were condensed with amine 7a. The acetyl group was introduced after Fmoc removal, 
and amides 10a,b were finally debenzylated to yield the (R)- and (S)-N-acetyl-N’-[3-(2-
oxoperhydropyrimidin-1-yl)propyl]-O-phosphonotyrosinamides, (R)- and (S)-1k (Scheme 3). 













Reagents: (a) (i) NMM, tBuMe2SiCl, CH3CN, rt; (ii) 1H-tetrazole, iPr2NP(OBn)2, rt; (iii) tBuOOH aq., -20 ºC; (b) 
EDC, HOBt, CH2Cl2, 7a, rt; (c) piperidine, CH3CN, 0 ºC; (ii) iPr2NEt, Ac2O, DMF, rt; (d) H2/Pd(C), ethanol, rt.
L or D 8a,b
(b)


















10a,b: R1 = Ac
(d)
R = N NH
O
 
Scheme 3. Synthesis of enantiopure derivatives (R)- and (S)-1k. 
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The ability of (R)-, (S)-, and (R,S)-1k to bind the Grb2-SH2 domain was determined as 
described previously and the results are shown in Table 3. 
 










Compound W Spacer Terminal G. IC50 (μM)a,b 
1a 








a-c See footnote of Table 2 for detailed explanation. 
Among all compounds of series I, (S)-1k showed the highest affinity and was therefore 
selected as an initial hit for future optimization. From these results it stands out clearly the 
importance of the S configuration in the only chiral tyrosine carbon of the molecule for it to bind 
the Grb2-SH2 domain in a significant manner.  
3.2.2. Series II 
The synthesis of compounds 2a-i and 3a-c is outlined in Scheme 4. O-alkylation of 4-
benzyloxyphenol with the adequate ethyl ω-bromoalkanoate in presence of potassium 
carbonate yielded intermediates 11a,b which were subsequently deprotected by catalytic 
hydrogenation. Treatment of esters 12a,b with the corresponding amines in presence of 
trimethylaluminium yielded amides 13a-h and 14a-c, which were phosphorylated in a two-step 
procedure that involved the preparation of the benzylated phosphate precursors 15a-h and 16a-
c followed by their deprotection, to yield designed compounds 2a-i, 3a-c.  
 




Reagents: (a) Br(CH2)nCOOEt, K2CO3, crown ether, acetone, 60 ºC; (b) H2/Pd(C), ethanol, rt; (c) R-NH2, AlMe3, 
toluene, 120 ºC; (d) (i) 1H-tetrazole, iPr2NP(OBn)2, 25 ºC; (ii) tBuOOH aq., -20 ºC.
11a: n = 3, X = Bn
11b: n = 4, X = Bn
12a: n = 3, X = H
12b: n = 4, X = H
R =
13a-h: n = 3






















15a-h: n = 3, X = Bn
16a-c: n = 4, X = Bn
2a-i: n = 3, X = H





2a,3a 2b 2c 2d 2e 2f, 3b 2g 2h, 3c 2i
 
Scheme 4. Synthesis of compounds of series II (2a-i and 3a-c). 





Reagents: (a) NC(CH2)P(O)(OC2H5)2,  6 M K2CO3 aq., rt; (b) H2 /Ni-Ra, ethanol, rt.
17
 
Scheme 5. Synthesis of 3-(1-naphthyl)propylamine (17). 
Unfortunately, none of the synthesized compounds, 2a-i and 3a-c, were able to bind 
Grb2-SH2 domain in a significant manner (IC50 > 1 mM). This result could be due to an 
excessive flexibility of these structures or to the lack of some of the interactions with the key 
residues of Grb2-SH2 (according to the initial design, series II lacked one of the interactions 
with Arg67 and the interaction with His107, Figure 25). 
In order to distinguish between these two possibilities, a rigid analogue (18) was 
designed. Compound 18 contains the common phenylphosphate group and a benzimidazole 
ring separated by a single methylene unit. According to the computational model, it should be 
capable of interacting with both the backbone N–H and/or C=O groups of Lys109 (βD6) 
mimicking the N–HK109···O=CpY+2 and/or the C=OK109···H2NpY+2 interactions of the pentapeptide 
(Figure 29).  
 
                                                     
91 See citation 65. 
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a          b 
          
Figure 29. Representative structure obtained in the MD simulations of Grb2-SH2 in complex with 18. a. 
Entire SH2 domain shown. b. Zoom-in detail of interacting amino acids. 
Compound 18 was prepared by cyclization of commercially available 3-nitrobenzene-1,2-
diamine with (4-hydroxyphenyl)acetic acid. Subsequent phosphorylation of the phenol group 
and simultaneous deprotection of the benzyl groups and reduction of the nitro substituent by 














Reagents: (a) 4-OH-C6H4-CH2COOH, 6 M HCl, Δ; (b) (i) 1H-tetrazole, iPr2NP(OBn)2, 25 ºC; (ii) tBuOOH aq., rt; 
(c) H2/Pd(C), ethanol, rt.
(c) 20: Y = NO2, X = Bn
Y
(a) (b)
18: Y = NH2, X = H
 
Scheme 6. Synthesis of compound 18. 
Derivative 18 resulted inactive in the ELISA test (IC50 > 1 mM), which suggests that 
interactions with Arg67 (αA2) and His107 (βD4), are crucial for binding to Grb2-SH2. Therefore, 
compound (S)-1k, from series I, was selected as the most promising hit for further optimization. 
3.3. Optimization of the hit compound (S)-1k 
Hit optimization was addressed by NMR chemical shift perturbation experiments and 
computational models. 
In order to carry out a rational optimization of (S)-1k, it was necessary to experimentally 
identify the amino acids involved in the binding of the compound to the Grb2-SH2 domain. 
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the design of new compounds with either additional or optimized interactions with the target 
protein.  
The amino acids involved in a protein-ligand interaction can be identified using NMR 
chemical shift perturbation experiments with the N15-labelled protein; these experiments were 
carried out in collaboration with Dr. Pedro Serrano and Prof. Kurt Wüthrich at The Scripps 
Research Institute (La Jolla, California, USA). 
The NMR experiments were performed using the 98-residue Grb2-SH2 construct 
described by Waugh and colleagues, which comprises the polypeptide segment 55–153.92 The 
assignments of the backbone amide resonances were taken from the work by Thanabal and 
colleagues.93 The resonance assignments of Grb2-SH2 in the complex with (S)-1k were 
obtained by analyzing a series of [15N,1H]-Heteronuclear Single Quantum Coherence (HSQC) 
spectra of samples containing 15N-labeled Grb2-SH2 and different ratios of compound (S)-1k 
(5:1→1:5). Figure 30 shows a superposition of two 2D [15N,1H]-HSQC spectra of Grb2-SH2 
acquired in the absence and presence (1:1 molar protein:compound ratio) of (S)-1k, from which 
the residues with large chemical shift changes were identified.  
 
 
Figure 30. 2D [15N,1H]-HSQC spectra of the Grb2-SH2 domain free (blue) and in complex with (S)-1k (red) 
(molar ratio protein:compound 1:1). 
  
                                                     
92 See citation 76d. 
93 See citation 53. 
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To rule out that these shifts arise solely from interactions due to the presence of pTyr, 
which is a common moiety in all the Grb2-SH2 inhibitors reported so far, [15N,1H]- HSQC 
spectrum of the protein in the presence of a two-fold excess of N-acetylphosphotyrosine was 
obtained under identical experimental conditions. It was found that this compound induces 
chemical shifts exclusively in a small number of Grb2 amino acid residues, which are all located 
in the pTyr binding pocket (Figure 31). 
 
 
Figure 31. 2D [15N,1H]-HSQC spectra of the Grb2-SH2 domain free (blue) and in complex with N-
acetylphosphotyrosine (red) (molar ratio protein:compound 1:2). 
A plot of the combined 1H and 15N chemical shifts for each residue, Δδav, versus the 
Grb2-SH2 amino acid sequence shows five regions, I–V, that undergo significant chemical shift 
differences, which are indicative of structural rearrangements upon binding of (S)-1k (Figure 
32). The most strongly affected residue in region I is Arg67 (αA2), which interacts with the N-
terminal carbonyl and phosphate groups of (S)-1k, similarly to previous observations with 
different ligands.94 Sequence regions II and III correspond to a hydrophilic, positively charged 
surface area involved in the stabilization of the phosphate group by means of electrostatic and 
hydrogen bond interactions. The chemical shift differences observed for Arg86 (βB5), Ser88 
(βB7) and Ser96 (βC3) are particularly relevant, since these residues have previously been 
reported to be fundamental for the interaction with pTyr. In regions IV and V, large chemical 
                                                     
94 (a) Vu, C. B. Curr. Med. Chem. 2000, 7, 1081-1100. (b) See citation 57. (c) Ogura, K.; Shiga, T.; Yokochi, M.; 
Yuzawa, S.; Burke, T. R. Jr.; Inagaki, F. J. Biomol. NMR 2008, 42, 197-207. (d) Nioche, P.; Liu, W.-Q.; Broutin, I.; 
Charbonnier, F.; Latreille, M.-T.; Vidal, M.; Roques, B.; Garbay, C.; Ducruix, A. J. Mol. Biol. 2002, 315, 1167-1177. 
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shift differences are seen for His107 (βD4) and Lys109 (βD6), which are engaged in hydrogen 
bond interactions with (S)-1k through their backbone amide groups. The neighboring residues 
Phe108, Val110, Leu111 and Trp121 (EF1) form a lipophilic pocket that stabilizes the protein-
inhibitor complex by van der Waals interactions with the C-terminal segment of (S)-1k. The 
strong effect on Trp121 (EF1, region V) is of special interest, since this residue is responsible 




Figure 32. Plot of the 1H–15N chemical shift changes in the backbone of the Grb2–SH2 domain versus 
amino acid sequence. Δδav is a weighted average of the 1H and 15N chemical shift differences, Δδ = 
{0.5[Δδ (1HN)2 + (0.2Δδ (15N))2]}1/2, determined from comparison of the two [15N,1H]-HSQC spectra that are 
superimposed in Figure 30. 
Overall, these results indicate that the residues with significant chemical shift 
perturbations due to the presence of bound (S)-1k (Figure 33) coincide with those found to form 
a binding pocket in several crystal or solution structures of Grb2-SH2,96 and validate the 
assumptions used to design this new family of HER2-Grb2 interaction blockers.  
 
 
                                                     
95 See citation 76d. 
96 See citation 76d. 
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Figure 33. Ribbon representation of the Grb2-SH2 domain. The side chains of the residues that exhibit 
chemical shift differences (Δδav, as represented in Figure 32) larger than 0.1 ppm are identified. 
Hence, the moderate affinity of (S)-1k (IC50 = 174±22 μM; Table 3) could be due to the 
high degree of conformational freedom associated to the methylene spacer, so that improved 
binding might be achieved by introducing conformational restrictions in this part of the molecule. 
Thus, a new compound, (S)-1l, was designed introducing in the spacer a cyclohexyl ring (see 
Figure 35b for the structure of (S)-1l). MD simulations in an explicit water environment with (S)-
1l, and (S)-1k for comparison, were performed to evaluate the rigidity introduced by the 
cyclohexyl group in terms of the χ1 and χ2 angles (Figure 34).  
 
 
Figure 34. Evolution of dihedral angles χ1 (black line) and χ2 (grey line) in the vicinity of the cyclohexyl ring 
of (S)-1k (a) and the analogous angles in (S)-1l (b) obtained during the MD simulations of the ligands in 
bulk water. Representative structures of (S)-1k and (S)-1l obtained during the simulations in water are 
shown. 
The molecule (S)-1k is highly flexible, adopting different conformations during the 
simulation time, while the cyclohexyl ring of (S)-1l constrains the backbone, thus favoring the β-
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turn conformation required for Grb2 binding and the interactions with Phe108 (βD5) and Trp121 
(EF1) (Figure 35).  
 
a         b 
           
Figure 35. a. Representative structures obtained in the molecular dynamics (MD) simulations of Grb2-SH2 
in complex with (S)-1l. a. Entire SH2 domain shown. b. Zoom-in detail of interacting amino acids. 
The stability of (S)-1l in complex with Grb2-SH2 was also evaluated using the MM-GBSA 
methodology97 and compared with the results obtained previously for the pentapeptide 2-Abz-
Glu-pTyr-Ile-Asn-Gln-NH2 and (S)-1k. The binding free energy decomposition on a per-residue 
basis is shown for the three complexes in Figure 36, where compounds (S)-1k and (S)-1l exhibit 
similar interaction profiles to 2-Abz-Glu-pTyr-Ile-Asn-Gln-NH2, with the exceptions of Ser90 
(βC2) and Leu120 (βE4). The absence of the anthranyl moiety of the peptide in (S)-1k and (S)-
1l seems to facilitate the interaction between Ser90 and pTyr, whereas the terminal groups of 
(S)-1k and (S)-1l cannot interact with the backbone amide of Leu120 (βE4). 
 
 
Figure 36. a. Binding free energy decomposition on a per residue basis for Grb2-SH2 in the complexes 
with 2-Abz-Glu-pTyr-Ile-Asn-Gln-NH2 (blue), (S)-1k (red) and (S)-1l (green) calculated from the MD 
ensembles of structures (1250 structures per simulation collected every 4 ps during the last 5 ns), using 
the MM-GBSA methodology. 
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In order to experimentally evaluate the effect of the introduction of a cyclohexyl group in 














Reagents: (a) (i) NMM, tBuMe2SiCl, CH3CN, rt; (ii) 1H-tetrazole, iPr2NP(OBn)2, rt; (iii) tBuOOH aq., -20 ºC; (b)
DIC, HOBt, THF, 21, rt; (c) (i) piperidine, acetonitrile, 0 ºC; (ii) iPr2NEt, Ac2O, DMF, rt; (d) H2/Pd(C), ethanol, rt.
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Scheme 7. Synthesis of derivative (S)-1l. 
Non-commercial amine 21 was prepared starting from 1-(2-aminoethyl)-N-Boc-
cyclohexylamine and 3-[(benzyloxycarbonyl)amino]propionaldehyde (Scheme 8). They were 
coupled under reductive amination conditions to yield intermediate 22. After removal of its Cbz 
protecting group by catalytic hydrogenation, resulting amine 23 was cyclized in the presence of 
1,1’-carbonyldiimidazole (CDI) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) as base. Boc 
removal of the tetrahydropyrimidinone 24 under acid conditions followed by treatment with base 















Reagents: (a) 4 
A
 Molecular sieves, NaCNBH3, methanol, AcOH, 35 ºC; (b)  H2, Pd(OH)2(C), methanol, rt; (c) CDI, 




























Scheme 8. Synthesis of 1-[2-(1-aminocyclohexyl)ethyl]tetrahydropyrimidin-2(1H)-one (21). 
Results & Discussion                                                                                                                       55 
In the ELISA test, constrained compound (S)-1l showed an affinity for the Grb2-SH2 
domain three-fold higher than the initial hit (S)-1k (IC50 [(S)-1k] = 174 μM, IC50 [(S)-1l] = 56 μM). 
This result indicates that iterative application of NMR and computational models has enabled 
optimization of (S)-1k leading to the identification of compound (S)-1l as a new small molecule 
with affinity for the Grb2-SH2 domain. This compound could represent a new scaffold for the 
development of efficient HER2-Grb2 binding blockers. 
In order to attest its worthiness as a compound for future development, it is critical to start 
to validate its biological potential. This validation involves at least two fundamental aspects: 
a) To determine whether the compound shows an interesting inhibitory profile in terms of 
in vitro cellular assays that can be ascribed to the blockade of the HER2-Grb2 molecular 
pathways. 
b) To study whether the compound actually affects the MAPKs pathway as expected from 
a molecule that blocks the Grb2-associated transduction pathway. 
The following sections provide a detailed description of these two approaches aimed at 
outlining the biological potential of (S)-1l. 
3.4. In vitro profile of (S)-1l 
Compound (S)-1l binds the Grb2-SH2 domain with an IC50 value of 56 μM. However, the 
interest on this scaffold for future structural modifications that eventually allow for optimized 
affinities is directly linked to its activity in cell systems. Therefore, its cytotoxic effect on a HER2-
overexpressing breast cancer line (MCF7-HER2+) has been assessed using a standard 3-(4,5-
dimethyl-1,3-thiazol-2-yl)-2,5-diphenyl-2H-tetrazol-3-ium bromide (MTT) cytotoxicity assay. 
To measure cell viability, inhibitor-treated and non-treated cells were incubated in the 
presence of MTT. Those cells still viable after treatment with (S)-1l were able to metabolize the 
MTT reagent to formazan, a compound of bright purple colour. Determination of the absorbance 
at 450 nm at different concentrations of the compound under study enabled the determination of 
cell viability expressed as percentage of the control. To rule out general toxicity of the 
compound, parallel experiments were performed with N1 fibroblasts, a non-tumour cell line. The 
obtained results (Figure 37) indicate that (S)-1l is selectively cytotoxic towards MCF7-HER2+ vs 
fibroblasts with an EC50 value of 100 μM. 
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Figure 37. a. In vitro cytotoxic activity of (R)-1k, (S)-1k and (S)-1l towards N1 fibroblasts at concentrations 
of 50 μM (white) and 100 μM (light grey), and towards MCF7-HER2+ human breast cancer cells at 
concentrations of 50 μM (dark grey) and 100 μM (black). Results represent averages ± SEM of at least two 
experiments carried out in triplicate.* p < 0.01 vs control. 
These results support that (S)-1l is cytotoxic in tumour cells that overexpress HER2, while 
not significantly affecting the non-tumour fibroblasts. If this effect is due to a direct blockade of 
the HER2-Grb2 interaction, the cytotoxic effect should disappear in tumour cells that do not 
overexpress HER2 (MCF7-HER2- and MDA-231). In line with this, an additional experiment of 
cell cytotoxicity in MCF7-HER2- and MDA-231 breast tumour cells was carried out (Figure 38a).  
The lack of activity of (S)-1l in these cells further supported the fact that this compound is 
actually interfering with the HER2-Grb2 interaction. Final proof of this mechanism was 
addressed by immunoprecipitation. In this experiment MCF7-HER2+ cells were treated with (S)-
1l or vehicle, washed, and lysed. HER2 was immunoprecipitated and both HER2 and Grb2 
immunoblotted using specific antibodies (Figure 38b), and the bands were densitometered.  
 a         b  
 
Figure 38. a. In vitro cytotoxic activity of (S)-1l towards HER2 negative MDA-231 and MCF7-HER2- 
human breast cancer cells at 50 μM (gray) and 100 μM (black). b. Inhibition of the HER2-Grb2 interaction 
by (S)-1l. MCF7-HER2+ cells were treated with (S)-1l or vehicle as in (a), washed, and lysed. HER2 was 
immunoprecipitated, and HER2 and Grb2 were immunoblotted using specific antibodies. 
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Our results showed a 30% decrease of the interaction between HER2 and Grb2 in the 
presence of (S)-1l. Taken together, these results clearly support that the cytotoxic effect of (S)-
1l can be at least partially ascribed to its binding to the Grb2-SH2 domain and the concomitant 
inhibition of the HER2-Grb2 interaction. 
In conclusion, (S)-1l can be considered as a new compound in the development of small-
molecule inhibitors capable of blocking the HER2-Grb2 interaction, currently understood as one 
of the most critical steps downstream the HER2 oncogenic signalling. 
Up to this point, it seemed logical to probe what signal transduction pathways were really 
affected by the (S)-1l-induced HER2-Grb2 blockade. In order to attain this objective, a 
proteomic platform was set up as explained hereunder. 
3.5. Development of a proteomic platform to study the effect of a 
compound in transduction pathways 
This strategy was conceived to generate information in an efficient throughput manner 
about expression and/or activation of downstream proteins being directly affected by the HER2-
Grb2 interaction blockade. 
Mass spectrometry (MS) of proteins is nowadays the best suited methodology for this 
objective. Therefore, we have designed a proteomic platform based on protein enrichment via 
affinity purification (AP) and further analysis by MS. In the last years, the growing development 
of AP-MS proteomic platforms has greatly contributed to advance our current understanding of 
protein interaction networks and their dynamic behaviour as a function of time and cell state. 
Various large-scale efforts have successfully enabled definition of protein interactomes in 
several organisms, including humans.98 Some of the advantages of AP-MS include that 
analyses can be performed under near physiological conditions with no further modifications or 
restrictions on the cell type. It can search for multiple interactions among protein assemblies in 
one single run without perturbing relevant post-translational modifications. Furthermore, it can 
be used to probe dynamic changes in the composition of protein complexes, especially when 
used in combination with quantitative proteomic techniques.99  
AP, also called affinity chromatography, makes use of specific binding interactions 
between molecules. A particular ligand is chemically immobilized or “coupled” to a solid support, 
a resin (e.g. sepharose), so that when a complex mixture is passed through the column, those 
molecules having specific binding affinity to the ligand become bound. In a second step, the 
bound molecule is stripped from the support, resulting in its purification from the original sample. 
In its simplest version, the ligand, also called “the bait”, is a small molecule holding specific 
binding properties for a given protein or set of proteins, “the prey(s)”. In this type of 
                                                     
98 Choudhary, C.; Mann, M. Nat. Rev. Mol. Cell Biol. 2010, 11, 427-439. 
99 (a) Kratchmarova, I.; Blagoev, B.; Haack-Sorensen, M.; Kassem, M.; Mann, M. Science 2005, 308, 1472-1477. (b) 
Xu, X.; Song, Y; Li, Y; Chang, J; Zhang, H; An, L. Protein Expr. Purif. 2010, 72, 149-156. 
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chromatography, the proteins “fished out” with the bait are eluted by a molar excess of the same 
ligand in solution and identified by MS (Figure 39). 
 
 
Figure 39. General scheme of AP-MS strategy. 
In order to collect a reliable deal of information about proteins related to the MAPKs 
pathway, or, more generally, about proteins involved in cell proliferation and/or differentiation, 
three nucleotides extensively implicated in this type of molecular processes where chosen as 
bait molecules: 7-methylguanosine triphosphate (m7GTP), adenosine-5'-triphosphate (ATP), 
and cyclic adenosine monophosphate (cAMP). 
A second optional approach would deal with direct pulldown of Grb2 and its interacting 
partner proteins by means of chemically modifying the most potent inhibitor. This could be done 
by attaching to the inhibitor an alkyl-elongated biotin moiety not supposed to disrupt interactions 
of the former with the Grb2-SH2 domain, and then fixing this chain to streptavidin-sepharose 
beads in order to fish out and identify the bound protein complexes. 
Recent experiments carried out by Bottaro et al., have made use of an open-chain 
biotinylated version of one of their most potent Grb2-SH2 peptide ligand in order to explore its 
selectivity through immobilization on streptavidin-coated beads and subsequent MS analysis. 
They detected Grb2, Sos and other related proteins, thus confirming this technique as a 
powerful tool for identifying target proteins along with their associated partners.100  
Any of these two options could be used to track the overall effect of a Grb2-SH2 ligand 
in the physiology of the downstream signalling proteins.101,102 
The general strategy followed in this work can be outlined into eight main steps (Figure 
40). Firstly, the proteome is pre-cleared by incubation with sepharose beads in order to remove 
non-specific binding proteins randomly adhered (Figure 40a). The supernatant is then incubated 
with the corresponding nucleotide-sepharose beads (the bait) to allow for the specific 
nucleotide-binding proteins (the prey) to attach to the resin. This stage is followed by washes 
                                                     
100 Giubellino, A.; Shi, Z. D.; Jenkins, L. M.; Worthy, K. M.; Bindu, L. K.; Athauda, G.; Peruzzi, B.; Fisher, R. J.;  Appella, 
E.; Burke, T. R.; Bottaro, D. P. J. Med. Chem. 2008, 51, 7459-7468. 
101 Kumar, R.; Gururaj, A. E.; Barnes, C. J. Nat. Rev. Cancer. 2006, 6, 459-471. 
102 (a) McLean, G. W.; Carragher, N. O.; Avizienyte, E.; Evans, J; Brunton, V. G.; Frame, M. C. Nat. Rev. Cancer. 2005, 
5, 505-515. (b) Mitra, S. K.; Mikolon, D.; Molina, J. E.; Hsia, D. A.; Hanson, D. A.; Chi, A.; Lim, S. T.; Bernard-Trifilo, J. 
A.; Ilic, D.; Stupack, D. G.; Cheresh, D. A.; Schlaepfer, D. D. Oncogene 2006, 25, 5969-5984. 
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containing an analogue (the corresponding diphosphate version) of the assayed nucleotide. At 
this point, proteins forming complexes with the actual prey proteins are also expected to be 
captured (Figure 40b). The specific proteins are finally eluted with a molar excess of the 
nucleotide under study (Figure 40c). This mixture is separated by sodium dodecylsulphate-
polyacrylamide gel electrophoresis (SDS-PAGE), followed by staining with coomassie blue and 
band slicing (Figure 40d). Afterwards, in-gel digestion of the extracted proteins is carried out 
using trypsin (Figure 40e). Peptides are separated in a nano-high performance liquid 
chromatography (nano-HPLC) system, eluted, and analyzed by MS. In a routine analysis, two 
MS events are automatically performed: in the first scan, the mass/charge ratio (m/z) of the 
intact peptides is measured. The most abundant peptides are then specifically selected and 
subjected to fragmentation, yielding a tandem MS (MS/MS) spectrum (Figure 40f). Finally, 
database searching powered by the MASCOT algorithm is used to interpret the MS data to yield 
a list of proteins present in the initial sample (Figure 40g). 
 
 
Figure 40. Schematic representation of the nucleotide AP-MS strategy. a. Pre-clearing step. b. Capture of 
target proteins. c. Elution of target protein complexes. d. SDS-PAGE separation of the eluted proteins and 
gel slicing. e. Trypsin digestion. f. Tandem MS analysis. g. MASCOT output. 
The classification of the pulled-down hits has been done using the specialized software 
ProteinCenter© (Proxeon Bioinformatics A/S) according to the guidelines and annotations set 
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Figure 42. Schematic representation of the eukaryotic 5’ cap-dependent mRNA translation and how the 
alterations of its components could contribute to a malignant phenoptype. (Source: See citation 106) 
Although still under revision, several highly compelling data suggest that the increased 
phosphorylation of eIF4E at serine 209 may also be a key factor contributing to cancer 
development and progression.106 Interestingly, sorafenib (Nexavar®; Bayer), an approved TKI 
for the treatment of advanced renal and liver cancers that targets the MAPKs pathway,107 also 
promotes dephosphorylation of p-eIF4E. It is clear that the translation initiation apparatus 
serves as a critical site of integration and amplification of oncogenic signals. This makes eIF4E 
and the rest of eIFs interesting tumour biomarkers, and gives an idea about expected protein 
hits using m7GTP as bait. m7GTP-sepharose beads were used following the general protocol 
(Figure 40). 
A representative SDS-PAGE (Figure 43) shows the selective isolation of m7GTP-binding 
proteins (lane E). MS identification of the proteins in this lane yielded a total of 85 hits and the 
most relevant are compiled in Table 4. 
                                                                                                                                                           
105 Silvera, D.; Formenti, S. C.; Schneider, R. J. Nat. Rev. Cancer 2010, 10, 254-266. 
106 Silva, R. L.; Wendel, H. G. Cell Cycle 2008, 7, 553-555. (b) Graff, J. R.; Konicek, B. W.; Lynch, R. L.; Dumstorf, C. 
A.; Dowless, M. S.; McNulty, A. M.; Parsons, S. H.; Brail, L. H.; Colligan, B. M.; Koop, J. W.; Hurst, B. M.; Deddens, J. 
A.; Neubauer, B. L.; Stancato, L. F.; Carter, H. W.; Douglass, L. E.; Carter, J. H. Cancer Res. 2009, 69, 3866-3873. 
107 Liu, L.; Cao, Y.; Chen, C.; Zhang, X.; McNabola, A.; Wilkie, D.; Wilhelm, S.; Lynch, M.; Carter, C. Cancer Res. 2006, 
66, 11851-11858. 
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Figure 43. Silver stained 4-20% SDS-PAGE of a representative m7GTP-AP experiment showing the 
following lanes: M: marker, FT: flow-through, Wi: sequential washes, and E: elution. 
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Table 4. Most relevant m7GTP-related proteins. 
Acc. No. a Protein Name Gene Code 
P60842 Eukaryotic translation initiation factor 4A-I EIF4A1 
P06730 Eukaryotic translation initiation factor 4E EIF4E 
P68104 Eukaryotic translation elongation factor-1-alpha EEF1A1 
P24534 Eukaryotic translation elongation factor-1-beta EEF1B2 
38522 Eukaryotic translation elongation factor-1-delta EEF1D 
P13639 Eukaryotic translation elongation factor-2 EEF2 
P62249 40S ribosomal protein S16 RPS16 
189306 Nucleolin NCL 
P22626-2 Heterogenous nuclear ribonucleoproteins A2-B1 HNRNPA2-B1 
P16930 Fumarylacetoacetase FAH 
P00326 Alcohol dehydrogenase 1C ADH1C 
157834561 Aldehyde reductase (chain A) AKR1A1 
1065362 GDP-complexed human ADP-ribosylation factor (chain B) ARF1 
1403050 Phosphoenolpyruvate carboxykinase (GTP) PCK2 
P43490 Nicotinamide phosphoribosyltransferase PBEF1 
Q9BYF0 Aldehyde oxidase AOX1 
179987 Chlordecone reductase AKR1C4 
IPI00219953.5 Cytidylate kinase CMPK 
P78417 Glutathione transferase omega-1 GSTO1 
P99024 Tubulin beta-5 chain Tubb5 
P10809 60 kDa heat shock protein HSPD1 
Q16715 Pyruvate kinase PKLR 
P30047 GTP cyclohydrolase 1 feedback regulatory protein GCHFR 
   
a Accession numbers (Acc. No.) listed in this table are those used by the UniProt database (http://www.uniprot.org). 
In order to assess the biological significance of the identified proteins, they were 
classified according to the main molecular functions and their binding preferences using data 
available in the GO catalogue (Figure 44). 
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one or two of its anhydride bonds provides the energy needed for the cellular function. More 
importantly from the cellular signalling point of view, ATP is also used as a substrate by kinases 
that phosphorylate proteins and lipids, as well as by adenylyl cyclase, which uses ATP to 





















Figure 45. Adenosine-5'-triphosphate (ATP). 
Therefore, the use of ATP as a bait molecule should enable the identification of a number 
of kinases and their associated proteins. In this case, the assay was carried out following our 
previously described methodology using ATP-sepharose beads (Figure 40) but in the presence 
of 30 mM MgCl2 during the AP step, since MgCl2 is required to decrease the dissociation 
constant of ATP from its target protein(s).108  
A representative SDS-PAGE (Figure 46) shows the selective isolation of ATP-binding 
proteins (lane E). MS identification of the proteins in this lane yielded a total of 23 hits and the 
most relevant are compiled in Table 5. 
 
 
Figure 46. Silver stained 4-20% SDS-PAGE of a representative ATP-AP experiment showing the following 
lanes: M: marker, FT: flow-through, Wi: sequential washes, and E: elution. 
                                                     
108 Lin, X.; Ayrapetov, M. K.; Sun, G. BMC Biochem. 2005, 6, 1-8. 
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Confirming the significance of the methodology, hits are mostly representative of kinases 
and other proteins involved in metabolic or developmental processes. Though not included in 
the above summary because of their low frequency of identification, very likely related to their 
low real cell concentration, there are several MAPK representatives. 
It is conceivable that another proteome different from human liver used here to set up the 
methodology, would result in an increase in this class of hit proteins. For instance, the analysis 
of tumour cells had probably yielded a higher number of signalling kinases, as the intrinsic 
nature of constantly growing and dividing of such cells imposes. 
3.5.3. AP using cAMP 
cAMP is an important second messenger in the signal transduction of many biological 
processes (Figure 48). It is synthesised from ATP by adenylyl cyclase. One of the most 
important functions of cAMP is the activation of the protein kinase A (PKA) which will lead to 
phosphorylation of its downstream substrates, including other proteins as well as the cAMP 
response element-binding (CREB) transcription factor, which binds to certain DNA sequences 
increasing or decreasing gene transcription. The cAMP/PKA pathway has been reported to 
stimulate cell growth in many cell types while inhibiting it in others.109 Data collected from 
literature about some PKA-related genes indicate an involvement of PKA in neoplastic 
transformation and tumour growth, especially in the onset and maintenance of endocrine 
tumours (hormone-responsive tissues).110 Genes regulated by CREB are in most cases 
implicated in cell proliferation, differentiation and survival. Therefrom, CREB-increased 
expression and phosphorylation can correlate with some types of neoplasias, being the best 
studied the non-small cell lung cancer (NSCLC), where the patient survival is inversely 













Figure 48. Cyclic adenosine monophosphate (cAMP) 
In general, it is assumed that the proliferative features of PKA, besides the already 
mentioned possible deregulation of CREB phosphorylation, are related to its crosstalk with the 
                                                     
109 Dumaz, N.; Marais, R. FEBS J. 2005, 272, 3491-3504 
110 (a) Rosenberg, D.; Groussin, L.; Jullian, E.; Perlemoine, K.; Bertagna, X.; Bertherat, J. Ann. N. Y. Acad. Sci. 2002, 
968, 65-74. (b) Rivas, M.; Santisteban, P. Mol. Cell. Endocrinol. 2003, 213, 31-45. 
111 Seo, H. S.; Liu, D. D.; Bekele, B. N.; Kim, M. K.; Pisters, K.; Lippman, S. M.; Wistuba, I. I.; Koo, J. S. Cancer Res. 
2008, 68, 6065-6073. 
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MAPKs such as B-Raf,112 C-Raf,113 Rap1,114 Rap1GAP,115 or Src.116 Therefore, the use of cAMP 
as a bait would conceivably enable the identification of an important number of signalling 
kinases belonging to the MAPKs family (Figure 49). 
 
 
Figure 49. Crosstalk between the cAMP-PKA and the MAPK pathways. 
cAMP-sepharose beads were used following the general protocol (Figure 40). In Figure 
50 a representative SDS-PAGE shows the selective enrichement of cAMP-interacting proteins 
(lane E). Their MS identification resulted in 21 hits and the most relevant are compiled in Table 
6. 
                                                     
112 (a) Peraldi, P.; Frödin, M.; Barnier, J.V.; Calleja, V.; Scimeca, J. C.; Filloux, C.; Calothy, G.; Van Obberghen, E. 
FEBS Lett. 1995, 357, 290-296. (b) Konig, S.; Guibert, B.; Morice, C.; Vernier, P.; Barnier, J. V. C. R. Acad. Sci. III 
2001, 324, 673-68. 
113 See citation 34. 
114 Lerosey, I.; Pizon, V.; Tavitian, A.; de Gunzburg, J. Biochem. Biophys. Res. Commun. 1991,175, 430-436. 
115 Polakis, P.; Rubinfeld, B.; McCormick, F J. Biol. Chem. 1992, 267, 10780-10785. 
116 Schmitt, J. M. Stork, P. J. Mol. Cell 2002, 9, 85-94. 
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Figure 50. Silver stained 4-20% SDS-PAGE of a representative cAMP-AP experiment showing the 
following lanes: M: marker, FT: flow-through, Wi: sequential washes, and E: elution. 
 
Table 6. Most relevant cAMP-related proteins. 
Acc. No.a Protein Name Gene Code 
P10644 cAMP-dependent protein kinase type I-alpha regulatory subunit 
PRKAR1A 
P13861 cAMP-dependent protein kinase type II-alpha regulatory subunit 
PRKAR2A 
915392 Fatty acid synthase FASN 
P07741 Adenine phosphoribosyltransferase APRT 
1093492 4-aminobutyrate aminotransferase GABA 
Q06278 Aldehyde oxidase AOX1 
3860238 4-hydroxyphenylpyruvate-dioxygenase HPD 
226527 Nucleoside diphosphate kinase NDK 
P26038 Moesin MSN 
178027 Alpha-actin ACTA2 
37492 Alpha-tubulin TUBA1A 
338695 Beta-tubulin TUBB 
a Accession numbers (Acc. No.) listed in this table are those used by the UniProt database (http://www.uniprot.org). 
The graphical assortment according to the indicated GO standards and the binding 
preferences of the identified proteins are represented in Figure 51. 
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 4. Experimental Section 
4.1. Molecular dynamics simulations 
Molecular dynamics (MD) simulations of Grb2-SH2 in complex with the high-affinity 2-
Abz-Glu-pTyr-Ile-Asn-Gln-NH2 pentapeptide (PDB code 1ZFP)117 and with the designed 
compound (S)-1k were performed with the Sander module of AMBER 9.118 To generate an 
electro-neutral system, a chloride ion was added to the system formed by Grb2 and the 
compound (S)-1k. These structures were placed in a rectangular box (~70 Å x 65 Å x 73 Å in 
size) containing ~9200 Monte Carlo-equilibrated TIP3P water molecules. The general Amber 
force field (GAFF)119 was used with the parameters proposed for phosphorylated amino acids120 
and HF/6-31G*-derived RESP atomic charges. The simulations were carried out with a 2-fs 
integration time step during 10 ns at constant pressure, at constant temperature coupled to a 
heat bath, using the particle mesh Ewald method to evaluate electrostatic interactions, and the 
ff03 force field for peptides. Structures were collected every 4 ps during the last 5 ns (1250 
structures per simulation).  These structures were then used to evaluate free energies of 
binding using the MM-GBSA methodology.121 
4.2. Synthetic procedures, analytical and spectral characterization 
Melting points (uncorrected) were determined on a Stuart Scientific electrothermal 
apparatus. Infrared (IR) spectra were measured on a Bruker Tensor 27 instrument equipped 
with a Specac ATR accessory of 5200-650 cm-1 transmission range. Frequencies (ν) are 
expressed in cm-1. NMR spectra were recorded on a Bruker Avance 300-AM (1H, 300 MHz; 13C, 
75 MHz; 19F, 235 MHz) or Bruker 200-AC spectrometer (1H, 200 MHz; 13C, 50 MHz) at the 
UCM’s facility. Chemical shifts (δ) are expressed in parts per million (ppm) relative to internal 
tetramethylsilane used as internal reference; coupling constants (J) are expressed in hertz (Hz). 
The following abbreviations are used to describe peak patterns when appropriate: s (singlet), d 
(doublet), t (triplet), q (quadruplet), qt (quintuplet), sx (sextuplet), sp (septuplet), m (multiplet), 
and br (broad). Mass spectrometry (MS) was carried out on a Bruker LC-Esquire in electrospray 
mode (ESI) at the UCM’s facility. Optical rotations were recorded with a Perkin Elmer 781 
polarimeter. Elemental analyses (C, H, N) were performed on a LECO CHNS-932 apparatus at 
the UCM’s facility and are within 0.5% of the theoretical values, confirming a purity of at least 
                                                     
117 See citation 52. 
118 Case, D. A.; Darden, T. A.; Cheatham III, T. E.; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Merz, K. M.; 
Pearlman, D. A.; Crowley, M.; Walker, R. C.; Zhang, W.; Wang, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Wong, K. F.; 
Paesani, F.; Wu, X.; Brozell, S.; Tsui, V.; Gohlke, H.; Yang, L.; Tan, C.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; 
Mathews, D. H.; Schafmeister, C.; Ross, W. S.; Kollman, P. A. AMBER 9, University of California, San Francisco. 
119 Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. J. Comput. Chem. 2004, 25, 1157-1174. 
120 Homeyer, N.; Horn, A. H.; Lanig, H.; Sticht, H. J. Mol. Model. 2006, 12, 281-289. 
121 See citation 85. 
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95% for all tested compounds. Hydrogenation reactions were carried out in a 3900 Parr 
hydrogenation apparatus. Analytical thin-layer chromatography (TLC) was run on silica gel 
plates (Merck, Kieselgel 60 F-254) with detection by UV light, iodine, 10% phosphomolybdic 
acid solution in ethanol or 10% ninhydrine in ethanol. Flash chromatography was performed on 
glass column using silica gel 60 (Merck, particle size 230-400 mesh). Starting materials, 
reagents, and solvents were purchased as high-grade commercial products from Sigma-Aldrich, 
Fluka, Panreac, SDS, Lancaster, Bachem, Cymit, Novabiochem or Scharlab, and were used 
without further purification unless otherwise noted. Toluene, methylene chloride, and 
tetrahydrofuran were used freshly distilled over P2O5, CaH2, and Na turnings respectively. 
Methanol was used after immediate drying with activated molecular sieves. 
4.2.1. Synthesis of compounds of series I (1a-l) 
4.2.1.1. Synthesis of intermediate amines 7a,b and 21. 
Amines 7a,b were synthesized according to previously described procedures and their 1H 
NMR spectroscopic data coincide with those previously reported.122 
1-(3-Aminopropyl)tetrahydropyrimidin-2(1H)-one (7a). Yield: 41%. Yellowish oil. 
IR (CH2Cl2, cm-1): 3293 (NH), 1639 (C=O), 1522 (NH), 1451 (C–N–H), 1273.  
1H-NMR (CDCl3, δ): 1.67 (qt, J = 6.7 Hz, 2H, CH2), 1.89 (qt, J = 5.9 Hz, 2H, CH2), 2.07 (s, 2H, 
NH2), 2.67 (t, J = 6.6 Hz, 2H, CH2NH2), 3.21-3.30 (m, 4H, CH2N, CH2NH), 3.38 (t, J = 6.8 Hz, 
2H, NCH2), 5.09 (s, 1H, NH). 
13C-NMR (CDCl3, δ): 22.3, 31.0, 38.9, 40.5, 44.4, 45.2 (6 x CH2), 156.6 (CO). 
 
1-(2-Aminoethyl)imidazolin-2-one (7b). Yield: 50%. Yellowish oil. 
IR (CH2Cl2, cm-1): 3294 (NH), 1678 (C=O), 1498 (NH), 1452 (C–N–H), 1273. 
1H-NMR (CDCl3, δ): 1.66 (s, 2H, NH2), 2.78 (t, J = 6.1 Hz, 2H, CH2NH2), 3.18 (t, J = 6.1 Hz, 2H, 
NCH2), 3.39-3.40 (m, 4H, 2 x CH2), 4.58 (s, 1H, NH). 




To a stirred solution of 1-(2-aminoethyl)-N-Boc-cyclohexylamine (1.65 mmol, 1.25 equiv) 
over 4 Ǻ molecular sieves (~4 g) in freshly distilled anhydrous methanol (25 mL) were 
successively added 3-[(benzyloxycarbonyl)amino]propionaldehyde (1.32 mmol, 1 equiv) 
acidified with acetic acid (0.15 mL) and NaCNBH3 (1.98 mmol, 1.5 equiv) under argon 
atmosphere. After being stirred at 35 ºC for 24 h, the mixture was filtered over a celite bed, 
thoroughly washed out with ethyl acetate, concentrated under reduced pressure and purified by 
flash column chromatography to afford the pure protected triamine 22 as a colourless oil.  
                                                     
122 See citation 88. 
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Chromatography: dichloromethane:ethyl acetate:ammonia, 8:1.5:0.5 → 5:4.5:0.5. Yield: 86%.  
IR (CH2Cl2, cm-1): 3402 (NH), 1693 (C=O), 1525 (CAr-CAr), 1256, 1164 (O-CO-N).  
1H-NMR (CDCl3, δ): 1.26-1.57 (m, 18H, 3 x CH3, 4 x CH2, CH2a), 1.92-2.11 (m, 5H, 2 x CH2, 
CH2b), 2.97-3.01 (m, 4H, 2 x CH2NH), 3.31-3.33 (m, 2H, CH2NH), 3.81 (br s, 1H, NH), 4.55 (br s, 
1H, NH), 5.11 (s, 2H, CH2O), 5.59 (br s, 1H, NH), 7.27-7.37 (m, 5H, Ar).  
13C-NMR (CDCl3, δ): 21.6 (2 x CH2), 25.6, 28.2 (2 x CH2), 28.5 (3 x CH3), 35.2 (2 x CH2), 36.9, 
38.8, 44.6, 46.8 (4 x CH2), 53.7 (C), 66.9 (CH2), 80.1 (C), 128.1 (CH Ar), 128.2 (2 x CH Ar), 
128.6 (2 x CH Ar), 136.5 (C Ar), 156.2, 157.4 (2 x CO).  
 
tert-Butyl 1-{2-[(3-aminopropyl)amino]ethyl}cyclohexylcarbamate (23). 
Protected triamine 22 (0.92 mmol, 1 equiv) was dissolved in methanol (~15 mL), 
Pearlman’s catalyst (20% Pd(OH)2 on carbon, 500 mg x mmol) was added, and the suspension 
was hydrogenated with shaking at rt for 48 h under an initial pressure of 45-50 psi. The catalyst 
was filtered through a celite bed and the filtrate concentrated under reduced pressure to obtain 
the amine 23 as a colourless oil, which was set to cyclize immediately with no further 
purification. 
 
Yield: 97%.  
IR (CH2Cl2, cm1): 3377 (NH), 1689 (C=O).  
1H-NMR (CH3OD, δ): 1.29-1.49 (m, 13H, 3 x CH3, 2 x CH2), 1.69-2.04 (m, 10H, 5 x CH2), 2.58-
2.75 (m, 6H, 3 x CH2N).  
13C-NMR (CH3OD, δ): 14.5, 21.5, 21.7 (3 x CH2), 25.9 (2 x CH2), 27.9 (3 x CH3), 29.8, 31.5, 
35.1, 39.5, 44.5 (5 x CH2), 53.7, 78.4 (2 x C), 155.7 (CO).  
 
tert-Butyl 1-[2-(2-oxotetrahydropyrimidin-1(2H)-yl)ethyl]cyclohexylcarbamate (24). 
To a solution of CDI (0.44 mmol, 2 equiv) in THF (10 mL/mmol CDI) under argon 
atmosphere at 70 ºC, a mixture of the previously prepared triamine 23 (0.29 mmol, 1 equiv) and 
DBU (1 equiv) in THF (50 mL/mmol triamine) was added dropwise and stirred for 24 h. 
Afterwards, an identical amount of CDI was added, and the mixture was left to react for 
additional 24 h. The crude was then concentrated under reduced pressure, resuspended in 
ethyl acetate and successively washed with saturated NH4Cl (3 x 40 mL) and brine (2 x 30 mL). 
The organic extract was dried over anhydrous Na2SO4, the solvent evaporated under reduced 
pressure and purified by flash column chromatography to yield the cyclic urea derivative 24 as a 
colourless oil.  
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Chromatography: dichloromethane:ethyl acetate, 1:1 → ethyl acetate:ethanol 9:1. 
Yield: 38%.  
IR (CH2Cl2, cm-1): 3323 (NH), 1707, 1647 (C=O), 1522, 1450 (N-CO-N).  
1H-NMR (CDCl3, δ): 1.36-1.49 (m, 17H, 3 x CH3, 4 x CH2), 1.91-1.93 (m, 6H, 3 x CH2), 3.24-3.34 
(m, 6H, 3 x CH2N), 4.49 (br s, 1H, NH), 5.25 (br s, 1H, NH).  
13C-NMR (CDCl3, δ): 21.9 (2 x CH2), 22.6, 26.1 (2 x CH2), 29.3 (3 x CH3), 30.1 (2 x CH2), 32.3, 




Cyclic Boc-protected amine 24 (0.28 mmol, 1 equiv) was treated with TFA (20 equiv) in 
dichloromethane (30 mL x mmol Boc-amine) and stirred under argon atmosphere for 1.5 h. The 
crude was concentrated under reduced pressure and washed with diethyl ether (6 x 5 mL) to 
yield the amine 21 as its TFA salt.  
 
Yield: 77%. Amorphous solid.  
IR ((CH3)2CO, cm-1): 3326 (NH), 1677 (C=O), 1625, 1536 (N-CO-N).  
19F-NMR ((CD3)2CO, δ): -76 (s, 3F). 
1H-NMR ((CD3)2CO, δ): 1.29-1.97 (m, 14H, 7 x CH2), 3.28 (t, J = 5.2 Hz, 2H, CH2N), 3.39 (t, J = 
5.7 Hz, 2H, CH2N), 3.54 (t, J = 5.9 Hz, 2H, CH2N), 6.34 (br s, 1H, NH), 8.58 (br s, 3H, NH3+).  
13C-NMR ((CD3)2CO, δ): 21.5 (2 x CH2), 22.1, 25.2, 33.2 (3 x CH2), 35.0 (2 x CH2), 40.0, 42.9, 
45.7 (3 x CH2), 55.2 (C), 158.0 (CO). 
 
1-[2-(1-Aminocyclohexyl)ethyl]tetrahydropyrimidin-2(1H)-one (21). 
Free amine 21 was obtained after addition of 2 equiv of K2CO3 (15 mL of a 0.050 M 
K2CO3 solution in water) to its TFA salt 25 (0.19 mmol, 1 equiv) in dichloromethane (15 mL). 
This binary phase was stirred for 12 h at 25 ºC, extracted with dichloromethane (3 x 10 mL), 
dried over Na2SO4, and concentrated under reduced pressure to yield free amine 21 as a 
yellowish oil. 
 
Yield: quantitaitive.  
IR (CH2Cl2, cm-1): 3325 (NH), 1678 (C=O), 1621, 1533 (N-CO-N).  
1H-NMR (CDCl3, δ): 1.39-1.96 (m, 14H, 7 x CH2), 2.39-2.43 (m, 2H, NH2), 3.30 (t, J = 5.7 Hz, 
2H, CH2NH), 3.44 (t, J = 6.0 Hz, 2H, CH2N), 3.65 (m, 2H, CH2N), 5.48 (br s, 1H, NH).  
13C-NMR (CDCl3, δ): 22.1 (2 x CH2), 23.1, 25.8 (2 x CH2), 30.1 (2 x CH2), 37.0, 40.6, 43.1, 45.9 
(4 x CH2), 55.9 (C), 157.4 (CO). 
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4.2.1.2. Synthesis of N-butyryl-L-tyrosine (4) 
Compound 4 was synthesized according to previously described procedures and its 1H-
NMR spectroscopic data coincide with those previously reported.123 
 
IR (CH3OH, cm-1): 3296 (NH), 1736, 1647 (C=O), 1531 (N–C=O), 1516 (NH), 1222 (ArC–O). 
1H-RMN (CH3OD, δ): 0.82 (t, J = 7.3, 3H, CH3), 1.53 (sx, J = 7.4, 2H, CH2), 2.12 (t, J = 7.4, 2H, 
CH2), 2.82 (dd, J = 14.0, 9.3, 1H, CH2 Tyr), 3.09 (dd, J = 14.0, 4.9, 1H, CH2 Tyr), 4.58 (dd, J = 
9.1; 5.0, 1H, CH Tyr), 6.67 (d, J = 8.5, 2H, Ar Tyr), 7.02 (d, J = 8.5, 2H, Ar Tyr). 
13C-RMN (CH3OD, δ): 13.9 (CH3), 20.2 (CH2), 37.6 (CH2 Tyr), 38.6 (CH2), 55.1 (CH Tyr), 116.1 
(2 x CH Ar), 129.1 (C Ar), 131.2 (2 x CH Ar), 157.1 (C Ar), 175.0, 175.9 (2 x CO).  
4.2.1.3. General procedure for the synthesis of N-acyl-O-
(dibenzylphosphono)-L-tyrosines (5a-c) and O-
(dibenzylphosphono)-N-Fmoc-L- and D-tyrosines (8a,b). 
N-methylmorpholine (4.48 mmol, 1 equiv) in dry acetonitrile (0.25 mL x mmol) and tert-
butyldimethylsilyl chloride (1 equiv) were successively added to a solution of 4, or of the 
commercially available N-acetyl-L-tyrosine, N-benzoyl-L-tyrosine, N-Fmoc-L-tyrosine or N-
Fmoc-D-tyrosine (1 equiv) in dry acetonitrile (2.5 mL x mmol). After 10 min at rt, dibenzyl 
diisopropylphosphoramidite (1.1 equiv) and a solution of 1H-tetrazole (3 equiv) in dry 
acetonitrile were added. After 3 h, the solution was cooled to -20 ºC and 70% aqueous tert-butyl 
hydroperoxide (1 equiv) was added. After 10 min, an aqueous solution of 10% Na2S2O3 (2 mL x 
mmol) was added at -20 ºC. The mixture was subsequently transferred to a separating funnel, 
extracted with dichloromethane (6 mL x mmol), and washed again with aqueous 10% Na2S2O3 
(3 mL x mmol). The solvent was removed under reduced pressure, and the residue was 
dissolved in a mixture of acetic acid/THF/H2O (2:1:1.6) and stirred for 60 min at rt. The organic 
solvent was evaporated under reduced pressure, and the resultant oil was redissolved in diethyl 
ether (40 mL) and extracted with a saturated solution of NaHCO3 (3 x 10 mL). The combined 
aqueous layers were acidified to pH 2 with concentrated HCl, and extracted with 
dichloromethane (3 x 10 mL). The organic extract was dried over anhydrous Na2SO4, and the 
solvent was evaporated under reduced pressure to yield compounds 5a-c, 8a,b as colourless 
oils. 
 
N-Acetyl-O-[bis(benzyloxy)phosphoryl]-L-tyrosine (5a).  
Chromatography: dichloromethane → dichloromethane:methanol, 8:2. Yield: 77%. 
Spectroscopic data coincide with those previously reported.124  
                                                     
123 See citation 86. 
124 Llinás-Brunet, M.; Beaulieu, P. L.; Cameron, D. R.; Ferland, J.-M.; Gauthier, J.; Ghiro, E.; Gillard, J.; Gorys, V.; 
Poirier, M.; Rancourt, J.; Wernic, D.; Betageri, R.; Cardozo, M.; Jakes, S.; Lukas, S.; Patel, U.; Proudfoot, J.; Moss, N. J. 
Med. Chem. 1999, 42, 722-729. 
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IR (CH2Cl2, cm-1): 3289 (NH), 1733 (OC=O), 1655 (NC=O), 1547 (N–CO), 1507 (NH), 1268, 
1215 (P–OC), 1015, 960 (C–OP). 
1H-NMR (CDCl3, δ): 1.83 (s, 3H, CH3), 2.97 (dd, J = 13.9, 5.8 Hz, 1H, CH2 Tyr), 3.16 (dd, J = 
13.6, 3.8 Hz, 1H, CH2 Tyr), 4.80-4.95 (m, 1H, CH Tyr), 5.05 (s, 2H, OCH2), 5.09 (s, 2H, OCH2), 
6.64 (d, J = 8.3 Hz, 1H, NH), 6.92 (s, 4H, Ar Tyr), 7.28 (m, 10H, Ar), 10.50 (s, 1H, OH). 
13C-NMR (CDCl3, δ): 22.7 (CH3), 36.5 (CH2 Tyr), 53.2 (CH Tyr), 70.4, 70.5 (2 x OCH2), 120.1, 
120.2 (2 x CH Ar), 128.1 (2 x CH Ar), 128.2 (2 x CH Ar), 128.7 (2 x CH Ar), 128.9 (2 x CH Ar), 
130.8 (2 x CH Ar), 133.4 (2 x CH Ar), 135.0, 135.1, 149.3, 149.4 (4 x C Ar), 171.3, 173.9 (2 x 
CO). 
 
O-[Bis(benzyloxy)phosphoryl]-N-butyryl-L-tyrosine (5b).  
Chromatography: dichloromethane:ethanol, 9.6:0.4 → 9:1. Yield: 78%.  
IR (CH2Cl2, cm-1): 3290 (NH), 1735 (OC=O), 1650 (NC=O), 1545 (N–CO), 1507 (NH), 1267, 
1214 (P–OC), 1014, 1000 (C–OP).  
1H-NMR (CDCl3, δ): 0.87 (t, J = 7.3 Hz, 3H, CH3), 1.58 (sx, J = 7.3 Hz, 2H, CH2), 2.13 (t, J = 7.3 
Hz, 2H, CH2), 3.14 (d, J = 4.9 Hz, 2H, CH2 Tyr), 4.83-4.92 (m, 1H, CH Tyr), 5.09 (s, 2H, OCH2), 
5.13 (s, 2H, OCH2), 6.43 (d, J = 7.0 Hz, 1H, NH), 6.98-7.09 (m, 4H, Ar Tyr), 7.32 (m, 10H, CH 
Ar). 
13C-NMR (CDCl3, δ): 13.8 (CH3), 19.1 (CH2), 36.6 (CH2 Tyr), 38.3 (CH2), 53.0 (CH Tyr), 70.3, 
70.4 (2 x OCH2), 120.0, 120.1 (2 x CH Ar), 128.2 (4 x CH Ar), 128.7 (4 x CH Ar), 128.9 (2 x CH 
Ar), 130.9 (2 x CH Ar), 133.5, 135.2, 135.3, 149.4 (4 x C Ar), 173.0, 173.6 (2 x CO). 
 
N-Benzoyl-O-[bis(benzyloxy)phosphoryl)-L-tyrosine (5c).  
Chromatography: dichloromethane → dichloromethane:ethanol, 9:1. Yield: 66%. 
IR (CH2Cl2, cm-1): 3291 (NH), 1733 (OC=O), 1640 (NC=O), 1514 (NH), 1215 (P–OC), 1016, 
962 (C–OP).  
1H-NMR (CDCl3, δ): 3.00-3.22 (m, 2H, CH2 Tyr), 4.83-4.88 (m, 1H, CH Tyr), 4.92 (s, 2H, OCH2), 
4.97 (s, 2H, OCH2), 6.86 (d, J = 8.5 Hz, 2H, Ar Tyr), 6.95 (d, J = 8.4 Hz, 2H, Ar Tyr), 7.14-7.34 
(m, 12H, Ar), 7.50-7.54 (m, 3H, Ar).  
13C-NMR (CDCl3, δ): 36.5 (CH2 Tyr), 53.9 (CH Tyr), 70.4 (2 x OCH2), 115.7 (2 x CH Ar), 120.1 
(2 x CH Ar), 126.9 (C Ar), 127.2 (4 x CH Ar), 128.2 (4 x CH Ar), 128.9 (2 x CH Ar), 130.5 (2 x 
CH Ar), 130.9 (2 x CH Ar), 132.1 (CH Ar), 133.4 (C Ar), 135.1 (2 x C Ar), 155.8 (C Ar), 167.9, 
173.7 (2 x CO). 
 
O-[Bis(benzyloxy)phosphoryl]-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-tyrosine (8a). 
Chromatography: dichloromethane:ethanol, 9.9:0.1 → 9.6:0.4. Yield: 63%. [α]D -5.0 (c 0.5, 
methanol).  
IR (CH2Cl2, cm-1): 3300 (COO–H), 1720 (OC=O), 1607 (NC=O), 1507, 1451 (CAr-CAr), 1259, 
1214 (P–OC), 1016, 962 (C–OP). 
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1H-NMR (CDCl3, δ): 3.06-3.07 (m, 2H, CH2 Tyr), 3.99-4.16 (m, 1H, CH Fmoc), 4.22-4.44 (m, 2H, 
CH2 Fmoc), 4.63-4.64 (m, 1H, CH Tyr), 5.01 (s, 2H, OCH2), 5.05 (s, 2H, OCH2), 5.42 (d, J = 7.8 
Hz, 1H, NH), 6.96 (s, 4H, Ar Tyr), 7.19-7.35 (m, 14H, CH Ar), 7.49 (d, J = 7.1 Hz, 2H, CH Ar), 
7.67 (d, J = 7.2 Hz, 2H, CH Ar).  
13C-NMR (CDCl3, δ): 37.1 (CH2 Tyr), 47.2 (CH Fmoc), 54.5 (CH Tyr), 66.8 (CH2 Fmoc), 70.1, 
70.3 (2 x OCH2), 119.9 (2 x CH Ar), 125.1 (C Ar), 127.1 (2 x CH Ar), 127.7 (2 x CH Ar), 128.1 (4 
x CH Ar), 128.4 (4 x CH Ar), 128.6 (2 x CH Ar), 128.7 (2 x CH Ar), 130.8 (2 x CH Ar), 133.1 (2 x 





Data of this compound were identical to those reported for its enantiomer 8a except for the 
specific rotation. [α]D +5.0 (c 0.5, methanol). 
4.2.1.4. General procedure for the synthesis of N-acyl-O-
(dibenzylphosphono)-L-tyrosinamides (6a-j) and O-
(dibenzylphosphono)-N-Fmoc-L- and D-tyrosinamides (9a-c). 
To a solution of the corresponding compound 5a-c, 8a,b (1 equiv) in dry dichloromethane 
(5 mL x mmol), were added HOBt (1.0-1.5 equiv) and EDC (1.0-1.5 equiv) and the mixture was 
vigorously stirred at rt for 30 min under argon atmosphere. The temperature was then lowered 
to 0 ºC and a solution of the appropriate amine (0.9-1.2 equiv) in dichloromethane (2 mL x 
mmol) was added. After 10 min the temperature was raised to rt and stirring was continued for 2 
h. Then, the reaction mixture was washed with water (3 x 10 mL x mmol) and brine (3 x 10 mL x 
mmol), dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. 
Alternatively, for 9c, to a solution of amine 21 (0.20 mmol, 1 equiv) in anhydrous THF (30 
mL x mmol) under argon atmosphere and vigorous stirring, a previously activated mixture of 8a 
(0.23 mmol, 1.15 equiv), DIC (0.25 mmol, 1.3 equiv) and HOBt (0.25 mmol, 1.3 equiv) in 
anhydrous THF (10 mL x mmol 8a) was added and left to react for 24 h at 25 ºC. The crude was 
then successively washed with 1 M HCl (3 x 30 mL) and brine (3 x 30 mL), dried over 
anhydrous Na2SO4, and the solvent was removed under reduced pressure.  
In all cases the resultant crudes were purified by flash column chromatography to afford 
pure amides 6a-j and 9a-c as colourless oils. 
 
N-Acetyl-O-[bis(benzyloxy)phosphoryl)-N-[3-(2-oxotetrahydropyrimidin-1(2H)-yl)propyl]-
L-tyrosinamide (6a).  
Chromatography: ethyl acetate → ethyl acetate:ethanol, 9:1. Yield: 51%.  
IR (CH2Cl2, cm-1): 3292 (NH), 1639 (C=O), 1524 (N–CO), 1508 (NH), 1278, 1215 (P–OC), 
1015, 955 (C–OP). 
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1H-NMR (CDCl3, δ): 1.45-1.54 (m, 2H, CH2), 1.86 (qt, J = 5.8 Hz, 2H, CH2), 1.97 (s, 3H, CH3), 
2.92-3.25 (m, 10H, 4 x CH2N, CH2 Tyr), 4.65 (dd, J = 14.6, 6.5 Hz, 1H, CH Tyr), 4.88 (br s, 1H, 
NH), 5.01 (s, 2H, OCH2), 5.12 (s, 2H, OCH2), 6.38 (d, J = 8.3 Hz, 1H, NH), 7.04 (d, J = 8.7 Hz, 
2H, Ar Tyr), 7.13 (d, J = 8.5 Hz, 2H, Ar Tyr), 7.29-7.33 (m, 10H, Ar), 7.61 (t, J = 5.9 Hz, 1H, NH).  
13C-NMR (CDCl3, δ): 22.1 (CH3), 23.4, 26.6, 35.1, 37.9, 40.4, 43.6, 45.1 (7 x CH2), 54.6 (CH 
Tyr), 70.0, 70.1 (2 x OCH2), 120.0 (2 x CH Ar), 120.1 (2 x CH Ar), 128.1 (4 x CH Ar), 128.7 (4 x 
CH Ar), 130.8 (2 x CH Ar), 133.9, 135.5, 149.5, 149.7 (4 x C Ar), 157.0, 170.0, 170.5 (3 x CO).  
 
N-Acetyl-O-[bis(benzyloxy)phosphoryl)-N-[2-(2-oxoimidazolidin-1-yl)ethyl]-L-
tyrosinamide (6b).  
Chromatography: ethyl acetate:methanol, 9:1 → 7:3. Yield: 56%.  
IR (CH2Cl2, cm-1): 2934 (NH), 1772, 1711 (C=O), 1488, 1434 (CAr–CAr), 1509 (NH), 1213 (P–
OC), 1097 (C–OP). 
1H-NMR (CDCl3, δ): 1.73 (s, 3H, CH3), 2.84-2.94 (m, 2H, CH2 Tyr), 3.14-3.32 (m, 8H, 4 x 
CH2N), 4.60-4.67 (m, 1H, CH Tyr), 5.01 (s, 2H, OCH2), 5.05 (s, 2H, OCH2), 6.50 (d, J = 8.4 Hz, 
1H, NH), 6.96 (d, J = 8.4 Hz, 2H, Ar Tyr), 7.05 (d, J = 8.4 Hz, 2H, Ar Tyr), 7.26-7.27 (m, 10H, 
Ar). 
13C-NMR (CDCl3, δ): 22.9 (CH3), 36.9, 37.8, 38.1, 42.6, 45.1 (5 x CH2), 53.9 (CH Tyr), 69.7, 
69.9 (2 x OCH2), 119.6 (2 x CH Ar), 119.7 (2 x CH Ar), 127.8 (4 x CH Ar), 128.4 (4 x CH Ar), 




Chromatography: dichloromethane → dichloromethane:methanol 9:1. Yield: 25%.  
IR (CH2Cl2, cm-1): 3282 (NH), 1644 (C=O), 1526 (N–CO), 1509 (NH), 1229 (P–OC), 1090 (C–
OP). 
1H-NMR (CDCl3, δ): 1.61 (s, 3H, CH3), 2.57 (t, J = 6.4 Hz, 2H, CH2), 2.87-2.91 (m, 2H, CH2 Tyr), 
3.29-3.32 (m, 2H, CH2NH), 4.45-4.52 (m, 1H, CH Tyr), 5.02 (s, 2H, OCH2), 5.06 (s, 2H, OCH2), 
6.35 (s, 1H, imid), 6.78-6.84 (m, 1H, NH), 6.90 (d, J = 7.9 Hz, 2H, Ar Tyr), 7.03 (d, J = 8.5 Hz, 
2H, Ar Tyr), 7.26-7.27 (m, 10H, Ar), 7.39 (s, 1H, imid). 
13C-NMR (CDCl3, δ): 21.9 (CH3), 25.9, 37.5, 39.0 (3 x CH2), 54.8 (CH Tyr), 69.9, 70.1 (2 x 
OCH2), 116.7, 119.8, 120.0, 127.1 (4 x CH Ar), 127.4 (2 x CH Ar), 128.0 (2 x CH Ar), 128.7 (2 x 
CH Ar), 130.3, 132.2, 133.7, 134.3 (4 x CH Ar), 135.0 (2 x CH Ar), 135.5, 136.7, 139.9, 149.1, 
149.3 (5 x C Ar), 170.1, 171.3 (2 x CO). 
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N-Acetyl-O-[bis(benzyloxy)phosphoryl]-N-[3-(2-oxopyrrolidin-1-yl)propyl]-L-
tyrosinamide (6d). 
Chromatography: dichloromethane → dichloromethane:methanol, 9.5:0.5. Yield: 65%.  
IR (CH2Cl2, cm-1): 3278 (NH), 1660 (C=O), 1548 (N–CO), 1508 (NH), 1283, 1216 (P–OC), 
1016, 956 (C–OP). 
1H-NMR (CDCl3, δ): 1.51-1.52 (m, 2H, CH2), 1.90-1.95 (m, 2H, CH2), 1.93 (s, 3H, CH3), 2.27 (t, 
J = 8.1 Hz, 2H, CH2CO), 2.97-3.27 (m, 8H, 3 x CH2N, CH2 Tyr), 4.61-4.64 (m, 1H, CH Tyr), 5.05 
(s, 2H, OCH2), 5.08 (s, 2H, OCH2), 6.76-6.78 (m, 1H, NH), 7.02 (d, J = 8.5 Hz, 2H, Ar Tyr), 7.12 
(d, J = 8.5 Hz, 2H, Ar Tyr), 7.28-7.34 (m, 10H, Ar).  
13C-NMR (CDCl3, δ): 17.8 (CH2), 23.1 (CH3), 26.4, 30.8, 35.6, 37.5, 39.3, 47.2 (6 x CH2), 54.6 
(CH Tyr), 69.9, 70.0 (2 x OCH2), 119.9 (2 x CH Ar), 128.0 (4 x CH Ar), 128.6 (6 x CH Ar), 130.6 
(2 x CH Ar), 134.0, 135.3, 149.3, 149.5 (4 x C Ar), 170.3, 170.9, 175.7 (3 x CO).  
 
O-[Bis(benzyloxy)phosphoryl]-N-butyryl-N-[3-(2-oxotetrahydropyrimidin-1(2H)-
yl)propyl]-L-tyrosinamide (6e).  
Chromatography: dichloromethane → dichloromethane:ethanol, 9.5:0.5. Yield: 80%.  
IR (CH2Cl2, cm-1): 3289 (NH), 1644 (C=O), 1508 (NH), 1277, 1215 (P–OC), 1015, 953 (C–OP). 
1H-NMR (CDCl3, δ): 0.71 (t, J = 7.6 Hz, 3H, CH3), 1.34-1.48 (m, 4H, 2 x CH2), 1.70-1.73 (m, 2H, 
CH2), 2.00 (t, J = 7.01 Hz, 2H, CH2), 2.77-3.11 (m, 10H, 4 x CH2N, CH2 Tyr), 4.46-4.47 (m, 1H, 
CH Tyr), 4.91 (s, 2H, OCH2), 4.95 (s, 2H, OCH2), 6.21 (d, J = 7.9 Hz, 1H, NH), 6.88 (d, J = 8.5 
Hz, 2H, Ar Tyr), 6.97 (d, J = 8.6 Hz, 2H, Ar Tyr), 7.12-7.16 (m, 10H, Ar), 7.30 (br s, 1H, NH). 
13C-NMR (CDCl3, δ): 13.8 (CH3), 19.0, 21.8, 26.6, 35.3, 37.9, 38.4, 40.2, 44.0, 45.0 (9 x CH2), 
54.5 (CH Tyr), 70.1 (2 x OCH2), 120.0 (2 x CH Ar), 127.6 (2 x CH Ar), 128.1 (2 x CH Ar), 128.5 
(2 x CH Ar), 128.6 (2 x CH Ar), 128.7 (2 x CH Ar), 129.5 (2 x CH Ar), 134.0, 135.5 (2 x C Ar), 
149.4 (2 x C Ar), 157.0, 170.8, 173.0 (3 x CO).  
 
O-[Bis(benzyloxy)phosphoryl]-N-butyryl-N-[2-(2-oxoimidazolidin-1-yl)ethyl]-L-
tyrosinamide (6f).  
Chromatography: dichloromethane:ethanol, 9.7:0.3 → 9.5:0.5. Yield: 40%.  
IR (CH2Cl2, cm-1): 3287 (NH), 1647 (C=O), 1545 (N–CO), 1506 (NH), 1273, 1214 (P–OC), 
1015, 955 (C–OP). 
1H-NMR (CDCl3, δ): 0.78 (t, J = 7.3 Hz, 3H, CH3), 1.50 (sx, J = 7.4 Hz, 2H, CH2), 2.08 (t, J = 7.2 
Hz, 2H, CH2CO), 2.96 (d, J = 6.6 Hz, 2H, CH2 Tyr), 3.15-3.40 (m, 8H, 4 x CH2N), 4.58-4.66 (m, 
1H, CH Tyr), 5.01 (s, 2H, OCH2), 5.05 (s, 2H, OCH2), 6.36 (d, J = 8.2 Hz, 1H, NH), 6.93 (d, J = 
8.3 Hz, 2H, Ar Tyr), 7.06 (d, J = 8.6 Hz, 2H, Ar Tyr), 7.21-7.30 (m, 10H, Ar). 
13C-NMR (CDCl3, δ): 13.5 (CH3), 18.8, 29.5, 37.1, 37.8, 38.1, 42.7, 45.1 (7 x CH2), 53.7 (CH 
Tyr), 69.7, 69.8 (2 x OCH2), 119.6 (2 x CH Ar), 119.7 (2 x CH Ar), 127.8 (4 x CH Ar), 128.4 (4 x 
CH Ar), 130.5 (2 x CH Ar), 133.7 (C Ar), 135.3 (2 x C Ar), 149.2 (C Ar), 163.2, 171.2, 172.9 (3 x 
CO). 
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O-[Bis(benzyloxy)phosphoryl]-N-butyryl-N-[3-(2-oxopyrrolidin-1-yl)propyl]-L-
tyrosinamide (6g).  
Chromatography: ethyl acetate:ethanol, 9.7:0.3 → 9.4:0.6. Yield: 68%.  
IR (CH2Cl2, cm-1): 3292 (NH), 1650 (C=O), 1542 (N–CO), 1507 (NH), 1277, 1214 (P–OC), 
1015, 955 (C–OP). 
1H-NMR (CDCl3, δ): 0.71 (t, J = 7.4 Hz, 3H, CH3), 1.34-1.53 (m, 4H, 2 x CH2), 1.87 (sx, J = 7.4 
Hz, 2H, CH2), 2.01 (td, J = 7.5, 2.5 Hz, 2H, CH2NH), 2.17 (t, J = 8.1 Hz, 2H, CH2CO), 2.79-3.16 
(m, 8H, 2 x CH2N, CH2 Tyr, CH2CO), 4.50-4.51 (m, 1H, CH Tyr), 4.91 (s, 2H, OCH2), 4.95 (s, 
2H, OCH2), 6.07 (d, J = 8.0 Hz, 1H, NH), 6.88 (d, J = 8.6 Hz, 2H, Ar Tyr), 6.98 (d, J = 8.8 Hz, 
2H, Ar Tyr), 7.11-7.19 (m, 10H, Ar).  
13C-NMR (CDCl3, δ): 13.5 (CH3), 17.7, 18.7, 26.2, 30.6, 35.2, 37.5, 38.2, 39.0, 47.0 (9 x CH2), 
54.1 (CH Tyr), 69.7, 69.8 (2 x OCH2), 119.8, 119.9 (2 x CH Ar), 127.8 (4 x CH Ar), 128.4 (2 x 
CH Ar), 128.5 (4 x CH Ar), 130.4 (2 x CH Ar), 133.6, 135.2, 135.3, 149.3 (4 x C Ar), 170.6, 
172.7, 175.6 (3 x CO).  
 
N-Benzoyl-O-[bis(benzyloxy)phosphoryl)-N-[3-(2-oxotetrahydropyrimidin-1(2H)-
yl)propyl]-L-tyrosinamide (6h).  
Chromatography: ethyl acetate:ethanol, 9.8:0.2 → 9:1. Yield: 30%.  
IR (CH2Cl2, cm-1): 3292 (NH), 1639 (C=O), 1524 (N–CO), 1508 (NH), 1278, 1215 (P–OC), 
1015, 955 (C–OP). 
1H-NMR (CDCl3, δ): 1.42-1.64 (m, 2H, CH2), 1.83 (qt, J = 5.5 Hz, 2H, CH2), 3.05-3.30 (m, 10H, 
4 x CH2N, CH2 Tyr), 4.82-4.92 (m, 1H, CH Tyr), 5.05 (s, 2H, OCH2), 5.09 (s, 2H, OCH2), 7.04 (d, 
J = 8.5 Hz, 2H, Ar Tyr), 7.17 (d, J = 8.3 Hz, 2H, Ar Tyr), 7.27-7.49 (m, 13H, Ar), 7.64 (br t, J = 
5.7 Hz, 1H, NH), 7.77 (dd, J = 6.3, 1.6 Hz, 2H, Ar).  
13C-NMR (CDCl3, δ): 21.8, 26.5, 35.3, 38.0, 40.1, 43.7, 44.9 (7 x CH2), 54.9 (CH Tyr), 69.8, 69.9 
(2 x OCH2), 119.8 (2 x CH Ar), 127.1 (2 x CH Ar), 127.9 (4 x CH Ar), 128.4 (2 x CH Ar), 128.5 (6 
x CH Ar), 130.7 (2 x CH Ar), 131.4 (CH Ar), 133.8, 134.1, 135.3, 135.5, 149.2 (5 x C Ar), 166.8 
(CO), 170.3 (2 x CO). 
 
N-Benzoyl-O-[bis(benzyloxy)phosphoryl]-N-[2-(2-oxoimidazolidin-1-yl)ethyl]-L-
tyrosinamide (6i).  
Chromatography: dichloromethane:ethanol, 9.8:0.2 → 9.5:0.5. Yield: 35%.  
IR (CH2Cl2, cm-1): 3295 (NH), 1688, 1655 (C=O), 1540 (N–CO), 1509 (NH), 1276, 1217 (P–
OC), 1017, 958 (C–OP). 
1H-NMR (CDCl3, δ): 3.14-3.45 (m, 10H, 4 x CH2N, CH2 Tyr), 4.17 (br s, 1H, NH), 4.80-5.00 (m, 
1H, CH Tyr), 5.06 (s, 2H, OCH2), 5.10 (s, 2H, OCH2), 7.02 (d, J = 7.8 Hz, 2H, Ar Tyr), 7.16 (d, J 
= 8.3 Hz, 2H, Ar Tyr), 7.24-7.35 (m, 13H Ar), 7.78 (d, J = 6.8 Hz, 2H, Ar).  
13C-NMR (CDCl3, δ): 37.2, 37.9, 38.2, 42.8, 45.2 (5 x CH2), 54.5 (CH Tyr), 69.8, 70.0 (2 x 
OCH2), 119.7, 119.8 (2 x CH Ar), 127.1 (2 x CH Ar), 127.9 (4 x CH Ar), 128.4 (2 x CH Ar), 128.5 
Experimental Section                                                                                                                     83 
(2 x CH Ar), 128.6 (4 x CH Ar), 130.7 (2 x CH Ar), 131.6 (CH Ar), 133.8 (2 x C Ar), 135.3 (2 x C 
Ar), 149.2 (C Ar), 167.1 (CO), 171.1 (2 x CO).  
 
N-Benzoyl-O-[bis(benzyloxy)phosphoryl]-N-[3-(2-oxopyrrolidin-1-yl)propyl]-L-
tyrosinamide (6j).  
Chromatography: ethyl acetate → ethyl acetate:ethanol, 9:1. Yield: 42%.  
IR (CH2Cl2, cm-1): 3290 (NH), 1654 (C=O), 1537 (N–CO), 1508 (NH), 1276, 1215 (P–OC), 
1015, 956 (C–OP). 
1H-NMR (CDCl3, δ): 1.57 (qt, J = 6.6 Hz, 2H, CH2), 1.98 (qt, J = 6.6 Hz, 2H, CH2), 2.34 (t, J = 
7.8 Hz, 2H, CH2), 3.05-3.19 (m, 6H, 3 x CH2), 3.30 (t, J = 6.6 Hz, 2H, CH2), 4.86-4.88 (m, 1H, 
CH Tyr), 5.07 (s, 2H, OCH2), 5.11 (s, 2H, OCH2), 7.06 (d, J = 8.5 Hz, 2H, Ar Tyr), 7.11 (br s, 1H, 
NH), 7.20 (d, J = 8.3 Hz, 2H, Ar Tyr), 7.32-7.52 (m, 13H, Ar), 7.78 (m, 2H, Ar).  
13C-NMR (CDCl3, δ): 17.9, 26.4, 30.8, 35.6, 37.9, 39.3, 47.3 (7 x CH2), 55.0 (CH Tyr), 69.9, 70.0 
(OCH2), 120.0, 120.1 (2 x CH Ar), 127.2 (2 x CH Ar), 128.0 (4 x CH Ar), 128.5 (2 x CH Ar), 
128.6 (4 x CH Ar), 128.7 (2 x CH Ar), 130.7 (2 x CH Ar), 131.7 (CH Ar), 133.7, 133.9, 135.3, 
135.6, 149.5 (5 x C Ar), 167.0, 170.7, 175.9 (3 x CO).  
 
O-[Bis(benzyloxy)phosphoryl]-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-[3-(2-
oxotetrahydropyrimidin-1(2H)-yl)propyl]-L-tyrosinamide (9a).  
Chromatography: dichloromethane → dichloromethane:ethanol, 9.8:0.2. Yield: 55%.  
[α]D -11.2 (c 1.0, methanol). 
IR (CH2Cl2, cm-1): 3361 (NH), 1737 (C=O), 1260 (P–OC), 1030 (C–OP). 
1H-NMR (CDCl3, δ): 1.48-1.51 (m, 2H, CH2), 1.80-1.86 (m, 2H, CH2), 2.95-3.18 (m, 10H, 4 x 
CH2N, CH2 Tyr), 4.14 (t, J = 7.1 Hz, 1H, CH Fmoc), 4.27-4.31 (m, 3H, CH2 Fmoc, CH Tyr), 4.65 
(br s, 1H, NH), 5.01 (s, 2H, OCH2), 5.06 (s, 2H, OCH2), 5.53 (d, J = 8.5 Hz, 1H, NH), 6.99 (d, J = 
8.2 Hz, 2H, Ar Tyr), 7.13 (d, J = 7.8 Hz, 2H, Ar Tyr), 7.19-7.32 (m, 14H, Ar), 7.50-7.56 (m, 3H, 
Ar, NH), 7.68 (d, J = 7.3 Hz, 2H, Ar).  
13C-NMR (CDCl3, δ): 22.1, 26.6, 35.4, 38.5, 40.5, 43.9, 45.1 (7 x CH2), 47.2 (CH Fmoc), 56.5 
(CH Tyr), 67.1 (CH2 Fmoc), 70.5 (2 x OCH2), 120.0 (2 x CH Ar), 121.0 (2 x CH Ar), 125.3 (2 x 
CH Ar), 127.2 (2 x CH Ar), 127.8 (2 x CH Ar), 128.3 (4 x CH Ar), 128.7 (6 x CH Ar), 130.7 (2 x 
CH Ar), 133.9 (C Ar), 135.6 (2 x C Ar), 141.1 (2 x C Ar), 143.9 (2 x C Ar), 149.5 (C Ar), 155.8 
(CO), 170.4 (2 x CO).  
 
O-[Bis(benzyloxy)phosphoryl]-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-[3-(2-
oxotetrahydropyrimidin-1(2H)-yl)propyl]-D-tyrosinamide (9b).  
Yield: 81%. Data of this compound were identical to those reported for its enantiomer 9a except 
for the specific rotation. [α]D +11.2 (c 1.0, methanol). 
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O-[Bis(benzyloxy)phosphoryl]-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-{1-[2-(2-
oxotetrahydropyrimidin-1(2H)-yl)ethyl]cyclohexyl}-L-tyrosinamide (9c). 
Chromatography: dichloromethane → dichloromethane:ethanol, 9.5:0.5. Yield: 50%.  
IR (CH2Cl2, cm-1): 3295 (NH), 1709, 1664, 1632 (C=O), 1525 (N–CO), 1261 (P–OC), 1017 (C–
OP). 
1H-NMR (CDCl3, δ): 1.44-1.69 (m, 14H, 7 x CH2), 2.34-3.23 (m, 8H, 3 x CH2N, CH2 Tyr), 3.64 
(br s, 1H, NH), 4.14-4.41 (m, 4H, CH Fmoc, CH2 Fmoc, CH Tyr), 5.09 (s, 2H, OCH2), 5.31 (s, 
2H, OCH2), 5.37 (br s, 1H, NH), 7.07-7.26 (m, 4H, Ar Tyr), 7.33-7.36 (m, 14H, Ar), 7.38-7.74 (m, 
5H, 4 x Ar, NH). 
13C-NMR (CDCl3, δ): 21.7, 21.9, 22.8, 25.6 (4 x CH2), 29.8 (2 x CH2), 35.0, 37.9, 40.3, 43.0, 
45.2 (5 x CH2), 47.2 (CH Fmoc), 53.6 (C), 55.7 (CH Tyr), 67.2 (CH2 Fmoc), 70.0, 70.1 (2 x 
OCH2), 120.1 (2 x CH Ar), 120.2 (2 x CH Ar), 125.2 (C Ar), 127.2 (2 x CH Ar), 127.8 (2 x CH 
Ar), 128.1 (4 x CH Ar), 128.5 (6 x CH Ar), 130.8 (2 x CH Ar), 134.1 (2 x C Ar), 135.5 (2 x C Ar), 
141.4 (2 x CH Ar), 143.9 (2 x C Ar), 149.5 (C Ar), 156.3 (CO), 171.9 (2 x CO). 
4.2.1.5. General procedure for the synthesis of N-Acetyl-O-
[bis(benzyloxy)phosphoryl]-N-[3-(2-oxotetrahydropyrimidin-1(2H)-
yl)propyl]tyrosinamides (10a-c). 
To a solution containing the corresponding amide 9a-c (1 equiv) in dry acetonitrile at 0 
ºC, piperidine (13.5 equiv) was added dropwise under argon atmosphere. The solution was 
stirred for 2 h at rt. The reaction mixture was evaporated to dryness, the residue redissolved in 
dimethylformamide (7.5 mL x mmol) and N,N-diisopropylethylamine (DIPEA, 2 equiv) and acetic 
anhydride (2 equiv) were added. The reaction was stirred for 3 h at rt. Finally, the solvent was 
removed under reduced pressure and the resulting crude mixture was resuspended in ethyl 
acetate and sequentially washed with 1 M HCl (3 x 30 mL) and brine (3 x 30 mL). The organic 
extract was dried over anhydrous Na2SO4 and the solvent evaporated under reduced pressure. 
The crudes were purified by flash column chromatography to afford pure target compunds 10a-
c as oils. 
 
N-Acetyl-O-[bis(benzyloxy)phosphoryl]-N-[3-(2-oxotetrahydropyrimidin-1(2H)-
yl)propyl]-L-tyrosinamide (10a).  
Chromatography: dichloromethane:ethanol, 9.7:0.3 → 9.3:0.7. Yield: 47%. Data of this 




yl)propyl]-D-tyrosinamide (10b).  
Chromatography: dichloromethane:ethanol, 9.7:0.3 → 9.3:0.7. Yield: 75%. Data of this 
compound were identical to those reported for its enantiomer 6a except for the specific rotation. 
[α]D -1.1 (c 1.0, methanol). 
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N-Acetyl-O-[bis(benzyloxy)phosphoryl]-N-{1-[2-(2-oxotetrahydropyrimidin-1(2H)-
yl)ethyl]cyclohexyl}-L-tyrosinamide (10c).  
Chromatography: dichloromethane:ethanol, 9.9:0.1→ 9.2:0.8. Yield: 66%. 
IR (CH2Cl2, cm-1): 3315 (NH), 1728, 1653 (C=O), 1539 (N–CO), 1234 (P–OC), 1088 (P=O).  
1H-NMR (CDCl3, δ): 1.40-2.22 (m, 17H, 7 x CH2, CH3), 2.97-3.37 (m, 8H, 3 x CH2N, CH2 Tyr), 
4.61-4.69 (m, 2H, CH Tyr, NH), 5.07 (s, 2H, OCH2), 5.10 (s, 2H, OCH2), 6.12 (br s, 1H, NH), 
6.79 (d, J = 8.1 Hz, 1H, NH), 7.05 (d, J = 6.0 Hz, 2H, Ar Tyr), 7.18 (d, J = 6.0 Hz, 2H, Ar Tyr), 
7.27-7.32 (m, 10H, Ar).  
13C-NMR (CDCl3, δ): 21.6 (2 x CH2), 22.1 (CH2), 23.2 (CH3), 25.5, 34.4, 34.9 (3 x CH2), 37.3 (2 
x CH2), 40.4, 42.6, 45.2 (3 x CH2), 54.8 (CH Tyr), 55.6 (C), 69.9, 70.0 (2 x OCH2), 119.9 (2 x CH 
Ar), 128.0 (4 x CH Ar), 128.6 (6 x CH Ar), 130.7 (2 x CH Ar), 134.2, 135.4, 135.5, 149.4 (4 x C 
Ar), 156.0, 170.2, 170.3 (3 x CO).  
4.2.1.6. General procedure for the synthesis of N-acyl-O-
phosphonotyrosinamides (1a-l). 
To a solution of the corresponding amide 6a-j or 10a-c (1 equiv) in absolute ethanol (10 
mL x mmol), 10% Pd(C) was added (200 mg x mmol), and the suspension was hydrogenated at 
rt at an initial pressure of 45 psi, until disappearance of the starting benzylated amide (TLC). 
The reaction mixture was filtered over celite and the solvent was removed under reduced 




tyrosinamide (1a).  
Yield: 71%; mp: 141-143 ºC (dichloromethane/methanol); [α]D +0.5 (c 1.0, methanol). 
IR (CH3OH, cm
-1
): 3275 (NH), 1644 (C=O), 1535 (N–CO), 1509 (NH), 1221 (P–OC), 1025, 956 
(C–OP). 
1H-NMR (CD3OD, δ): 1.59 (t, J = 7.0 Hz, 2H, CH2), 1.86-1.93 (m, 2H, CH2), 1.92 (s, 3H, CH3), 
2.78-3.35 (m, 10H, 4 x CH2N, CH2 Tyr), 4.46 (t, J = 6.5 Hz, 1H, CH Tyr), 7.14-7.15 (m, 4H, Ar 
Tyr).  
13C-NMR (CD3OD, δ): 22.5 (CH3), 23.0, 28.2, 37.5, 38.3, 41.1, 45.7, 46.5 (7 x CH2), 56.8 (CH 
Tyr), 121.4 (2 x CH Ar), 131.0 (2 x CH Ar), 133.1, 158.8 (2 x C Ar), 173.3 (CO), 173.6 (2 x CO). 
MS (ESI) 441.9 (M-H)-. Anal. Calcd. for C18H27N4O7P: C, 48.87; H, 6.15; N, 12.66. Found: C, 
48.23; H, 5.99; N, 12.17. 
 
N-Acetyl-N-[2-(2-oxoimidazolidin-1-yl)ethyl]-O-phosphono-L-tyrosinamide (1b).  
Yield: 91%; mp: 105-108 ºC (dichloromethane/methanol); [α]D +1.5 (c 1.0, methanol). 
IR (CH3OH, cm
-1
): 3261 (NH), 1654 (C=O), 1542 (N–CO), 1508 (NH), 1271, 1228 (P–OC), 
1080, 1025 (C–OP). 
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1H-NMR (CD3OD, δ): 1.90 (s, 3H, CH3), 2.83-3.10 (m, 2H, CH2), 3.21-3.42 (m, 8H, 4 x CH2N), 
4.47-4.55 (m, 1H, CH Tyr), 7.11 (d, J = 8.4 Hz, 2H, Ar Tyr), 7.35 (d, J = 8.4 Hz, 2H, Ar Tyr). 
13C-NMR (CD3OD, δ): 22.3 (CH3), 38.1, 38.6, 39.2, 43.9, 46.4 (5 x CH2), 56.4 (CH Tyr), 121.5 (2 
x CH Ar), 131.0 (2 x CH Ar), 133.1, 153.3 (2 x C Ar), 165.4, 173.2, 173.8 (3 x CO). 
MS (ESI) 413.3 (M-H)-. Anal. Calcd. for C16H23N4O7P: C, 46.38; H, 5.59; N, 13.52. Found: C, 
45.97; H, 5.99; N, 13.21. 
 
N-Acetyl-N-[2-(1H-imidazol-5-yl)ethyl]-O-phosphono-L-tyrosinamide (1c).  
Yield: 34%; mp: 81-83 ºC (ethanol/water); [α]D -0.5 (c 0.6, methanol) 
IR (CH3OH, cm
-1
): 3282 (NH), 1644 (C=O), 1526 (N–CO), 1509 (NH), 1229 (P–OC), 1090 (C–
OP). 
1H-NMR (D2O, δ): 1.82 (s, 3H, CH3), 2.56 (t, J = 6.4 Hz, 2H, CH2), 2.70-2.87 (m, 2H, CH2N), 
3.13-3.18 (m, 1H, ½ CH2 Tyr), 3.28-3.35 (m, 1H, ½ CH2 Tyr), 4.23-4.25 (m, 1H, CH Tyr), 6.82 
(s, 1H, imid), 6.93 (d, J = 9.6 Hz, 2H, Ar Tyr), 7.03 (d, J = 8.0 Hz, 2H, Ar Tyr), 7.22-7.31 (m, 1H, 
imid), 8.56 (s, 1H, NH). 
13C-NMR (CD3OD, δ): 21.9 (CH3), 23.9, 36.6, 37.7 (3 x CH2), 55.8 (CH Tyr), 116.1 (CH Ar), 
120.7 (2 x CH Ar), 130.5 (2 x CH Ar), 130.8, 132.0 (2 x C Ar), 133.3 (CH Ar), 151.1 (C Ar), 
173.5, 174.2 (2 x CO). 
MS (ESI) 577.1 (M+H)+. Anal. Calcd. for C16H21N4O6P: C, 48.49; H, 5.34; N, 14.14. Found: C, 
47.98; H, 5.62; N, 13.97. 
 
N-Acetyl-N-[3-(2-oxopyrrolidin-1-yl)propyl]-O-phosphono-L-tyrosinamide (1d).  
Yield: 93%; mp: 77-79 ºC (dichloromethane/ethanol); [α]D +2.7 (c 1.0, methanol). 
IR (CH3OH, cm
-1
): 3279 (NH), 1650 (C=O), 1549 (N–CO), 1508 (NH), 1294, 1219 (P–OC), 
1025, 960 (C–OP).  
1H-NMR (CD3OD, δ): 1.46-1.49 (m, 2H, CH2), 1.75 (s, 3H, CH3), 1.89-1.92 (m, 2H, CH2), 2.21 (t, 
J = 8.0 Hz, 2H, CH2CO), 2.64-3.15 (m, 8H, 3 x CH2N, CH2 Tyr), 4.32-4.35 (m, 1H, CH Tyr), 6.95 
(d, J = 8.5 Hz, 2H, Ar Tyr), 7.05 (d, J = 8.4 Hz, 2H, Ar Tyr). 
13C-NMR (CD3OD, δ): 19.0 (CH2), 22.7 (CH3), 27.8, 32.2, 37.7, 38.4, 41.2, 48.8 (6 x CH2), 56.8 
(CH Tyr), 121.4 (2 x CH Ar), 131.6 (2 x CH Ar), 135.0, 152.0 (2 x C Ar), 173.4, 173.6, 178.2 (3 x 
CO). 
MS (ESI) 370.1 (M-CH3CONH), 426.4 (M-H)-. Anal. Calcd. for C18H26N3O7P: C, 50.58; H, 6.13; 
N, 9.83. Found: C, 50.93; H, 6.46; N, 9.84. 
 
N-Butyryl-N-[3-(2-oxotetrahydropyrimidin-1(2H)-yl)propyl]-O-phosphono-L-
tyrosinamide (1e).  
Yield: 90%; mp: 87-89 ºC (dichloromethane/ethanol); [α]D -0.7 (c 1.0, methanol). 
IR (CH3OH, cm
-1
): 3299 (NH), 1641 (C=O), 1536 (N–CO), 1508 (NH), 1220 (P–OC), 1024 (C–
OP). 
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1H-NMR (CD3OD, δ): 0.85 (t, J = 7.5 Hz, 3H, CH3), 1.44-1.66 (m, 4H, 2 x CH2), 1.83-1.93 (m, 
2H, CH2), 2.16 (t, J = 7.2 Hz, 2H, CH2), 2.61-2.92 (m, 2H, CH2 Tyr), 3.00-3.25 (m, 8H, 4 x 
CH2N), 4.51 (t, J = 7.6 Hz, 1H, CH Tyr), 7.13 (d, J = 9.0 Hz, 2H, Ar Tyr), 7.21 (d, J = 8.8 Hz, 2H, 
Ar Tyr). 
13C-NMR (CD3OD, δ): 12.5 (CH3), 18.5, 21.5, 26.8, 35.8, 36.5, 36.9, 39.0, 44.0, 45.3 (9 x CH2), 
54.9 (CH Tyr), 120.0 (2 x CH Ar), 129.7 (2 x CH Ar), 133.0, 151.0 (2 x C Ar), 172.4, 173.6, 
177.1 (3 x CO). 
MS (ESI) 469.6 (M-H)-. Anal. Calcd. for C20H31N4O7P: C, 51.06; H, 6.64; N, 11.91. Found: C, 
51.64; H, 6.96; N, 11.55. 
 
N-Butyryl-N-[2-(2-oxoimidazolidin-1-yl)ethyl]-O-phosphono-L-tyrosinamide (1f).  
Yield: 90%; mp: 143-145 ºC (dichloromethane/ethanol); [α]D -0.4 (c 0.5, methanol). 
IR (CH3OH, cm
-1
): 3281 (NH), 1654 (C=O), 1541 (N–CO), 1507 (NH), 1273, 1227 (P–OC), 
1080 (C–OP). 
1H-NMR (CD3OD, δ): 0.39 (t, J = 7.3 Hz, 3H, CH3), 1.47-1.59 (m, 2H, CH2), 2.15 (t, J = 7.3 Hz, 
2H, CH2), 2.76-3.65 (m, 10H, 4 x CH2N, CH2 Tyr), 4.49-4.57 (m, 1H, CH Tyr), 7.13 (d, J = 9.0 
Hz, 2H, Ar Tyr), 7.19 (d, J = 8.8 Hz, 2H, Ar Tyr). 
13C-NMR (CD3OD, δ): 13.3 (CH3), 20.0, 37.7, 38.2, 38.3, 38.8, 43.4, 46.0 (7 x CH2), 55.8 (CH 
Tyr), 121.0 (2 x CH Ar), 130.6 (2 x CH Ar), 133.0, 152.0 (2 x C Ar), 165.0, 173.5, 175.5 (3 x 
CO). 
MS (ESI) 441.7 (M-H)-. Anal. Calcd. for C18H27N4O7P: C, 48.87; H, 6.15; N, 12.66. Found: C, 
48.32; H, 6.40; N, 12.22. 
 
N-Butyryl-N-[3-(2-oxopyrrolidin-1-yl)propyl]-O-phosphono-L-tyrosinamide (1g).  
Yield: 90%; mp: 99-102 ºC (dichloromethane/ethanol); [α]D -1.2 (c 1.0, methanol). 
IR (CH3OH, cm
-1
): 3272 (NH), 1649 (C=O), 1544 (N–CO), 1508 (NH), 1292, 1220 (P–OC), 
1017, 957 (C–OP).  
1H-NMR (CD3OD, δ): 0.85 (t, J = 6.7 Hz, 3H, CH3), 1.45-1.67 (m, 4H, 2 x CH2), 2.04 (t, J = 6.8 
Hz, 2H, CH2CO), 2.17 (t, J = 6.4 Hz, 2H, CH2CO), 2.38 (t, J = 7.6 Hz, 2H, CH2), 2.81-3.21 (m, 
6H, 2 x CH2, CH2 Tyr), 3.42 (t, J = 5.7 Hz, 2H, CH2), 4.52 (t, J = 6.8 Hz, 1H, CH Tyr), 7.13 (d, J 
= 7.8 Hz, 2H, Ar Tyr), 7.21 (d, J = 7.8 Hz, 2H, Ar Tyr). 
13C-NMR (CD3OD, δ): 12.3 (CH3), 17.0, 18.6, 26.0, 30.8, 36.0, 37.0, 37.2, 39.8, 48.0 (9 x CH2), 
54.9 (CH Tyr), 120.0 (2 x CH Ar), 130.0 (2 x CH Ar), 131.0, 150.9 (2 x C Ar), 172.0, 174.5, 176.2 
(3 x CO). 
MS (ESI) 454.5 (M-H)-. Anal. Calcd. for C20H30N3O7P: C, 52.74; H, 6.64; N, 9.23. Found: C, 
52.35; H, 6.44; N, 9.13. 
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N-Benzoyl-N-[3-(2-oxotetrahydropyrimidin-1(2H)-yl)propyl]-O-phosphono-L-
tyrosinamide (1h).  
Yield: 80%; mp: 174-177 ºC (dichloromethane/methanol); [α]D -0.4 (c 0.8, methanol). 
IR (CH3OH, cm
-1
): 3293 (NH), 1636 (C=O), 1535 (N–CO), 1509 (NH), 1224 (P–OC), 956 (C–
OP). 
1H-NMR (CD3OD, δ): 1.63 (qt, J = 6.3 Hz, 2H, CH2), 1.90 (qt, J = 5.6 Hz, 2H, CH2), 2.98-3.27 
(m, 10H, 4 x CH2N, CH2 Tyr), 4.71 (t, J = 7.7 Hz, 1H, CH Tyr), 7.14 (d, J = 8.5 Hz, 2H, Ar Tyr), 
7.26 (d, J = 7.8 Hz, 2H, Ar Tyr), 7.40-7.52 (m, 3H, Ar), 7.76 (d, J = 6.8 Hz, 2H, Ar). 
13C-NMR ((CD3)2SO, δ): 22.0, 27.3, 36.2, 36.6, 41.1, 44.2, 45.0 (7 x CH2), 55.3 (CH Tyr), 119.5 
(2 x CH Ar), 127.5 (2 x CH Ar), 128.2 (2 x CH Ar), 130.0 (2 x CH Ar), 131.3 (CH Ar), 133.4, 
134.2, 150.5 (3 x C Ar), 155.6, 166.4, 171.1 (3 x CO). 
MS (ESI) 503.4 (M-H)-. Anal. Calcd. for C23H29N4O7P: C, 54.76; H, 5.79; N, 11.11. Found: C, 
54.42; H, 5.84; N, 10.95. 
 
N-Benzoyl-N-[2-(2-oxoimidazolidin-1-yl)ethyl]-O-phosphono-L-tyrosinamide (1i).  
Yield: 78%; mp: 137-139 ºC (dichloromethane/methanol); [α]D +0.6 (c 1.0, methanol). 
IR (CH3OH, cm
-1
): 3304 (NH), 1646 (C=O), 1508 (NH), 1270, 1221 (P–OC), 1019, 959 (C–OP). 
1H-NMR (CD3OD, δ): 2.51-3.39 (m, 10H, 4 x CH2N, CH2 Tyr), 4.57-4.60 (m, 1H, CH Tyr), 7.03 
(d, J = 7.8 Hz, 2H, Ar Tyr), 7.24 (d, J = 7.7 Hz, 2H, Ar Tyr), 7.42 (m, 3H, Ar), 7.83 (d, J = 7.5 Hz, 
2H, Ar), 8.17 (br s, 1H, NH), 8.54 (d, J = 8.2 Hz, 1H, NH). 
13C-NMR ((CD3)2SO, δ): 39.0, 42.5, 43.3, 44.1, 45.7 (5 x CH2), 56.1 (CH Tyr), 120.4 (2 x CH Ar), 
128.3 (2 x CH Ar), 128.9 (2 x CH Ar), 130.7 (2 x CH Ar), 132.1 (CH Ar), 135.0, 136.0, 152.9 (3 x 
C Ar), 161.3, 167.2, 172.3 (3 x CO). 
MS (ESI) 475.2 (M-H)-. Anal. Calcd. for C21H25N4O7P: C, 52.94; H, 5.29; N, 11.76. Found: C, 
52.73; H, 5.68; N, 11.95. 
 
N-Benzoyl-N-[3-(2-oxopyrrolidin-1-yl)propyl]-O-phosphono-L-tyrosinamide (1j).  
Yield: 90%; mp: 124-126 ºC (dichloromethane/methanol); [α]D -0.2 (c 1.5, methanol). 
IR (CH3OH, cm
-1
): 3290 (NH), 1644 (C=O), 1539 (N–CO), 1508 (NH), 1294 (P–OC), 1025 (C–
OP). 
1H-NMR (CD3OD, δ): 1.63 (qt, J = 6.9 Hz, 2H, CH2), 2.03 (qt, J = 7.7 Hz, 2H, CH2), 2.36 (t, J = 
8.0 Hz, 2H, CH2CO), 3.00-3.23 (m, 6H, 3 x CH2N), 3.43-3.44 (m, 2H, CH2 Tyr), 4.70-4.71 (m, 
1H, CH Tyr), 7.13 (d, J = 7.6 Hz, 2H, Ar Tyr), 7.26 (d, J = 8.2 Hz, 2H, Ar Tyr), 7.40-7.56 (m, 3H, 
Ar), 7.76 (d, J = 6.6 Hz, 2H, Ar). 
13C-NMR (CD3OD, δ): 17.3, 26.2, 30.5, 36.2, 36.7, 39.6, 47.2 (7 x CH2), 55.6 (CH Tyr), 119.8 (2 
x CH Ar), 127.0 (2 x CH Ar), 128.0 (2 x CH Ar), 129.8 (2 x CH Ar), 131.3 (CH Ar), 132.8, 133.7, 
150.9 (3 x C Ar), 168.6, 171.1, 172.1 (3 x CO). 
MS (ESI) 488.6 (M-H)-. Anal. Calcd. for C23H28N3O7P: C, 56.44; H, 5.77; N, 8.59. Found: C, 
56.15; H, 5.57; N, 8.07. 
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N-Acetyl-N-[3-(2-oxotetrahydropyrimidin-1(2H)-yl)propyl]-O-phosphono-L-
tyrosinamide ((S)-1k).  
Yield: 47%. Data of this compound were identical to those reported for 1a except for the 
specific rotation. [α]D +3.2 (c 1.0, methanol). 
Anal. Calcd. for C18H27N4O7P: C, 48.87; H, 6.15; N, 12.66. Found: C, 48.45; H, 6.20; N, 12.33. 
 
N-Acetyl-N-[3-(2-oxotetrahydropyrimidin-1(2H)-yl)propyl]-O-phosphono-D-
tyrosinamide ((R)-1k).  
Yield: 51%. Data of this compound were identical to those reported for (S)-1k except for the 
specific rotation. [α]D -3.0 (c 1.0, methanol). 
Anal. Calcd. for C18H27N4O7P: C, 48.87; H, 6.15; N, 12.66. Found: C, 48.46; H, 5.99; N, 12.29. 
 
N-Acetyl-N-[3-(2-oxotetrahydropyrimidin-1(2H)-yl)propyl]-O-phosphono-D,L-
tyrosinamide ((R,S)-1k).  
Yield: 35%. Data of this compound were identical to those reported for enantiomers (R)- and 
(S)-1k except for the specific rotation. 
Anal. Calcd. for C18H27N4O7P: C, 48.87; H, 6.15; N, 12.66. Found: C, 48.70; H, 6.20; N, 12.53. 
 
N-Acetyl-N-{1-[2-(2-oxotetrahydropyrimidin-1(2H)-yl)ethyl]cyclohexyl}-O-phosphono-L-
tyrosinamide (1l).  
Yield: 88%; mp: 166-167 ºC (diethyl ether); [α]D +0.7 (c 1.0, methanol). 
IR (CH3OH, cm
-1
): 3291 (NH), 1642 (C=O), 1548 (N–CO), 1517 (NH), 1234 (P–OC), 1106 
(P=O), 1030 (C–OP).  
1H-NMR (CD3OD, δ): 1.17-2.11 (m, 17H, 7 x CH2, CH3), 2.81 (dd, J = 15.0, 9.0 Hz, 1H, ½ CH2 
Tyr), 3.03 (dd, J = 15.0, 6.3 Hz, 1H, ½ CH2 Tyr), 3.12-3.27 (m, 6H, 3 x CH2N), 4.54 (dd, J = 8.8, 
6.4 Hz, 1H, CH Tyr), 7.18-7.21 (m, 4H, Ar Tyr).  
13C-NMR (CD3OD, δ): 22.4 (CH3), 22.7 (2 x CH2), 23.1, 26.8, 35.5, 35.7, 36.3, 38.1, 41.1, 43.9, 
46.5 (9 x CH2), 56.6 (CH Tyr), 57.0 (C), 121.3 (CH Ar), 121.4 (CH Ar), 130.7 (2 x CH Ar), 131.8, 
154.6 (2 x C Ar), 158.6, 173.1, 173.5 (3 x CO). 
MS (ESI) 509.1 (M-H)-. Anal. Calcd. for C23H35N4O7P: C, 54.11; H 6.91; N, 10.97. Found: C, 
53.88; H, 6.25; N, 10.35. 
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4.2.2. Synthesis of compounds of series II (2a-i, 3a-c) 
4.2.2.1. Synthesis of 3-(1-naphthyl)propylamine (17) 
Amine 17 was prepared as previously reported and 1H- and 13C-NMR data are consistent 
with those described.125  
3-(1-naphthyl)propylamine (17).  
Yield: 70%. Yellowish oil. 
1H-NMR (CDCl3, δ): 1.80 (qt, J = 7.5 Hz, 2H, CH2), 2.65 (t, J = 7.3 Hz, 2H, CH2), 3.00 (t, J = 7.7 
Hz, 2H, CH2N), 7.20-7.43 (m, 4H, 4 x CH Ar), 7.60-7.61 (m, 1H, CH Ar), 7.70-7.80 (m, 1H, CH 
Ar), 7.95 (d, J = 7.6 Hz, 1H, CH Ar). 
13C-RMN (CD3OD, δ): 33.6, 36.0 (2 x CH2), 44.4 (CH2N), 127.2, 129.0, 129.3, 129.5, 130.3, 
132.2 (7 x CH Ar), 135.6, 137.9, 141.4 (3 x C Ar). 
4.2.2.2. General procedure for the synthesis of ethyl ω-[4-
(benzyloxy)phenoxy]alkanoates (11a,b) 
Ethyl 4-bromobutyrate or ethyl 5-bromovalerate (1.5 equiv), K2CO3 (2 equiv) and 18-
crown ether (0.1 equiv) were added to a solution of 4-benzyloxyphenol (1 equiv) in acetone (3 
mL x mmol). The mixture was refluxed overnight, then cooled to rt and the solvent was 
evaporated under reduced pressure. The residue was resuspended in water and extracted with 
diethyl ether. The organic layer was washed with 1 M NaOH and brine, dried over anhydrous 
Na2SO4 and the solvent was eliminated under reduced pressure to afford 11a,b as white solids 
that were purified by column chromatography. 
 
Ethyl 4-[4-(benzyloxy)phenoxy]butanoate (11a).  
1H-NMR data coincide with those previously described.126 
Chromatography: hexane → hexane:ethyl acetate, 9.5:0.5. Yield: 92%; mp: 53-55 ºC. 
IR (neat, cm-1): 1731 (C=O), 1507 (CAr-CAr), 1228, 1178 (C-O). 
1H-NMR (CDCl3, δ): 1.18 (t, J = 7.1 Hz, 3H, CH3), 2.00 (qt, J = 6.7 Hz, 2H, CH2), 2.43 (t, J = 7.3 
Hz, 2H, CH2CO), 3.87 (t, J = 6.1 Hz, 2H, CH2O), 4.06 (q, J = 7.1 Hz, 2H, CH2O), 4.93 (s, 2H, 
CH2O), 6.65-6.86 (m, 4H, 4 x CH Ar), 7.19-7.36 (m, 5H, 5 x CH Ar).  
13C-NMR (CDCl3, δ): 14.4 (CH3), 24.9 (CH2CO), 31.0 (CH2), 60.6, 67.5, 70.9 (3 x CH2O), 115.6, 
116.0, 127.6, 128.0, 128.7 (9 x CH Ar), 137.2, 152.9, 153.1 (3 x C Ar), 173.1 (CO). 
  
                                                     
125 See citation 65. 
126 Zhang, W. X.; Fan, C. Q.; Tu, B.; Zhao, X.; Jiang, X. K.; Li, Z. T. Chinese J. Chem. 2003, 21, 739-745. 
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Ethyl 5-[4-(benzyloxy)phenoxy]pentanoate (11b).  
1H-NMR data coincide with those previously described.127 
Chromatography: hexane → hexane:ethyl acetate, 9.5:0.5. Yield: 95%; mp: 55-57 ºC. 
IR (neat, cm-1): 1724 (C=O), 1512 (CAr-CAr), 1255, 1188 (C-O). 
1H-NMR (CDCl3, δ): 1.17 (t, J = 7.1 Hz, 3H, CH3), 1.65-1.85 (m, 4H, 2 x CH2), 2.30 (t, J = 7.1 
Hz, 2H, CH2CO), 3.83 (t, J = 5.8 Hz, 2H, CH2O), 4.04 (q, J = 7.1 Hz, 2H, CH2O), 4.92 (s, 2H, 
CH2O), 6.70-7.00 (m, 4H, 4 x CH Ar), 7.20-7.40 (m, 5H, 5 x CH Ar).  
13C-NMR (CDCl3, δ): 14.3 (CH3), 21.7, 28.8 (2 x CH2), 34.0 (CH2CO), 60.4, 68.0, 70.8 (3 x 
CH2O), 115.4, 116.0, 127.5, 128.0, 128.6 (9 x CH Ar), 137.5, 153.0, 153.5 (3 x C Ar), 173.6 
(CO). 
4.2.2.3. General procedure for the synthesis of ethyl ω-(4-
hydroxyphenoxy)alkanoates (12a,b). 
To a solution of 11a or 11b (1 equiv) in absolute ethanol (20 mL x mmol), 10% Pd(C) was 
added (50 mg x mmol), and the suspension was hydrogenated at rt at an initial pressure of 50 
psi, until disappearance of starting material. The reaction mixture was filtered over celite and the 
solvent was removed under vacuum to afford pure debenzylated 12a,b as amorphous solids 
which were purified by column chromatography. 
 
Ethyl 4-(4-hydroxyphenoxy)butanoate (12a).  
Chromatography: dichloromethane → dichloromethane:ethanol, 9.8:0.2. Yield: 92%. 
IR (neat, cm-1): 3390 (OH), 1731, 1707 (C=O), 1510 (CAr-CAr), 1230, 1211 (C–O). 
1H-NMR (CDCl3, δ): 1.17 (t, J = 7.1 Hz, 3H, CH3), 1.98 (qt, J = 6.7 Hz, 2H, CH2), 2.43 (t, J = 7.3 
Hz, 2H, CH2CO), 3.83 (t, J = 6.1 Hz, 2H, CH2O), 4.07 (q, J = 7.1 Hz, 2H, CH2O), 6.60-6.76 (m, 
4H, 4 x CH Ar). 
13C-NMR (CDCl3, δ): 14.2 (CH3), 24.7 (CH2), 31.0 (CH2CO), 60.8, 67.5 (2 x CH2O), 115.7, 116.1 
(4 x CH Ar), 150.0, 152.5 (2 x C Ar), 173.8 (CO). 
 
Ethyl 5-(4-hydroxyphenoxy)pentanoate (12b).  
1H-NMR data coincide with those previously described.128  
Chromatography: dichloromethane → dichloromethane:ethanol, 9.9:0.1. Yield: 80%. 
IR (neat, cm-1): 3393 (OH), 1731, 1707 (C=O), 1510 (CAr-CAr), 1230, 1212 (C–O). 
1H-NMR (CDCl3, δ): 1.05 (t, J = 7.1 Hz, 3H, CH3), 1.51-1.69 (m, 4H, 2 x CH2), 2.19 (t, J = 7.1 
Hz, 2H, CH2CO), 3.67 (t, J = 5.8 Hz, 2H, CH2O), 3.94 (q, J = 7.1 Hz, 2H, CH2O), 6.51-6.66 (m, 
4H, 4 x CH Ar).  
                                                     
127 Ikura, M.; Nakatani, S.; Yamamoto, S.; Habashita, H.; Sugiura, T.; Takahashi, K.; Ogawa, K.; Ohno, H.; Nakai, H.; 
Toda, M. Bioorg. Med. Chem. 2006,14, 4241-4252. 
128 See citation 129. 
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13C-NMR (CDCl3, δ): 14.3 (CH3), 21.5, 28.6 (2 x CH2), 33.9, (CH2CO) 60.6, 68.0 (2 x CH2O), 
115.6, 116.0 (4 x CH Ar), 150.0, 152.5 (2 x C Ar), 174.3 (CO). 
4.2.2.4. General procedure for the synthesis of N-substituted 4-(4-
hydroxyphenoxy)butanamides (13a-h) and 5-(4-
hydroxyphenoxy)pentanamides (14a-c). 
A solution of appropriate freshly distilled amine (2 equiv) and AlMe3 (2 equiv) was ice-
cooled and stirred for 1 h under argon atmosphere. Then a solution of 12a or 12b (1 equiv) in 
dry toluene (0.5 mL x mmol) was added and the reaction refluxed for 4 h. After evaporating the 
solvent to dryness, the crude oil was purified by column chromatography. 
 
4-(4-Hydroxyphenoxy)-N-(2-phenylethyl)butanamide (13a).  
Chromatography: hexane:ethyl acetate, 9:1 → 7:3. Yield: 51%.  
IR (neat, cm-1): 3296 (OH), 1644 (C=O), 1543 (N–CO), 1509 (NH), 1229 (C–OH). 
1H-NMR (CDCl3, δ): 2.07 (qt, J = 6.7 Hz, 2H, CH2), 2.34 (t, J = 7.2 Hz, 2H, CH2CO), 2.80 (t, J = 
6.9 Hz, 2H, CH2), 3.50-3.57 (m, 2H, CH2NH), 3.91 (t, J = 5.9 Hz, 2H, CH2O), 5.59 (br s, 1H, 
NH), 6.70-6.79 (m, 4H, 4 x CH Ar), 7.15-7.31 (m, 5H, 5 x CH Ar). 
13C-NMR (CDCl3, δ): 26.1 (CH2), 33.1 (CH2CO), 35.8 (CH2), 40.7 (CH2NH), 67.1 (CH2O), 115.7 
(2 x CH Ar), 116.2, 126.6, 128.8 (7 x CH Ar), 141.5, 150.3, 152.8 (3 x C Ar), 172.7 (CO). 
 
4-(4-Hydroxyphenoxy)-N-(3-phenylpropyl)butanamide (13b).  
Chromatography: hexane:ethyl acetate, 9:1 → 7:3. Yield: 71%.  
IR (neat, cm-1): 3294 (OH), 1642 (C=O), 1548 (N–CO), 1509 (NH), 1229 (C–OH). 
1H-NMR (CDCl3, δ): 1.81 (qt, J = 7.3 Hz, 2H, CH2), 2.05 (qt, J = 6.3 Hz, 2H, CH2), 2.34 (t, J = 
7.2 Hz, 2H, CH2CO), 2.62 (t, J = 7.7 Hz, 2H, CH2), 3.29 (q, J = 6.7 Hz, 2H, CH2NH), 3.90 (t, J = 
5.9 Hz, 2H, CH2O), 5.70 (br s, 1H, NH), 6.73-6.80 (m, 4H, CH Ar), 7.12-7.38 (m, 5H, CH Ar). 
13C-NMR (CDCl3, δ): 25.4, 31.2 (2 x CH2), 33.2, 33.4 (CH2, CH2CO), 39.4 (CH2NH), 67.6 
(CH2O), 115.5, 116.2, 126.0, 128.4, 128.6 (9 x CH Ar), 141.3, 150.2, 152.6 (3 x C Ar), 172.7 
(CO). 
 
4-(4-Hydroxyphenoxy)-N-(isobutyl)butanamide (13c).  
Chromatography: dichlromethane:ethyl acetate, 9:1 → 8:2. Yield: 76%.  
IR (neat, cm-1): 3217 (OH), 1643 (C=O), 1551 (N–CO), 1510 (NH), 1217 (C–OH). 
1H-NMR (CDCl3, δ): 0.80 (d, J = 6.6 Hz, 2 x CH3), 1.65 (sp, J = 6.7 Hz, 1H, CH), 1.98 (qt, J = 
6.6, 2H, CH2), 2.31 (t, J = 7.2 Hz, 2H, CH2CO), 3.00 (t, J = 6.4 Hz, 2H, CH2NH), 3.80 (t, J = 5.9 
Hz, 2H, CH2O), 5.90 (t, J = 5.7 Hz, 1H, NH), 6.60-6.70 (m, 4H, 4 x CH Ar), 7.50-7.70 (s, 1H, 
OH). 
13C-NMR (CDCl3, δ): 20.1 (2 x CH3), 27.1 (CH2), 28.5 (CH), 33.2 (CH2CO), 45.3 (CH2NH), 67.6 
(CH2O), 115.6, 116.1 (4 x CH Ar), 150.0, 152.0 (2 x C Ar), 173.0 (CO). 
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4-(4-Hydroxyphenoxy)-N-(3-methylbutyl)butanamide (13d).  
Chromatography: hexane:ethyl acetate, 1:1. Yield: 46%.  
IR (neat, cm-1): 3297 (OH), 1643 (C=O), 1550 (N–CO), 1509 (NH), 1228 (C–OH). 
1H-NMR (CDCl3, δ): 0.80 (d, J = 6.5 Hz, 6H, 2 x CH3), 1.26 (q, J = 7.4 Hz, 2H, CH2), 1.50 (sp, J 
= 6.7 Hz, 1H, CH), 1.94-2.11 (m, 2H, CH2), 2.31 (t, J = 7.2 Hz, 2H, CH2CO), 3.14-3.24 (m, 2H, 
CH2NH), 3.83 (t, J = 5.9 Hz, 2H, CH2O), 5.64 (br s, 1H, NH), 6.61-6.73 (m, 4H, 4 x CH Ar). 
13C-NMR (CDCl3, δ): 22.3 (2 x CH3), 25.4 (CH2), 25.7 (CH), 33.1 (CH2CO), 37.9, 38.3 (CH2NH, 
CH2), 67.5 (CH2O), 115.5, 116.0 (4 x CH Ar), 150.5, 152.5 (2 x C Ar), 172.9 (CO). 
 
N-(2-Ethylhexyl)-4-(4-hydroxyphenoxy)butanamide (13e).  
Chromatography: hexane:ethyl acetate, 8:2 → 6:4. Yield: 49%.  
IR (neat, cm-1): 3305 (OH), 1646 (C=O), 1552 (N–CO), 1511 (NH), 1231 (C–OH). 
1H-NMR (CDCl3, δ): 0.74-0.81 (m, 6H, 2 x CH3), 1.15-1.23 (m, 9H, 4 x CH2, CH), 2.00 (qt, J = 
6.5, 2H, CH2), 2.32 (t, J = 7.2 Hz, 2H, CH2CO), 3.12 (t, J = 5.9 Hz, 2H, CH2NH), 3.80 (t, J = 5.9 
Hz, 2H, CH2O), 5.70 (t, J = 5.5 Hz, 1H, NH), 6.60-6.73 (m, 4H, 4 x CH Ar), 7.30 (br s, 1H, OH). 
13C-NMR (CDCl3, δ): 10.6, 14.0 (2 x CH3), 23.0, 24.1, 25.5, 28.2, 30.9 (5 x CH2), 33.2 (CH2CO), 




Chromatography: hexane:ethyl acetate, 9:1 → 6:4. Yield: 82%.  
IR (neat, cm-1): 3267 (OH), 1640 (C=O), 1584 (CAr-CAr), 1533 (N–CO), 1509 (NH), 1227 (C–
OH). 
1H-NMR (CDCl3, δ): 1.89-2.01 (m, 2H, CH2), 2.26 (t, J = 7.1 Hz, 2H, CH2CO), 3.20 (t, J = 5.5 
Hz, 2H, CH2NH), 3.50 (q, J = 5.7 Hz, 2H, CH2NH), 3.70 (t, J = 5.8 Hz, 2H, CH2O), 4.93 (br s, 
1H, OH), 6.10 (t, J = 6.0 Hz, NH), 6.39 (d, J = 8.0 Hz, 1H, CH Ar), 6.48-6.60 (m, 4H, 4 x CH Ar), 
7.01-7.37 (m, 4H, 4 x CH Ar), 7.64-7.70 (m, 2H, 2 x CH Ar). 
13C-NMR (CDCl3, δ): 25.4 (CH2), 33.1 (CH2CO), 39.0, 45.0 (2 x CH2NH), 67.3 (CH2O), 103.7, 
115.5, 116.1, 117.4, 120.2, 124.9, 125.8, 126.5, 128.5 (11 x CH Ar), 134.2, 143.2, 150.1, 152.4 
(5 x C Ar), 174.4 (CO). 
 
4-(4-Hydroxyphenoxy)-N-[2-(dimethylamino)ethyl]butanamide (13g).  
Chromatography: ethyl acetate:ethanol, 8:2 → 7:3. Yield: 63%.  
IR (neat, cm-1): 3261 (OH), 1655 (C=O), 1552 (N–CO), 1510 (NH), 1222 (C–OH), 1053 (C-N).  
1H-NMR (CDCl3, δ): 1.94 (qt, J = 6.7 Hz, 2H, CH2), 2.24 (m, 6H, 2 x CH3), 2.45 (t, J = 6.2 Hz, 
2H, CH2CO ), 3.30-3.40 (m, 4H, CH2NH, CH2N), 3.75 (t, J = 6.1 Hz, 2H, CH2O), 6.40 (br s, 1H, 
NH), 6.64 (m, 4H, 4 x CH Ar). 
13C-NMR (CDCl3, δ): 25.2 (CH2), 32.7 (CH2CO), 36.3 (NCH2), 44.7 (2 x CH3), 58.0 (CH2NH), 
67.5 (CH2O), 115.5, 116.0 (4 x CH Ar), 150.4, 152.4 (2 x C Ar), 172.9 (CO). 
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4-(4-Hydroxyphenoxy)-N-[3-(1-naphthyl)propyl]butanamide (13h).  
Chromatography: dichloromethane → dichloromethane:ethyl acetate; 8:2. Yield: 76%. 
IR (neat, cm-1): 3294 (OH), 1643 (C=O), 1536 (N–CO), 1509 (NH), 1229 (C–OH).  
1H-NMR (CDCl3, δ): 1.94 (qt, J = 7.4 Hz, 2H, CH2), 2.03 (qt, J = 6.7 Hz, 2H, CH2), 2.32 (t, J = 
7.2 Hz, 2H, CH2CO), 3.08 (t, J = 7.6 Hz, 2H, CH2), 3.36 (q, J = 7.6 Hz, 2H, CH2NH), 3.88 (t, J = 
6.0 Hz, 2H, CH2O), 5.64 (br s, 1H, NH), 6.68-6.76 (m, 4H, 4 x CH Ar), 7.27 (d, J = 6.7 Hz, 1H, 
CH Ar), 7.38 (t, J = 7.6 Hz, 1H, CH Ar), 7.44-7.52 (m, 2H, 2 x CH Ar), 7.70 (d, J = 8.2 Hz, 1H, 
CH Ar), 7.85 (m, 1H, CH Ar), 7.98 (m, 1H, CH Ar). 
13C-NMR (CDCl3, δ): 25.8 (CH2), 30.7 (2 x CH2), 33.5 (CH2CO), 40.0 (CH2NH), 67.9 (CH2O), 
115.9, 116.5 (4 x CH Ar), 124.0 (CH Ar), 126.0 (2 x CH Ar), 126.4 (2 x CH Ar), 127.3, 129.2 (2 x 
CH Ar), 132.1, 134.3, 137.8, 150.9, 152.8 (5 x C Ar), 173.4 (CO). 
 
5-(4-Hydroxyphenoxy)-N-(2-phenylethyl)pentanamide (14a).  
Chromatography: hexane:ethyl acetate, 8:2 → 6:4. Yield: 95%.  
IR (neat, cm-1): 3292 (OH), 1643 (C=O), 1544 (N–CO), 1509 (NH), 1230 (C–OH). 
1H-NMR (CDCl3, δ): 1.61-1.70 (m, 4H, 2 x CH2), 2.12 (t, J = 6.9 Hz, 2H, CH2CO), 2.72 (t, J = 6.9 
Hz, 2H, CH2), 3.44 (q, J = 6.6 Hz, 2H, CH2NH), 3.72 (t, J = 5.6 Hz, 2H, CH2O), 5.70 (br s, 1H, 
NH), 6.59-6.71 (m, 4H, 4 x CH Ar), 7.08-7.23 (m, 5H, 5 x CH Ar). 
13C-NMR (CDCl3, δ): 22.5, 28.8 (2 x CH2), 35.6, 36.3 (CH2CO, CH2), 40.7 (CH2NH), 68.2 
(CH2O), 115.6, 116.2, 126.5, 128.5, 128.7 (9 x CH Ar), 138.6, 150.4, 152.4 (3 x C Ar), 173.3 
(CO). 
 
5-(4-Hydroxyphenoxy)-N-[2-[(1-naphthyl)amino]ethyl]pentanamide (14b).  
Chromatography: hexane:ethyl acetate, 8:2 → 6:4. Yield: 81%.  
IR (neat, cm-1): 3308 (OH), 1639 (C=O), 1581 (CAr-CAr), 1531 (N–CO), 1509 (NH), 1229 (C–
OH). 
1H-NMR (CDCl3, δ): 1.55-1.72 (m, 4H, 2 x CH2), 2.15 (t, J = 7.0 Hz, 2H, CH2CO), 3.20-3.28 (m, 
2H, CH2NH), 3.45-3.54 (m, 2H, CH2NH), 3.70 (t, J = 5.9 Hz, 2H, CH2O), 4.93 (br s, 1H, OH), 
6.06 (t, J = 6.0 Hz, 1H, NH), 6.42 (d, J = 7.5 Hz, 1H, CH Ar), 6.53-6.68 (m, 4H, 4 x CH Ar), 7.10-
7.37 (m, 4H, 4 x CH Ar), 7.64-7.70 (m, 2H, 2 x CH Ar). 
13C-NMR (CDCl3, δ): 23.0, 29.5, (2 x CH2), 36.2 (CH2CO), 39.0, 45.7 (2 x CH2NH), 68.6 (CH2O), 
103.6, 116.1, 116.4, 116.7, 121.6, 124.9, 126.2, 127.5, 128.9, (11 x CH Ar) 135.2, 145.0, 151.1, 
153.4 (5 x C Ar), 174.4 (CO). 
 
5-(4-Hydroxyphenoxy)-N-[3-(1-naphthyl)propyl]pentanamide (14c).  
Chromatography: hexane:ethyl acetate, 8:2 → 6:4. Yield: 42%.  
IR (neat, cm-1): 3274 (OH), 1640 (C=O), 1598 (N–CO), 1509 (NH), 1229 (C–OH). 
1H-NMR (CDCl3, δ): 1.60-1.80 (m, 4H, 2 x CH2), 1.90 (qt, J = 7.5 Hz, 2H, CH2), 2.02-2.20 (m, 
2H, CH2CO), 2.98-3.10 (m, 2H, CH2), 3.30 (q, J = 6.9 Hz, 2H, CH2NH), 3.71-3.90 (m, 2H, 
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OCH2), 5.50 (br s, 1H, NH), 6.66 (m, 4H, 4 x CH Ar), 7.23-7.47 (m, 4H, 4 x CH Ar), 7.60 (d, J = 
7.9 Hz, 1H, CH Ar), 7.76-7.80 (m, 1H, CH Ar), 7.90-7.95 (m, 1H, CH Ar). 
13C-NMR (CDCl3, δ): 22.6, 28.9, 30.4 (4 x CH2), 36.2 (CH2CO), 39.5 (CH2NH), 68.2 (CH2O), 
115.5, 116.0, 123.5, 125.5, 125.9, 126.8, 127.0, 128.8 (11 x CH Ar), 137.2, 150.0, 152.3 (5 x C 
Ar), 173.0 (CO). 
4.2.2.5.  General procedure for the synthesis of dibenzyl 4-{[ω-(alkylamino)-
ω-oxoalkyl]oxy}phenyl phosphates 15a-h and 16a-c. 
To a solution of the corresponding compound 13a-h or 14a-c (1 equiv) in acetonitrile (1 
mL x mmol), dibenzyl diisopropylphosphoramidite (1.5 equiv) and a solution of 1H-tetrazole in 
acetonitrile (2 equiv) were added. After vigorously stirring for 3 h under an argon atmosphere, 
the reaction was cooled to 0 ºC and 70% aqueous tert-butyl hydroperoxide (1 equiv) was added. 
After 1 h an aqueous solution of 10% Na2S2O3 (1 mL x mmol) was added, stirring was continued 
for 10 min, and the solution was then transferred to a separating funnel, extracted with 
dichloromethane and washed with 10% Na2S2O3 (10 mL x mmol) and brine. The organic layer 
was dried under anhydrous Na2SO4, the solvent removed by evaporation under reduced 
pressure, and the residue purified by column chromatography to obtain pure target compunds 
15a-h and 16a-c. 
 
Dibenzyl 4-{4-oxo-4-[(2-phenylethyl)amino]butoxy}phenyl phosphate (15a). 
Chromatography: dichloromethane:ethyl acetate, 9:1 → 6:4. Yield: 60%. Oil.  
IR (neat, cm-1): 3287 (NH), 1647 (C=O), 1547 (N–CO), 1505 (NH), 1211 (P–OC), 1081, 1020 
(C–OP). 
1H-NMR (CDCl3, δ): 1.90-2.20 (m, 2H, CH2), 2.25 (t, J = 7.0 Hz, 2H, CH2CO), 2.73 (t, J = 6.9 
Hz, 2H, CH2), 3.31-3.56 (m, 2H, CH2NH), 3.95 (t, J = 6.0 Hz, 2H, CH2O), 5.01 (s, 2H, CH2O), 
5.05 (s, 2H, CH2O), 5.50 (s, 1H, NH), 6.63 (d, J = 9.0 Hz, 2H, 2 x CH Ar), 6.93 (d, J = 9.0 Hz, 
2H, 2 x CH Ar), 7.07-7.29 (m, 15H, 15 x CH Ar). 
13C-NMR (CDCl3, δ): 31.0 (CH2), 32.6, 33.2 (CH2, CH2CO), 39.1 (CH2NH), 67.4 (CH2O), 69.7 (2 
x CH2O), 115.4, 120.8, 125.8, 127.5, 127.8, 128.2 (19 x CH Ar), 135.2, 141.4, 144.1, 155.9 (5 x 
C Ar), 172.3 (CO). 
 
Dibenzyl 4-{4-oxo-4-[(3-phenylpropyl)amino]butoxy}phenyl phosphate (15b). 
Chromatography: dichloromethane:ethyl acetate, 7:3. Yield: 40%. Oil. 
IR (neat, cm-1): 3304 (NH), 1649 (C=O), 1549 (N–CO), 1504 (NH), 1269, 1200 (P–OC), 1009, 
956 (C–OP). 
1H-NMR (CDCl3, δ): 1.80 (qt, J = 7.4 Hz, 2H, CH2), 2.07 (qt, J = 6.5 Hz, 2H, CH2), 2.34 (t, J = 
7.2 Hz, 2H, CH2CO), 2.61 (t, J = 7.7 Hz, 2H, CH2), 3.25 (q, J = 6.6 Hz, 2H, CH2NH), 3.89 (t, J = 
6.1 Hz, 2H, CH2O), 5.07 (s, 2H, CH2O), 5.11 (s, 2H, CH2O), 6.63 (t, J = 5.6 Hz, 1H, NH), 6.75 
(d, J = 9.0 Hz, 2H, 2 x CH Ar), 7.04 (d, J = 9.0 Hz, 2H, 2 x CH Ar), 7.12-7.34 (m, 15H, 15 x CH 
Ar). 
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13C-NMR (CDCl3, δ): 31.0 (2 x CH2), 32.6, 33.2 (CH2, CH2CO), 39.1 (CH2NH), 67.4 (CH2O), 
69.7 (2 x CH2O), 115.4, 120.8, 125.8, 127.5, 127.8, 128.2 (19 x CH Ar), 135.2, 141.4, 144.1, 
155.9 (5 x C Ar), 172.3 (CO). 
 
Dibenzyl 4-[4-(isobutylamino)-4-oxobutoxy]phenyl phosphate (15c). 
Chromatography: dichloromethane:ethyl acetate, 9:1 → 7:3. Yield: 75%. Amorphous solid. 
IR (neat, cm-1): 3320 (NH), 1650 (C=O), 1551 (N–CO), 1506 (NH), 1273, 1202 (P–OC), 1011, 
957 (C–OP). 
1H-NMR (CDCl3, δ): 0.80 (d, J = 6.6, 6H, 2 x CH3), 1.73 (sp, J = 6.0 Hz, 1H, CH), 2.1 (qt, J = 
6.0, 2H, CH2), 2.37 (t, J = 6.5 Hz, 2H, CH2CO), 3.06 (t, J = 6.0 Hz, 2H, CH2NH), 3.94 (t, J = 6.0 
Hz, 2H, CH2O), 5.07 (s, 2H, CH2O), 5.11 (s, 2H, CH2O), 5.82 (br s, 1H, NH), 6.76 (d, J = 9.0 Hz, 
2H, 2 x CH Ar), 7.03 (d, J = 9.0 Hz, 2H, 2 x CH Ar), 7.33 (m, 10H, 10 x CH Ar). 
13C-NMR (CDCl3, δ): 20.1 (2 x CH3), 25.3 (CH2), 28.5 (CH), 33.0 (CH2CO), 46.9 (CH2NH), 67.4 
(CH2O), 70.0 (2 x CH2O), 115.2, 121.0, 128.0, 128.6 (14 x CH Ar), 135.4, 144.1, 156.0 (4 x C 
Ar), 172.3 (CO). 
 
Dibenzyl 4-{4-[(3-methylbutyl)amino]-4-oxobutoxy}phenyl phosphate (15d). 
Chromatography: dichloromethane:ethyl acetate, 9:1 → 7:3. Yield: 41%. Amorphous solid. 
IR (neat, cm-1): 3297 (NH), 1644 (C=O), 1558 (N–CO), 1504 (NH), 1202 (P–OC), 1009, 963 
(C–OP). 
1H-NMR (CDCl3, δ): 0.76 (d, J = 6.5, 6H, 2 x CH3), 1.23 (q, J = 7.0 Hz, 2H, CH2), 1.46 (sp, J = 
6.7 Hz, 1H, CH), 1.94-2.02 (m, 2H, CH2), 2.30 (t, J = 7.2 Hz, 2H, CH2CO), 3.11 (q, J = 6.9 Hz, 
2H, CH2NH), 3.83 (t, J = 6.1 Hz, 2H, CH2O), 4.95 (s, 2H, CH2O), 5.00 (s, 2H, CH2O), 6.40 (br s, 
1H, NH), 6.64 (d, J = 9.0 Hz, 2H, 2 x CH Ar), 6.92 (d, J = 9.0 Hz, 2H, 2 x CH Ar), 7.19 (m, 10H, 
10 x CH Ar). 
13C-NMR (CDCl3, δ): 22.3 (2 x CH3), 25.1 (CH2), 25.5 (CH), 32.5 (CH2CO), 37.8, 38.5 (CH2NH, 
CH2), 67.7 (CH2O), 70.0 (2 x CH2O), 115.1, 120.7, 127.8, 128.5 (14 x CH Ar), 135.5, 144.1, 
156.2 (4 x C Ar), 172.5 (CO). 
 
Dibenzyl 4-{4-[(2-ethylhexyl)amino]-4-oxobutoxy}phenyl phosphate (15e). 
Chromatography: dichloromethane:ethyl acetate, 9:1 → 8:2. Yield: 65%. Oil. 
IR (neat, cm-1): 3325 (NH), 1649 (C=O), 1549 (N–CO), 1504 (NH), 1270, 1200 (P–OC), 1009, 
955 (C–OP). 
1H-NMR (CDCl3, δ): 0.82-0.88 (m, 6H, 2 x CH3), 1.21-1.32 (m, 9H, 4 x CH2, CH), 2.08 (qt, J = 
6.0 Hz, 2H, CH2), 2.35 (t, J = 7.2 Hz, 2H, CH2CO), 3.14-3.19 (m, 2H, CH2NH), 3.91 (t, J = 5.9 
Hz, 2H, CH2O), 5.07 (s, 2H, CH2O), 5.09 (s, 2H, CH2O), 5.98 (t, J = 6.3 Hz, 1H, NH), 6.75 (d, J 
= 9.0 Hz, 2H, 2 x CH Ar), 7.02 (d, J = 9.0 Hz, 2H, 2 x CH Ar), 7.31 (m, 10H, 10 x CH Ar). 
13C-NMR (CDCl3, δ): 11.2, 14.5 (2 x CH3), 23.4, 24.5, 25.6, 29.2, 31.3 (5 x CH2), 33.2 (CH2CO), 
39.7 (CH), 42.7 (CH2NH), 67.8, 70.2, 70.3 (3 x CH2O), 115.6, 121.3, 128.3, 129.0 (14 x CH Ar), 
135.8, 144.5, 156.5 (4 x C Ar), 172.7 (CO). 
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Dibenzyl 4-(4-{[2-[(1-naphthyl)amino]ethyl]amino}-4-oxobutoxy)phenyl phosphate 
(15f). 
Chromatography: dichloromethane:ethyl acetate, 8:2 → 1:1. Yield: 30%; mp: 91-92 ºC. 
IR (neat, cm-1): 3266 (NH), 1652 (C=O), 1551 (N–CO), 1504 (NH), 1246, 1205 (P–OC), 1081, 
935 (C–OP). 
1H-NMR (CDCl3, δ): 1.90-2.04 (m, 2H, CH2), 2.31 (t, J = 7.2 Hz, 2H, CH2CO), 3.22 (t, J = 5.4 
Hz, 2H, CH2NH), 3.53 (q, J = 5.6 Hz, 2H, CH2NH), 3.78 (t, J = 6.0 Hz, 2H, CH2O), 5.10 (s, 2H, 
CH2O), 5.12 (s, 2H, CH2O), 6.26 (br s, 1H, NH), 6.42 (m, 1H, NH), 6.61 (d, J = 9.0 Hz, 2H, 2 x 
CH Ar), 6.91 (d, J = 9.0 Hz, 2H, 2 x CH Ar), 7.14-7.41 (m, 15H, 15 x CH Ar), 7.69-7.95 (m, 2H, 2 
x CH Ar). 
13C-NMR (CDCl3, δ): 25.3 (CH2), 32.8 (CH2CO), 37.7 (CH2NH), 44.0 (CH2NH), 67.3 (CH2O), 
70.0 (2 x CH2O), 115.4, 120.6, 121.0, 126.0, 126.7, 128.1, 128.7 (21 x CH Ar), 134.4, 135.4, 
143.2, 156.1 (7 x C Ar), 173.8 (CO). 
 
Dibenzyl 4-(4-{[2-(dimethylamino)ethyl]amino}-4-oxobutoxy)phenyl phosphate (15g). 
Chromatography: ethyl acetate:ethanol, 9:1 → 6:4. Yield: 36%. Oil. 
IR (neat, cm-1): 3320 (NH), 1655 (C=O), 1552 (N–CO), 1510 (NH), 1270, 1900 (P–OC), 1011, 
955 (C–OP).  
1H-NMR (CDCl3, δ): 1.90-2.30 (m, 2H, CH2), 2.32 (s, 6H, 2 x CH3), 2.62 (t, J = 5.7 Hz, 2H, 
CH2CO), 3.29-3.43 (m, 4H, CH2NH, CH2N), 3.80 (t, J = 6.2 Hz, 2H, CH2O), 5.0 (s, 2H, CH2O), 
5.04 (s, 2H, CH2O), 6.59-6.73 (m, 2H, 2 x CH Ar), 6.90-6.94 (m, 2H, 2 x CH Ar), 6.97-7.03 (m, 
10H, 10 x CH Ar). 
13C-NMR (CDCl3, δ): 24.8 (CH2), 29.8 (CH2CO), 42.9 (NCH2), 49.5 (2 x CH3), 50.2 (NCH2), 67.5 
(CH2O), 70.3 (2 x CH2O), 114.9, 120.8, 126.7, 127.4, 128.3, 129.0, 132.7 (14 x CH Ar), 137.9, 
146.0, 154.5 (4 x C Ar), 173.7 (CO). 
 
Dibenzyl 4-(4-{[3-(1-naphthyl)propyl]amino}-4-oxobutoxy)phenyl phosphate (15h). 
Chromatography: dichloromethane:ethyl acetate; 9:1 → 8.5:1.5. Yield: 58%. Oil. 
IR (neat, cm-1): 3314 (NH), 1647 (C=O), 1649 (N–CO), 1506 (N–H), 1202 (P–OC), 1011, 958 
(C–OP). 
1H-NMR (CDCl3, δ): 1.95 (qt, J = 7.4 Hz, 2H, CH2), 2.05 (qt, J = 6.7 Hz, 2H, CH2), 2.29 (t, J = 
7.3 Hz, 2H, CH2CO), 3.10 (t, J = 7.6 Hz, 2H, CH2), 3.36 (q, J = 6.7 Hz, 2H, CH2NH), 3.90 (t, J = 
6.0 Hz, 2H, OCH2), 5,08 (s, 2H, CH2O), 5,10 (s, 2H, CH2O), 5.68 (t, J = 5.3 Hz, 1H, NH), 6.75 
(m, 2H, 2 x CH Ar), 7.03 (m, 2H, 2 x CH Ar), 7.28-7.52 (m, 14H, 14 x CH Ar), 7.71 (d, J = 8.1 
Hz, 1H, CH Ar), 7.82-7.85 (m, 1H, CH Ar), 7.97-8.00 (m, 1H, CH Ar). 
13C-NMR (CDCl3, δ): 25.6 (CH2), 30.8 (2 x CH2), 33.3 (CH2CO), 39.5 (CH2NH), 67.7 (CH2O), 
70.2 (2 x CH2O), 115.6 (2 x CH Ar), 121.3 (2 x CH Ar), 123.9 (CH Ar), 125.9 (2 x CH Ar), 126.4 
(2 x CH Ar), 127.3 (CH Ar), 128.4 (4 x CH Ar), 129.0 (6 x CH Ar), 129.3 (CH Ar), 132.1, 134.3, 
135.8, 135.9, 137.8, 142.5, 156.4 (7 x C Ar), 172.7 (CO). 
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Dibenzyl 4-({5-oxo-5-[(2-phenylethyl)amino]pentyl}oxy)phenyl phosphate (16a). 
Chromatography: hexane:ethyl acetate, 9:1 → 6:4. Yield: 51%. Amorphous solid. 
IR (neat, cm-1): 3311 (NH), 1646 (C=O), 1547 (N–CO), 1504 (NH), 1274, 1200 (P–OC), 1009, 
955 (C–OP). 
1H-NMR (CDCl3, δ): 1.62-1.71 (m, 4H, 2 x CH2), 2.11 (t, J = 6.0 Hz, 2H, CH2CO), 2.73 (t, J = 6.0 
Hz, 2H, CH2), 3.41-3.47 (m, 2H, CH2NH), 3.81 (t, J = 6.0 Hz, 2H, CH2O), 5,01 (s, 2H, CH2O), 
5.04 (s, 2H, CH2O), 5.50 (br s, 1H, NH), 6.68 (d, J = 9.0 Hz, 2H, 2 x CH Ar), 6.68 (d, J = 9.0 Hz, 
2H, 2 x CH Ar), 7.09-7.25 (m, 15H, 15 x CH Ar). 
13C-NMR (CDCl3, δ): 22.4, 28.7 (2 x CH2), 35.8, 36.3 (CH2, CH2CO), 41.0 (CH2NH), 68.0 
(CH2O), 70.0 (2 x CH2O), 115.3, 121.0, 126.5, 128.5, 129.0 (19 x CH Ar), 135.5, 138.9, 144.1, 
156.1 (5 x C Ar), 173.3 (CO). 
 
Dibenzyl 4-[(5-{[2-[(1-naphthyl)amino]ethyl]amino}-5-oxopentyl)oxy]phenyl phosphate 
(16b). 
Chromatography: hexane:ethyl acetate, 8:2 → 6:4. Yield: 37%; mp: 94-95 ºC. 
IR (neat, cm-1): 3278 (NH), 1652 (C=O), 1548 (N–CO), 1504 (NH), 1246, 1205 (P–OC), 1023, 
936 (C–OP). 
1H-NMR (CDCl3, δ): 1.61-1.77 (m, 4H, 2 x CH2), 2.19 (t, J = 7.0 Hz, 2H, CH2CO), 3.31 (t, J = 5.4 
Hz, 2H, CH2NH), 3.50-3.70 (m, 2H, CH2NH), 3.74 (t, J = 5.9 Hz, 2H, CH2O), 5.00 (s, 2H, CH2O), 
5.04 (s, 2H, CH2O), 6.18 (br s, 1H, NH), 6.50 (d, J = 7.2 Hz, 1H, CH Ar), 6.62 (d, J = 7.5 Hz, 2H, 
2 x CH Ar), 6.93 (d, J = 7.5 Hz, 2H, 2 x CH Ar), 7.12-7.38 (m, 14H, 14 x CH Ar), 7.70-7.82 (m, 
2H, 2 x CH Ar).  
13C-NMR (CDCl3, δ): 23.0, 29.5 (2 x CH2), 36.2 (CH2CO), 39.0, 45.7 (2 x CH2NH), 68.0, 70.0 (3 
x CH2O), 115.2, 120.9, 123.6, 125.6, 126.0, 126.9, 128.0, 128.6, 128.8 (21 x CH Ar), 131.7, 
133.9, 135.4, 137.5, 142.5, 156.1 (7 x C Ar), 172,5 (CO). 
 
Dibenzyl 4-[(5-{[3-(1-naphthyl)propyl]amino}-5-oxopentyl)oxy]phenyl phosphate (16c). 
Chromatography: hexane:ethyl acetate, 9:1 → 6:4. Yield: 56%. Oil. 
IR (neat, cm-1): 3305 (NH), 1647 (C=O), 1547 (N–CO), 1504 (NH), 1267, 1200 (P–OC), 1009, 
956 (C–OP). 
1H-NMR (CDCl3, δ): 1.60-1.80 (m, 4H, 2 x CH2), 1.90 (qt, J = 7.5 Hz, 2H, CH2), 2.02-2.20 (m, 
2H, CH2CO), 2.98-3.10 (m, 2H, CH2), 3.30 (q, J = 6.9 Hz, 2H, CH2NH), 3.71-3.90 (m, 2H, 
OCH2), 5,00 (s, 2H, CH2O), 5,03 (s, 2H, CH2O), 5.50 (br s, 1H, NH), 6.67 (d, J =9.0 Hz, 2H, 2 x 
CH Ar), 6.95 (d, J =9.0 Hz, 2H, 2 x CH Ar), 7.23-7.47 (m, 14H, 14 x CH Ar), 7.60 (d, J = 7.9 Hz, 
1H, CH Ar), 7.76-7.80 (m, 1H, CH Ar), 7.90-7.95 (m, 1H, CH Ar). 
13C-NMR (CDCl3, δ): 22.6, 28.7, 30.5 (4 x CH2), 36.2 (CH2CO), 39.5 (CH2NH), 68.0, 70.0 (3 x 
CH2O), 115.2, 120.9, 123.6, 125.6, 126.0, 126.9, 128.0, 128.6 128.8 (21 x CH Ar), 131.7, 133.9, 
135.4, 137.5, 142.5, 156.1 (7 x C Ar), 172.5 (CO). 
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4.2.2.6. General procedure for the synthesis of 4-{[ω-(alkylamino)-ω-
oxoalkyl]oxy}phenyl dihydrogen phosphates 2a-i and 3a-c. 
Final compounds 2a-i and 3a-c were obtained from their corresponding benzylated 
precursors 15a-h and 16a-c (1 equiv) following the general procedure previously described in 
5.2.1.6. Derivative 2i was obtained after 48 h of hydrogenation of its precursor 15h. 
 
4-{4-Oxo-4-[(2-phenylethyl)amino]butoxy}phenyl dihydrogen phosphate (2a). 
Yield: 72%; mp: 169-173 ºC (methanol/chloroform). 
IR (neat, cm-1): 3300 (OH), 1641 (C=O), 1553 (N–CO), 1505 (NH), 1202 (P–OC), 1028, 968 
(C–OP). 
1H-NMR (CD3OD, δ): 1.86-1.93 (m, 2H, CH2), 2.23 (t, J = 7.3 Hz, 2H, CH2CO), 2.67 (t, J = 7.2 
Hz, 2H, CH2), 3.30 (t, J = 7.2 Hz, 2H, CH2NH), 3.79 (t, J = 6.0 Hz, 2H, CH2O), 6.70 (d, J = 7.8 
Hz, 2H, 2 x CH Ar), 7.01-7.18 (m, 7H, 7 x CH Ar). 
13C-NMR (CD3OD, δ): 26.6 (CH2), 33.4 (CH2CO), 36.4 (CH2), 41.8 (CH2NH), 68.4 (CH2O), 
115.9, 122.2, 127.2, 129.3, 129.6 (9 x CH Ar), 142.3, 156.5 (3 x C Ar), 174.3 (CO). 
MS (ESI): 378.2 (M-H)-. Anal. Calcd. for C18H22NO6P: C, 56.99; H, 5.85; N, 3.69. Found: C, 
56.64; H, 5.60; N, 3.70. 
 
4-{4-Oxo-4-[(3-phenylpropyl)amino]butoxy}phenyl dihydrogen phosphate (2b). 
Yield: 52%; mp: 145-147 ºC (methanol/chloroform). 
IR (neat, cm-1): 3278 (OH), 1643 (C=O), 1572 (N–CO), 1504 (NH), 1202 (P–OC), 966 (C–OP). 
1H-NMR (CD3OD, δ): 1.77 (qt, J = 7.2 Hz, 2H, CH2), 1.90-2.15 (m, 2H, CH2), 2.36 (t, J = 7.2 Hz, 
2H, CH2CO), 2.55 (t, J = 7.2 Hz, 2H, CH2), 3.18 (t, J = 7.0 Hz, 2H, CH2NH), 3.93 (t, J = 6.1 Hz, 
2H, CH2O), 6.84 (m, 2H, 2 x CH Ar), 7.00-7.30 (m, 7H, 7 x CH Ar). 
 13C-NMR (CD3OD, δ): 26.8, 32.3 (2 x CH2), 33.7, 34.2 (CH2, CH2CO), 40.1 (CH2NH), 68.7 
(CH2O), 116.1, 116.6, 116.8, 122.4, 127.0, 127.9, 129.4, 130.4, 135.5 (9 CH Ar), 143.5, 157.0 
(3 C Ar), 173.2 (CO). 
MS (ESI): 392.0 (M-H)-. Anal. Calcd. for C19H24NO6P: C, 58.01; H, 6.15; N, 3.56. Found: C, 
57.95; H, 5.85; N, 3.75.  
 
4-[4-(Isobutylamino)-4-oxobutoxy]phenyl dihydrogen phosphate (2c). 
Yield: 65%; mp: 167-170 ºC (methanol/chloroform). 
IR (neat, cm-1): 3299 (OH), 1642 (C=O), 1553 (N–CO), 1506 (NH), 1208 (P–OC), 969 (C–OP). 
1H-NMR (CD3OD, δ): 0.96 (d, J = 6.7 Hz, 6H, 2 x CH3), 1.83 (sp, J = 6.7 Hz, 1H, CH), 2.12 (qt, J 
= 6.6 Hz, 2H, CH2), 2.46 (t, J = 7.3 Hz, 2H, CH2CO), 3.06 (d, J = 6.9 Hz, 2H, CH2NH), 4.02 (t, J 
= 6.1 Hz, 2H, CH2O), 6.90 (d, J = 8.2 Hz, 2H, 2 x CH Ar), 7.20 (d, J = 8.2 Hz, 2H, 2 x CH Ar). 
13C-NMR (CD3OD, δ): 20.3 (2 x CH3), 26.7 (CH2), 29.5 (CH), 33.5 (CH2CO), 47.8 (CH2NH), 68.4 
(CH2O), 115.9, 122.2 (4 x CH Ar), 147.0, 157.0 (2 x C Ar), 176.0 (CO). 
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MS (ESI): 330.0 (M-H)-. Anal. Calcd. for C14H22NO6P: C, 50.75; H, 6.69; N, 4.23. Found: C, 
51.08; H, 6.98; N, 4.23.  
 
4-{4-[(3-Methylbutyl)amino]-4-oxobutoxy}phenyl dihydrogen phosphate (2d). 
Yield: 63%; mp: 167-168 ºC (ethanol/chloroform).  
IR (neat, cm-1): 3298 (OH), 1640 (C=O), 1594 (N–CO), 1511 (NH), 1217, 1166 (P–OC), 1032, 
996 (C–OP). 
1H-NMR (CD3OD, δ): 0.80 (d, J = 7.0, 6H, 2 x CH3), 1.18-1.31 (m, 2H, CH2), 1.40-1.60 (m, 1H, 
CH), 1.80-2.05 (m, 2H, CH2), 2.15-2.38 (m, 2H, CH2CO), 3.10 (t, J = 7.0 Hz, 2H, CH2NH), 3.70-
3.92 (m, 2H, CH2O), 6.60-7.20 (m, 4H, 4 x CH Ar). 
 13C-NMR (CD3OD, δ): 22.9 (2 x CH3), 26.8 (CH2), 27.0 (CH), 33.7 (CH2CO), 38.7, 39.4 
(CH2NH, CH2), 68.7 (CH2O), 116.4, 122.5 (4 x CH Ar), 152.5, 157.1 (2 x C Ar), 173.6 (CO). 
MS (ESI): 344.0 (M-H)-. Anal. Calcd. for C15H24NO6P: C, 52.17; H, 7.01; N, 4.06. Found: C, 
52.13; H, 6.80; N, 4.12. 
 
4-{4-[(2-Ethylhexyl)amino]-4-oxobutoxy}phenyl dihydrogen phosphate (2e). 
Yield: 62%; mp: 177-179 ºC (methanol/chloroform). 
IR (neat, cm-1): 3296 (OH), 1656 (C=O), 1591 (N–CO), 1511 (NH), 1217, 1166 (P–OC), 997 
(C–OP). 
1H-NMR (CD3OD, δ): 0.69-0.95 (m, 6H, 2 x CH3), 1.13-1.39 (m, 9H, 4 x CH2, CH), 1.90 (qt, J = 
6.6 Hz, 2H, CH2), 2.23 (t, J = 7.2 Hz, 2H, CH2CO), 2.97 (d, J = 6.0 Hz, 2H, CH2NH), 3.80 (t, J = 
6.1 Hz, 2H, CH2O), 6.72 (d, J = 8.9 Hz, 2H, 2 x CH Ar), 6.98 (d, J = 8.5 Hz, 2H, 2 x CH Ar). 
13C-NMR (CD3OD, δ): 11.2, 14.4 (2 x CH3), 24.1, 25.2, 26.8, 30.0, 32.0 (5 x CH2), 33.5 
(CH2CO), 40.6 (CH), 43.4 (CH2NH), 68.6 (CH2O), 116.2, 122.2 (4 x CH Ar), 147.8, 158.8 (2 x C 
Ar), 175.6 (CO). 
MS (ESI): 386.1 (M-H)-. Anal. Calcd. for C18H30NO6P: C, 55.80; H, 7.81; N, 3.62. Found: C, 
55.46; H, 7.55; N, 3.74. 
 
4-(4-{[2-[(1-Naphthyl)amino]ethyl]amino}-4-oxobutoxy)phenyl dihydrogen phosphate 
(2f). 
Yield: 47%; mp: 82-84 ºC (methanol/chloroform). 
IR (neat, cm-1): 3286 (OH), 1641 (C=O), 1581 (CAr-CAr), 1535 (N–CO), 1504 (NH), 1207 (P–
OC), 1046, 943 (C–OP). 
1H-NMR (CD3OD, δ): 1.95 (qt, J = 6.0 Hz, 2H, CH2), 2.31 (t, J = 7.1 Hz, 2H, CH2CO), 3.20-3.30 
(m, 2H, CH2NH), 3.41-3.45 (m, 2H, CH2NH), 3.77 (t, J = 6.1 Hz, 2H, CH2O), 6.60-6.75 (m, 3H, 3 
x CH Ar), 6.95-7.34 (m, 6H, 6 x CH Ar), 7.64-7.68 (m, 1H, CH Ar), 7.85-7.89 (m, 1H, CH Ar). 
13C-NMR (CD3OD, δ): 26.6 (CH2), 33.6 (CH2CO), 39.5, 45.8 (2 x CH2NH), 68.4 (CH2O), 116.0, 
121.7, 122.2, 125.6, 126.6, 127.3, 129.3 (11 x CH Ar) 135.8, 144.1, 146.8, 156.7 (5 x C Ar), 
174.4 (CO). 
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MS (ESI): 443.3 (M-H)-. Anal. Calcd. for C22H25N2O6P: C, 59.46; H, 5.67; N, 6.30. Found: C, 
59.11; H, 5.33; N, 5.87. 
 
4-(4-{[2-(Dimethylamino)ethyl]amino}-4-oxobutoxy)phenyl dihydrogen phosphate (2g). 
Yield: 82%; mp: 175-176 ºC (methanol/chloroform). 
IR (neat, cm-1): 3247 (OH), 1656(C=O), 1556 (N–CO), 1505 (NH), 1215 (P–OC), 1099, 1049 
(C–OP). 
1H-NMR (CD3OD, δ): 2.10 (qt, J = 6.5 Hz, 2H, CH2), 2.48 (t, J = 7.1 Hz, 2H, CH2CO), 2.90 (s, 
6H, 2 x CH3), 3.25 (t, J = 6.2 Hz, 2H, CH2NH), 3.58 (t, J = 6.1 Hz, 2H, NCH2), 4.09 (t, J = 5.9 Hz, 
2H, CH2O), 7.00 (d, J = 9.1 Hz, 2H, 2 x CH Ar), 7.20 (d, J = 8.5 Hz, 2H, 2 x CH Ar). 
13C-NMR (CD3OD, δ): 24.7 (CH2), 32.5 (CH2CO), 34.6 (NCH2), 43.0 (2 x CH3), 56.6 (CH2N), 
68.0 (CH2O), 115.8, 121.6 (4 x CH Ar), 146.3, 154.2 (2 x C Ar), 177.1 (CO). 
MS (ESI): 345.0 (M-H)-. Anal. Calcd. for C14H23N2O6P: C, 48.55; H, 6.69; N, 8.09. Found: C, 
48.67; H, 6.98; N, 7.86. 
 
4-(4-{[3-(1-Naphthyl)propyl]amino}-4-oxobutoxy)phenyl dihydrogen phosphate (2h).  
Yield: 47%; mp: 169-171 ºC (diethyl ether). 
IR (DCM, cm-1): 3294 (O–H), 1641 (C=O), 1505 (N–H), 1205 (P–OC), 958 (C–OP). 
1H-NMR (CD3OD, δ): 1.92 (qt, J = 7.4 Hz, 2H, CH2), 2.05 (qt, J = 6.7 Hz, 2H, CH2), 2.39 (t, J = 
7.4 Hz, 2H, CH2CO), 3.09 (t, J = 7.8 Hz, 2H, CH2), 3.27 (m, 2H, CH2NH), 3.95 (t, J = 5.9 Hz, 2H, 
OCH2), 6.83 (m, 2H, 2 x CH Ar), 7.10 (m, 2H, 2 x CH Ar), 7.30-7.51 (m, 4H, 4 x CH Ar), 7.69 (d, 
J = 7.9 Hz, 1H, CH Ar), 7.82-7.85 (m, 1H, CH Ar), 8.02-8.05 (m, 1H, CH Ar).  
13C-NMR (CD3OD, δ): 25.7, 30.3, 30.6 (3 x CH2), 32.7 (CH2CO), 39.4 (CH2NH), 67.6 (CH2O), 
115.1 (2 x CH Ar), 121.3 (2 x CH Ar), 123.7, 125.5, 125.6, 125.9, 126.1, 126.7, 128.8 (7 x CH 
Ar), 132.1, 134.5, 138.3, 146.5, 155.9 (5 x C Ar), 174.9 (CO). 
MS (ESI): 442.0 (M-H)-. Anal. Calcd. for C23H26NO6P: C, 62.30; H, 5.91; N, 3.16. Found: C, 
61.85; H, 5.73; N, 3.24. 
 
4-(4-Oxo-4-{[3-(5,6,7,8-tetrahydronaphthalen-1-yl)propyl]amino}butoxy)phenyl 
dihydrogen phosphate (2i). 
Yield: 71%; mp: 157-159 ºC (diethyl ether). 
IR (neat, cm-1): 3293 (O–H), 1642 (C=O), 1507 (N–H), 1211 (P–OC), 956 (C–OP). 
1H-NMR (CD3OD, δ): 1.53-1.81 (m, 7H, 3 x CH2, ½ CH2), 2.05 (qt, J = 6.5 Hz, 2H, CH2), 2.37 (t, 
J = 7.1 Hz, 2H, CH2CO), 2.54-2.59 (m, 1H, ½ CH2), 2.65-2.76 (m, 4H, 2 x CH2), 3.30-3.33 (m, 
2H, CH2NH), 3.91-3.97 (m, 2H, OCH2), 6.81-7.13 (m, 7H, 7 x CH Ar). 
13C-NMR (CD3OD, δ): 24.1, 24.7, 26.8, 27.1, 31.0, 31.2, 33.7, 35.2 (8 x CH2), 40.4 (CH2NH), 
68.6 (CH2O), 115.9 (2 x CH Ar), 122.3 (CH Ar), 126.3 (2 x CH Ar), 127.2, 128.2 (2 x CH Ar), 
135.7, 138.3, 140.8, 142.1, 156.6 (5 x C Ar), 175.5 (CO). 
MS (ESI): 446.5 (M-1)-. Anal. Calcd. for C23H30NO6P: C, 61.74; H, 6.76; N, 3.13. Found: C, 
61.50; H, 6.75; N, 3.09. 
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4-({5-Oxo-5-[(2-phenylethyl)amino]pentyl}oxy)phenyl dihydrogen phosphate (3a). 
Yield: 58%; mp: 187-189 ºC (methanol/chloroform). 
IR (neat, cm-1): 3282 (OH), 1643 (C=O), 1555 (N–CO), 1504 (NH), 1246, 1203 (P–OC), 1021, 
964 (C–OP). 
1H-NMR (CD3OD, δ): 1.50-1.75 (m, 4H, 2 x CH2), 2.00-2.20 (m, 2H, CH2CO), 2.70 (t, J = 7.3 Hz, 
2H, CH2), 3.31 (t, J = 7.3 Hz, 2H, CH2NH), 3.70-3.90 (m, 2H, CH2O), 6.75 (d, J = 9.0 Hz, 2H, 2 x 
CH Ar), 7.00-7.20 (m, 7H, 7 x CH Ar). 
 13C-NMR (CD3OD, δ): 23.6, 29.7 (2 x CH2), 36.5, 36.7 (CH2CO, CH2), 41.8 (CH2NH), 69.0 
(CH2O), 116.1, 122.5, 127.5, 129.6, 130.0 (9 x CH Ar), 140.7, 157.4 (3 x C Ar), 176.0 (CO). 
MS (ESI): 392.0 (M-H)-. Anal. Calcd. for C19H24NO6P: C, 58.01; H, 6.15; N, 3.56. Found: C, 




Yield: 43%; mp: 65-67 ºC (methanol/chloroform). 
IR (neat, cm-1): 3297 (OH), 1641 (C=O), 1581 (CAr-CAr), 1530 (N–CO), 1509 (NH), 1230 (P–
OC), 1059, 935 (C–OP). 
1H-NMR (CD3OD, δ): 1.60-1.77 (m, 4H, 2 x CH2), 2.25 (t, J = 7.0 Hz, 2H, CH2CO), 3.30 (t, J = 
6.0 Hz, 2H, CH2NH), 3.55-3.64 (m, 2H, CH2NH), 3.80 (t, J = 6.0 Hz, 2H, CH2O), 6.52 (d, J = 7.0 
Hz, 1H, CH Ar), 6.60-6.71 (m, 4H, 4 x CH Ar), 7.09 (d, J = 8.0 Hz, 1H, CH Ar), 7.23 (d, J = 7.7 
Hz, 1H, CH Ar), 7.31-7.41 (m, 2H, CH Ar), 7.62-7.74 (m, 1H, CH Ar), 7.96-8.01 (m, 1H, CH Ar). 
13C-NMR (CD3OD, δ): 23.7, 29.9 (2 x CH2), 36.8 (CH2CO), 39.7, 45.2 (2 x CH2NH), 68.2 
(CH2O), 104.6, 116.7, 117.8, 121.8, 125.4, 126.6, 127.6, 129.3 (11 x CH Ar), 135.9, 140.8, 
145.1, 157.3 (5 x C Ar), 176.9 (CO). 
MS (ESI): 457.2 (M-H)-. Anal. Calcd. for C23H27N2O6P: C, 60.26; H, 5.94; N, 6.11. Found: C, 
60.03; H, 6.02; N, 6.41. 
 
4-[(5-{[3-(1-Naphthyl)propyl]amino}-5-oxopentyl)oxy]phenyl dihydrogen phosphate 
(3c). 
Yield: 45%; mp: 135-137 ºC (methanol/chloroform). 
IR (neat, cm-1): 3274 (OH), 1644 (C=O), 1557 (N–CO), 1504 (NH), 1203 (P–OC), 964 (C–OP). 
1H-NMR (CD3OD, δ): 1.60-1.80 (m, 4H, 2 x CH2), 1.87-1.93 (m, 2H, CH2), 2.04-2.24 (m, 2H, 
CH2CO), 2.99-3.12 (m, 2H, CH2), 3.25-3.35 (m, 2H, CH2NH), 3.75-3.85 (m, 2H, OCH2), 6.73 (d, 
J = 9.0 Hz, 2H, 2 x CH Ar), 7.10 (d, J = 9.0 Hz, 2H, 2 x CH Ar), 7.23-7.47 (m, 4H, 4 x CH Ar), 
7.56-7.62 (m, 1H, CH Ar), 7.66-7.80 (m, 1H, CH Ar), 7.90-7.95 (m, 1H, CH Ar). 
13C-NMR (CD3OD, δ): 23.6, 29.8, 31.2, 31.6 (4 x CH2), 36.7 (CH2CO), 40.3 (CH2NH), 68.9 
(CH2O), 116.0, 116.6, 122.2, 124.6, 126.4, 126.5, 126.8, 127.7, 129.7 (11 x CH Ar), 131.5, 
133.7, 137.2, 148.5, 156.2 (5 x C Ar), 176.0 (CO). 
MS (ESI): 456.3 (M-H)-. Anal. Calcd. for C24H28NO6P: C, 63.01; H, 6.17; N, 3.06. Found: C, 
63.02; H, 6.03; N, 2.96. 
Experimental Section                                                                                                                     103 
4.2.3. Synthesis of 4-[(4-amino-1H-benzimidazol-2-yl)methyl]phenyl dihydrogen 
phosphate (18) 
4-[(4-Nitro-1H-benzimidazol-2-yl)methyl]phenol (19). 
To a stirred suspension of 3-nitrobenzene-1,2-diamine (1 equiv) and 4-hydroxyphenyl 
acetic acid, an aqueous solution of 6 M HCl (1 mL x mmol) was added, and the reaction 
refluxed overnight. After cooled to rt, the mixture was neutralized with saturated NaHCO3 and 
extracted with ethyl acetate (3 x 15 mL x mmol). The organic layer was dried over anhydrous 
Na2SO4 and the solvent was eliminated under reduced pressure to afford 19 as a solid that was 
purified by column chromatography. 
 
Chromatography: dichloromethane → dichloromethane:ethyl acetate, 1:1. Yield: 58%; mp: 
228-230 ºC. 
IR (neat, cm-1): 1640, 1613, 1596 (NC=N), 1509 (N=O), 1341 (CAr-NO2). 
1H-NMR (CD3OD, δ): 4.13 (s, 2H, CH2), 6.63 (d, J = 8.6 Hz, 2H, CH Ar), 7.07 (d, J = 8.6 Hz, 2H, 
CH Ar), 7.27 (t, J = 8.09 Hz, 1H, CH Ar), 7.85 (d, J = 7.9 Hz, 1H, CH Ar), 8.03 (d, J = 8.2 Hz, 
1H, CH Ar).  
13C-NMR (CD3OD, δ): 33.8 (CH2), 115.5 (3 x CH Ar), 118.7 (CH Ar), 121.6 (CH Ar), 127.5 (C Ar), 
129.8 (2 x CH Ar), 133.8, 134.9, 146.0, 156.6, 158.7 (5 x C Ar). 
 
Dibenzyl 4-[(4-nitro-1H-benzimidazol-2-yl)methyl]phenyl phosphate (20). 
Derivative 20 was obtained following the general procedure described in 5.2.2.5. starting 
from 0.37 mmol of 19. 
 
Chromatography: dichloromethane:ethyl acetate, 9:1 → 7:3. Yield: 58%. Oil. 
IR (neat, cm-1): 1637, 1607, 1586 (N-C=N), 1507 (N=O), 1372 (CAr-NO2), 1267 (P-OC), 1015 
(C-OP). 
1H-NMR (CDCl3, δ): 4.15 (s, 2H, CH2), 5.04 (s, 2H, CH2O), 5.06 (s, 2H, CH2O), 6.98 (d, J = 8.7 
Hz, 2H, CH Ar), 7.07 (d, J = 8.5 Hz, 2H, CH Ar), 7.27 (m, 11H, CH Ar), 7.95 (d, J = 8.0 Hz, 1H, 
CH Ar), 8.03 (d, J = 8.2 Hz, 1H, CH Ar).  
13C-NMR (CDCl3, δ): 30.1 (CH2), 70.5, 70.6 (2 x CH2O), 119.4 (CH Ar), 120.9, 121.0, 121.9, 
127.1 (4 x CH Ar), 128.5 (4 x CH Ar), 129.0 (4 x CH Ar), 129.1 (2 x CH Ar), 130.6 (2 x CH Ar), 
133.1, 133.5, 135.6, 135.7, 146.4, 150.1, 150.2, 156.4 (8 x C Ar). 
  
104                                                                                                                     Experimental Section 
4-[(4-Amino-1H-benzimidazol-2-yl)methyl]phenyl dihydrogen phosphate (18). 
Derivative 18 was obtained following the general procedure described in 5.2.1.6. starting 
from 0.13 mmol of its benzylated precursor 20. 
 
Yield: 80%. Oil. 
IR (neat, cm-1): 3366 (N-H), 1610 (C=N), 1237 (P-OC), 1103 (C-OP). 
1H-NMR (CD3OD, δ): 4.02 (s, 2H, CH2), 6.39 (d, J = 7.6 Hz, 1H, CH Ar), 6.68 (d, J = 7.2 Hz, 1H, 
CH Ar), 6.83 (t, J = 7.8 Hz, 1H, CH Ar), 7.05 (d, J = 8.6 Hz, 2H, CH Ar), 7.16 (d, J = 8.4 Hz, 2H, 
CH Ar).  
13C-NMR (CD3OD, δ): 33.7 (CH2), 106.1, 119.5, 119.6, 122.4 (4 x CH Ar), 128.2 (2 x CH Ar), 
128.6 (CH Ar), 127.9, 133.5, 135.2, 147.0, 152.17, 153.8 (6 x C Ar).  
MS (ESI) 318.1 (M-H)-. Anal. Calcd. for C14H14N3O4P: C, 52.67; H, 4.42; N, 13.16. Found: C, 
52.23; H, 4.69; N, 13.37. 
4.3. Determination of the binding affinity by competition assays. 
Precoated streptavidin 96-well plates (Sigma-Aldrich, Spain) were incubated overnight at 
4 ºC with 100 μL/well of biotin-Ahx-PSpYVNVQN peptide (Sigma-Aldrich, Spain) at 200 nM in 
PBS. After four treatments with washing buffer (PBS containing 0.1% Tween-20), non-specific 
binding was blocked with PBS containing 5% skimmed powdered milk for 1 h at rt and washed 
three times with washing buffer. Reaction mixtures contained competitors, and 200 nM 
glutathione S-transferase fusion protein (GST)-Grb2(54-164) (Santa Cruz Biotechnology) in 
PBS containing 3% BSA, which had previously been preincubated by shaking for 2 h at rt. The 
components were added to the plate and the mixture was incubated for 2 h at rt without 
shaking. Unbound GST-Grb2(54-164) was removed by three washes with washing buffer. 
Bound GST-Grb2(54-164) was revealed after a sequence of incubation with a mouse anti-GST 
antibody (BD Biosciences; used for 1 h at rt at 1 μg/mL in PBS containing 3% BSA), three 
washes, incubation with HRP-conjugated goat anti-mouse (Biorad; used for 1 h at rt at 1/500 in 
PBS containing 5% skimmed powdered milk), three washes, and final addition of 3,3′,5,5′-
Tetramethylbenzidine (TMB, Sigma-Aldrich, Spain). The reaction was stopped with 0.5 M 
H2SO4, and absorbance at 450 nm was read in a microplate reader (UVM-340, ASYS Hitech 
GmbH). Controls were done by omitting each reagent separately, and no significant absorbance 
was observed in any of the incomplete assays. For each experiment, non-specific binding was 
measured and subtracted for each experimental point. Dose-response curves were constructed 
by nonlinear regression of the competition curves, using Prism. IC50 values are expressed as 
mean±SEM, and they correspond to at least three independent experiments carried out in 
duplicate. Compound 1224-130, kindly donated by Prof. T. R. Burke, was used as control of the 
ELISA test. This compound shows an IC50 value of 0.0148 μM in our assay, comparable to the 
value previously reported.129 
                                                     
129 See citation 90. 
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4.4. NMR Protein Spectroscopy sample preparation. 
These experiments were carried out as described previously.130 
4.5. HER2-Grb2 interaction 
HER2-positive MCF7 cells were exposed to the compound or to vehicle as described above for 
cell cytotoxicity experiments in 150 mm dishes. Cells were washed twice with ice-cold PBS and 
then scraped off the plates in cell-lysis buffer (1% NP-40, 20 mM Tris-HCl, pH = 7.4, 0.14 M 
NaCl, 1 mM EDTA, 1 mM EGTA) containing protease inhibitor cocktail (Roche) and 
phosphatase inhibitor cocktail I and II (Sigma). Lysates were prepared by glass-douncer 
homogenization in ice and followed by centrifugation in a microfuge (12000g for 10 min at 4 ºC). 
Supernatants were saved and protein concentration quantified by the Lowry-based DC protein 
assay (Biorad). For coimmunoprecipitation, 2 mg protein were incubated with 60 μL of an anti-
HER2 agarose immobilized antibody (Affibody AB, Sweden) in a final volume of 300 μL for 3 h 
with rotation at 4 ºC. Beads were washed five times with lysis buffer, eluted with 200 μL of 
electrophoresis sample (Laemmli) buffer and heated at 95 ºC for 10min. Thereafter, proteins 
were separated on a 10% SDS-polyacrylamide gel and transferred onto nitrocellulose 
membranes. Membranes were washed once with Tris-buffered solution (TBS, 10 mM Tris, 150 
mM NaCl, pH = 8.0), once with TBS-T (TBS with 0.1% Tween-20) and incubated for 1 h at rt in 
blocking buffer (1% BSA in TBS-T) to prevent non-specific antibody binding. Then, membranes 
were incubated with the corresponding primary antibodies anti-HER2 and anti-Grb2 (Santa Cruz 
Biotechnology) diluted in blocking buffer overnight at 4 ºC (1:500, 0.4 μg/mL). After three 5-min 
washes in TBS-T, membranes were incubated for 1 h with the corresponding HRP-conjugated 
secondary antibody (1:5000, Biorad), washed again three times with TBS-T and developed 
using a commercial kit (Amersham ECL western blotting detection reagents, GE Healthcare). 
Bands were densitometered to calculate the ratio of HER2-associated Grb2 in the presence or 
absence of the compound under study. 
4.6. Cell cytotoxicity  
Non-malignant fibroblasts N1 and breast tumor cell lines (HER2-positive and HER2-
negative MCF7 cells and MDA-231 cells) were kindly donated by Drs. R. Colomer (MD 
Anderson International Spain) and T. Puig (Institut Català d'Oncologia, Institut d'Investigació 
Biomèdica de Girona, and Universitat de Girona, Spain). Cells were routinely incubated in a 
humidified atmosphere at 37 ºC with 5% CO2 and passaged in DMEM medium (Invitrogen) 
containing 10% FBS (Gibco), 1% L-glutamine (Gibco), 1% sodium pyruvate (Gibco), 1% 
Penicillin-Streptomycin solution (Gibco). Cell cytotoxicity was determined using a standard 
colorimetric MTT assay (Sigma) following manufacturer´s instructions. Briefly, N1 or MCF7 cells 
were plated out at a density of 5 x 103 cells/100 μL/well in 96-well microtitre plates and 
                                                     
130 See citation 84. 
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incubated for 24 h. Then the medium was removed and cells were incubated for 24 h with fresh 
medium containing different concentrations of the compounds under study. Afterwards, fresh 
medium (100 μL/well) and 10 μL of a 5 mg/mL MTT solution were added and cells were 
incubated for 3 h at 37 ºC. After careful removal of the supernatants, the MTT-formazan crystals 
formed by metabolically viable cells were dissolved in DMSO (100 μL/well) and absorbance was 
measured at 570 nm in a UVM-340, ASYS Hitech GmbH multi-well plate reader. Absorbance at 
620 nm was used as background correction and substracted from each experimental point. 
Viability values are expressed as percentage of the control as mean±SEM, and they correspond 
to two independent experiments carried out in duplicate. 
4.7. Proteomic studies. 
4.7.1. m7GTP-binding proteins 
m7GTP-binding proteins were pulled-down using a procedure previously described.131 
Briefly 250 μL (5 mg of protein content approx.) of pooled cytosolic human liver lysates (Sigma-
Aldrich, Denmark) were added protease inhibitor cocktail (Sigma-Aldrich, Denmark) and pre-
cleared after incubation (under gentle toss) in 2 separate eppendorf tubes (100 μL beads + 125 
μL lysates each) at 4 ºC for 30 min with sepharose beads (20% in ethanol, Jena Bioscience) 
which had been previously washed with 50 mM HEPES buffer pH 7.6 (3 x 100 μL). After 
spinning down the beads, the non-bound supernatant was transferred to a new pair of 
previously HEPES-washed (3 x 100 μL) tubes (50 μL beads + 115 μL precleared extract 
approx.) containing γ-amino-hexyl-m7GTP-sepharose (20% in ethanol, Jena Bioscience). The 
tubes were again incubated at 4 ºC for 2 h and, once spun, the flow-through (FT) removed. 
Beads were then washed with buffer 1 (W1, 3 x 100 μL/ tube; 50 μM GDP, 250 mM KCl, 1 mM 
DTT, and 50 mM HEPES pH 7.6; spun dry and supernatant (W1) saved. Beads were washed 
twice (1 x 200 μL/ tube; 250 mM KCl, 1 mM DTT, and 50 mM HEPES pH 7.6) and, after 
spinning, washes were saved as W2 and W3. Finally, spun dry beads were eluted (1 x 30 μL/ 
tube) with elution buffer (E, 1 mM m7GTP, 200 mM KCl, 1 mM DTT, and 50 mM HEPES pH 
7.6). Eluted proteins were stored at -80 ºC for further processing, saving 15 μL, however, to be 
run with equivalent quantities of FT, W1, W2, and W3 in SDS-PAGE silver stained.  
4.7.2. cAMP-binding proteins 
A similar procedure to the one described in 5.7.1. was followed except for the use of 8-
amino-hexyl-cAMP-sepharose (50 μL beads + 115 μL precleared extract approx. per tube) and 
for the composition of washing and elution buffers: W1 (3 x 100 μL/ tube; 50 μM ADP, 500 mM 
KCl, 1mM DTT, and 50 mM HEPES pH 7.6); W2 and W3 (1 x 200 μL/ tube; 500 mM KCl, 1mM 
DTT, and 50 mM HEPES pH 7.6); E (1 x 30 μL/ tube; 10mM cAMP, 200 mM KCl, 1mM DTT, 
and 50 mM HEPES pH 7.6). 
                                                     
131 Webb, N. R.; Chari, R. V.; DePillis, G.; Kozarich, J. W.; Rhoads, R.E. Biochemistry 1984, 23, 177-181. 
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4.7.3. ATP-binding proteins 
The procedure was similar to the one described in 5.7.1. although with some minor 
modifications as detailed. Protease inhibited human cytosolic liver lysates were dialysed for 6 h 
at 4 ºC (Thermo Scientific Slide-A-Lyzer Dialysis Cassettes, 3.5K MWCO) to remove salts and 
small molecules. Then, 1 M MgCl2 solution was added to the dialysed lysates to a final 
concentration of 30 mM. Sepharose pre-clearing step was carried out as in the previous 
procedures and affinity purification was done employing γ-amino-hexyl-ATP-sepharose (50 μL 
beads + 115 μL precleared extract approx. per tube). After incubation for 2 h at 4 ºC, beads 
were washed an eluted using the following buffers composition: W1: (3 x 200 μL/ tube; 100 μM 
ADP, 500 mM KCl, 1mM DTT, and 50 mM HEPES pH 7.6). W2 and W3 (1 x 200 μL/ tube; 500 
mM KCl, 1mM DTT, and 50 mM HEPES pH 7.6). And E (1 x 30 μL/ tube; 10 mM ATP, 200 mM 
KCl, 1mM DTT, and 50 mM HEPES pH 7.6). 
4.7.4. Sample preparation for LC-MS. 
Eluates from the m7GTP, cAMP and ATP-sepharose columns were precipitated by 
incubation overnight at 4 ºC with two volumes of 50% solution of trichloroacetic acid (TCA). 
Precipitated proteins were isolated by centrifugation in a microfuge (12000g for 10 min at 4 ºC), 
the supernatant was removed and the pellets were further washed (2 x 200 μL) with a 1:1 
mixture of ethanol:ethyl ether. Pellets were dried for 15 min in an speed-vacuum system, 
resuspended in 13.5 μL of water and 4.5 μL of 4x reducing buffer, and loaded in a 4-20% 
polyacrylamide gel (PAGEr® Gold Precast Gel, Lonza USA). The gel was further stained for 1 h 
with ethanolic coomassie blue. 
Slices of gel were excised according to the silver pattern observed in the control gel of 
the corresponding experiments and introduced in pre-lubricated commercial eppendorf tubes. 
Alternative washes of acetonitrile and water (3 x 100 μL each) and spinning cycles (12000g for 
15 min) were carried until no coomassie blue came out of the gel pieces. After the last 
acetonitrile wash and spinning cycle, gel pieces were completely covered and incubated for 20 
min (on ice) with trypsin solution (6.66 ng/μL in NH4HCO3). Then, supernatant excess of trypsin 
was removed, substituted for ~30 μL of 50 mM NH4HCO3 and the tubes incubated at 37 ºC 
overnight. 
Digested peptides were desalted and filtered on in-house made C18-Oligo R3 
microcolumns. The peptide mixtures (~100 μL) were loaded, washed with 100 μL of 5% formic 
acid, and eluted with 30 μL of a 70% acetonitrile and 5% formic acid solution by applying air 
pressure with a small syringe. Eluates were collected in 1.5 mL eppendorf tubes, concentrated 
in a speed-vacuum system and analysed by nanoLC-MS/MS.  
4.7.5. NanoLC-MS/MS 
All digested peptide mixtures were separated by an on-line nano-LC system and 
analyzed by ESI tandem mass spectrometry on a LTQ/Orbitrap system (ThermoFisher 
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Scientific). Peptide mixtures were loaded onto a 40 mm trap column, packed with 25 mm Poros 
10R2 (10 μm) and 15 mm C18 (5 μm), at 10 μL/min flow. Separation was performed with a flow 
of 0.3 μl/min on a 20 cm reverse-phase column (Biosphere C18, 5 μm, Nanoseparations, The 
Netherlands). Peptides were separated using a 25 min-gradient and subsequently eluted with a 
flow of 0.3 μl/min with a gradient 5 to 60% B (acetonitrile with 0.1% formic acid [v/v]) in A (water 
with 0.1% formic acid [v/v]). ESI was performed with nano-LC spray tips, Nanoseparations, The 
Netherlands). General mass spectrometric conditions were: electrospray voltage, 1.8-2.0 kV; no 
sheath and auxiliary gas flow; ion transfer tube temperature, 125 °C; collision gas pressure, 






























 5. Conclusions 
1. Based on the crystal structure of the Grb2-SH2 domain in complex with the high-affinity 
pentapeptide 2-Abz-Glu-pTyr-Ile-Asn-Gln-NH2 ligand, we have designed and synthesized two 
series of novel non-peptide compounds that maintain all (series I) or some (series II) of the key 
interactions with the Grb2-SH2 domain. 
 
2. An ELISA-type competition assay was set up in order to determine the ability of all final 
compounds to bind the Grb2-SH2 domain. Among the tested compounds, derivative (S)-1k of 
series I showed the highest affinity (IC50 = 174 μM). The fact that none of the compounds of 
series II was able to bind the Grb2-SH2 domain in a significant manner is consistent with the 
importance of the interactions with Arg67 and His107. 
 
3. The binding mode of (S)-1k to the Grb2-SH2 domain has been experimentally validated 
using NMR chemical shift perturbation studies. Based on these data, optimization of (S)-1k by 
the introduction of conformational restriction in its structure has yielded (S)-1l. This compound, 
with an IC50 value of 56 μM, stands out as one of the highest affinity non-peptide compounds 






























4. Compound (S)-1l was further assessed for its cytotoxic in vitro potential in HER2-positive 
and negative human breast cancer cell lines, as well as in N1 fibroblasts. Importantly, (S)-1l 
exclusively affected proliferation of HER2-positive MCF7 cells (IC50 = 100 μM). This result 
supports that (S)-1l is devoid of general cytotoxicity towards non-tumour cells, and that it 
interferes specifically with the HER2 downstream pathway. Accordingly, using 
immunoprecipitation experiments, it has been demonstrated that (S)-1l directly impairs the 
interaction between HER2 and Grb2. 
 
5. Considering the promising profile of (S)-1l and the interest on the delineation of all the 
molecular pathways affected by the compound, a throughput proteomic platform has been 
designed and validated using different nucleotides. Currently, this platform is being used to 
compare a relevant proteome (HER2+ breast cancer cells) previously treated or not with (S)-1l. 
Then, the proteomic signature should reveal the identity and extent of the transduction 
pathway(s) affected. 
   
 UNIVERSIDAD COMPLUTENSE DE MADRID 
FACULTAD DE CIENCIAS QUÍMICAS 
Departamento de Química Orgánica I 
 
 
DESARROLLO DE NUEVOS INHIBIDORES DE LA 
INTERACCIÓN ENTRE EL RECEPTOR HER2 Y  
LA PROTEÍNA ADAPTADORA Grb2 
Memoria que para optar al 
Título de Doctor 
presenta 
Ángel Lorenzo Orcajo Rincón 
 
Directoras: 
Prof. Dra. María Luz López Rodríguez 
Prof. Dra. Bellinda Benhamú Salama 
































 1. Introducción General 
Cáncer es el término genérico con el que se describe a un grupo de más de cien 
enfermedades con un denominador común, la generación rápida de células anormales que 
crecen más allá de sus límites naturales. Siendo éstas capaces en muchos casos de invadir 
tejidos adyacentes o migrar a otras zonas del organismo, el resultado es casi siempre el 
mismo: disfunción orgánica progresiva y probablemente letal.  
Valoraciones recientes de la Organización Mundial de la Salud1 sitúan al cáncer como 
una de las principales causas de muerte a nivel mundial, y estiman su incidencia en 13,1 
millones de fallecimientos para el 2030. 
El cáncer es un proceso multi-etapas, y la visión más clásica sitúa su punto de partida en 
el daño al ADN de una célula, que resulta de mutaciones provocadas por diversos agentes 
externos (carcinógenos físicos, químicos o biológicos) sobre uno o varios genes. Procesos tan 
determinantes como la proliferación celular, crecimiento, diferenciación y apoptosis, pueden 
verse severamente afectados por estas mutaciones. La pérdida total de función de estos genes 
normalmente conlleva una rápida y permanente expansión clónica completamente alterada e 
independiente de estimulación externa (ej. factores de crecimiento, hormonas, etc), que 
desencadena la aparición del fenotipo de la enfermedad.2 En este punto, la masa celular se ha 
convertido en una neoplasia maligna cada vez más descontrolada, capaz de inducir la 
generación de nuevos vasos sanguíneos en su periferia (angiogénesis) y de iniciar un proceso 
de digestión de las capas celulares o endotelio en el que está contenido, para finalmente 
acceder al torrente sanguíneo y colonizar nuevos tejidos (metástasis).3 
Los genes cuya mutación implica la aparición de cáncer se denominan oncogenes, 
dentro de los cuales se cuentan muchos de los receptores de membrana implicados en los 
procesos de división y crecimiento celular. Tales receptores son activados por sus ligandos, los 
cuales pueden ser producidos por células vecinas (estimulación paracrina), o por ella misma 
(estimulación autocrina). La mayor parte de los receptores implicados en procesos de división y 
diferenciación celular son receptores con actividad proteína quinasa; es decir, son capaces de 
transferir grupos fosfato desde la molécula donadora, trifosfato de adenosina (adenosine 
triphosphate, ATP), a residuos de serina, treonina o tirosina de una proteína sustrato.4 La 
fosforilación de proteínas tiene dos funciones fundamentales: (i) cambiar la conformación de 
una proteína y como consecuencia modificar su actividad enzimática, y (ii) generar sitios de 
                                                     
1 http://www.who.int/mediacentre/factsheets/fs297/en/index.html. 
2 (a) Fukasawa, K. Nat. Rev. Cancer 2007, 7, 911-924. (b) Haber, D. A.; Gray, N. S.; Baselga, J. Cell 2011, 145, 19-24. 
3 (a) McSherry, E. A.; Donatello, S.; Hopkins, A. M.; McDonnell, S. Cell. Mol. Life Sci. 2007, 64, 3201-3218. (b) Brennan, 
K.; Offiah, G.; McSherry, E. A.; Hopkins, A. M. J. Biomed. Biotechnol., Hindawi Publishing Corporation, 
doi:10.1155/2010/460607 2010. (c) Arteaga, C. L.; Baselga, J. Clin. Cancer Res. 2012, 18, 612-618. 
4 (a) Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K.; Walter, P. Molecular Biology of the Cell, Taylor & Francis 
Inc., 5th Ed., 2007. (b) DeVita Jr., V. T.; Lawrence T. S.; Rosenberg, S. A.; DePinho, R. A.; Weinberg, R. A. Cancer: 
Principles and Practice of Oncology, Wolters Kluwer - Lippincott Williams & Wilkins, 9th Ed., 2011. 
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reconocimiento para otras proteínas señalizadoras. En general puede decirse que la 
fosforilación contribuye a la transmisión y amplificación de la señal mitogénica. Usualmente, 
este proceso de transmisión y amplificación tiene como consecuencia la activación secuencial 
de la proteína Ras y de la vía de las proteínas quinasas activadas por mitógenos (mitogen-
activated protein kinases, MAPKs).5 Son ellas las responsables últimas de la activación de los 
genes comprometidos en la división celular.6 
Los receptores con actividad tirosina quinasa (tyrosine kinase receptors, TKRs) se 
clasifican en cuatro familias en función de su similitud estructural. En particular, la subclase I, 
fundamental en los procesos tumorales, comprende los diferentes receptores de factor de 
crecimiento epidérmico (epidermal growth factor receptors, EGFRs). Este grupo de proteínas se 
compone de cuatro miembros bien diferenciados: HER1 (también llamado EGFR o ErbB1), 
HER2 (neu o ErbB2), HER3 (ErbB3) y HER4 (ErbB4).7 Los HERs se expresan en varios tipos 
de tejidos, siendo los más comunes del tipo epitelial, mesenquimal y neuronal. 
Estructuralmente los cuatro receptores de esta familia están constituidos por un dominio 
extracelular de unión a ligando, una hélice transmembrana de carácter hidrofóbico y un dominio 
intracelular con actividad tirosina quinasa (Figura 1a).8  
El dominio intracelular con actividad tirosina quinasa de los receptores HERs se 
encuentra altamente conservado dentro de la familia, excepto en el caso de HER3, que carece 
de actividad quinasa (Figura 1a). Por otra parte, los dominios extracelulares se encuentran 
poco conservados, lo que sugiere un alto grado de especialización en cuanto a la unión con 
sus respectivos ligandos.9 Tras la unión a su ligando específico (vía subdominios I y III), estos 
receptores sufren un importante cambio conformacional que deja expuesto el brazo de 
dimerización ubicado en el subdominio II y que permite su interacción con otro receptor vecino. 
Esta situación no es posible en HER2 dada la extensiva interacción entre los subdominios I y 
III, por lo que adopta una conformación constitutivamente activa y dispuesta a la dimerización 
(Figura 1b).10 Esta característica podría explicar la importante capacidad que tiene HER2 para 
inducir transformación celular en situación de sobreexpresión. 
 
                                                     
5 (a) Sebolt-Leopold, J. S. Oncogene 2000, 19, 6594-6599. (b) Chapman, M. S.; Miner, J. N. Expert Opin. Investig. 
Drugs 2011, 20, 209-220. 
6 (a) Barbacid, M. Ann. Rev. Biochem. 1987, 56, 779-827. (b) Young, A.; Lyons, J.; Miller, A. L.; Phan, V. T.; Alarcón, I. 
R.; McCormick, F. Adv. Cancer Res. 2009, 102, 1-17. 
7 Baselga, J.; Swain, S. M. Nat. Rev. Cancer 2009, 9, 463-475. 
8 (a) Olayioye, M. A.; Neve, R. M.; Lane, H. A.; Hynes, N. E. EMBO J. 2000, 19, 3159-3167. (b) Ferguson, K. M.; 
Berger, M. B.; Mendrola, J. M.; Cho, H. S.; Leahy, D. J.; Lemmon, M. A. Mol. Cell  2003, 11, 507-517. (c) Lurje, G.; 
Lenz, H. J. Oncology 2009, 77, 400-410. 
9 (a) Yarden, Y.; Sliwkowski, M. X. Nat. Rev. Mol. Cell Biol. 2001, 2, 127-137. (b) Burgess, A. W. Growth Factors 2008, 
26, 263-274. 
10 (a) Burgess, A. W.; Cho, H. S.; Eigenbrot, C; Ferguson, K. M.; Garrett, T. P. J.; Leahy, D. J.; Lemmon M. A.; 
Sliwkowski, M. X.; Ward, C. W.; Yokoyama, S. Mol. Cell  2003, 12, 541-552. (b) Lemmon, M. A. Exp. Cell Res. 2009, 
315, 638-648. 
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Figura 1. a. Representación esquemática de los cuatro receptores miembros de la familia ErbB (ErbB1-4). 
b. Cambio de la conformación plegada a la extendida tras la unión a su respectivo ligando; modificación 
imprescindible para que se produzca la dimerización receptor-receptor. (Reproducido de la cita 7) 
En condiciones fisiológicas normales la activación de los HERs es controlada por la 
expresión tanto espacial como temporal de sus ligandos endógenos, proteínas de la familia de 
los factores de crecimiento epidérmico (epidermal growth factors, EGFs). Este grupo está 
compuesto por trece miembros que en muchos casos solapan su acción sobre un mismo 
receptor (Figura 2a).11  
Así, cada receptor puede ser activado por más de un ligando, exceptuando HER2, del 
que aún no se conoce su ligando endógeno. A pesar de ello, es el que más interés ha atraído 
dentro de la oncología clínica y molecular por ser el receptor de heterodimerización preferido 
del resto de los miembros de esta familia.12 
En resumen, la unión específica de un ligando a su receptor induce la formación de 
homo- y heterodímeros, lo que conlleva la activación del dominio con actividad tirosina quinasa, 
resultando finalmente en la fosforilación de residuos específicos de tirosina en el dominio 
intracelular del receptor.13 Estos residuos fosforilados sirven como puntos de reconocimiento 
                                                     
11 (a) Citri, A.; Yarden, Y. Nat. Rev. Mol. Cell Biol. 2006, 7, 505-516. (b) Avraham, R.; Yarden, Y. Nat. Rev. Mol. Cell 
Biol. 2011, 12, 104-117. 
12 (a) Hynes, N. E.; Lane, H. A. Nat. Rev. Cancer 2005, 5, 341-354. (b) Zhang, H.; Berezov, A.; Wang, Q.; Zhang, G.; 
Drebin, J.; Murali, R.; Greene, M. I. J. Clin. Invest. 2007, 117, 2051-2058. (c) Hynes, N. E.; MacDonald, G. Curr. Opin. 
Cell Biol. 2009, 21,177-184. 
13 (a) Zhang, X.; Gureasko, J.; Shen, K.; Cole, P. A.; Kuriyan, J. Cell 2006, 125, 1137-1149. (b) Bose, R.; Zhang, X. 
Exp. Cell Res. 2009, 315, 649-658. 
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para una gran variedad de proteínas adaptadoras (como por ejemplo Shc, Grb7, Grb2, Nck, 
PLCγ, Figura 2b), cuya activación desencadena una cascada de fosforilaciones consecutivas 




Figura 2. a. Miembros de la familia EGF y sus respectivos receptores. b. Representación esquemática de 
los sitios de autofosforilación mejor estudiados en HER1-3 y sus proteínas adaptadoras relacionadas. 
(Reproducido de la cita 12a) 
La activación de la vía de las MAPKs15,16 se produce fundamentalmente a través de la 
proteína adaptadora Grb2,17 la cual reconoce los residuos de tirosina fosforilados en HER2 a 
través de su dominio SH2 (Src homology 2). Una vez unida a HER2, a través de otro dominio, 
SH3, se acopla a la proteína Sos, la cual finalmente activa Ras (Figura 3).18,19 
                                                     
14 (a) Mendelsohn, J.; Baselga, J. J. Clin. Oncol. 2003, 21, 2787-2799. (b) Cargnello, M.; Roux, P. P. Microbiol. Mol. 
Biol. Rev. 2011, 75, 50-83. 
15 Kolch, W. Biochem. J. 2000, 351, 289-305. 
16 Sebolt-Leopold, J. S.; Herrera, R. Nat. Rev. Cancer 2004, 4, 937-947. 
17 (a) Gale, N. W.; Kaplan, S.; Lowenstein, E. J.; Schlessinger, J.; Bar-Sagi, D. Nature 1993, 363, 88-92. (b) Tari, A. M.; 
Lopez-Berestein, G. Semin. Oncol. 2001, 28, 142-147. (c) Giubellino, A.; Burke, T. R. Jr.; Bottaro, D. P. Expert Opin. 
Ther. Targets  2008, 12, 1021-1033. 
18 McCormick, F. Nature 1993, 363, 15-16. 
19 (a) Downward, J. Nat. Rev. Cancer 2003, 3, 11-22. (b) Matallanas, D.; Crespo, P. Curr. Opin. Mol. Ther. 2010, 12, 
674-683. 
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Figura 3. Representación esquemática de la activación de Ras-MAPKs iniciada por la unión ligando-
receptor y mediada a través de Grb2. 
Una vez activa, Ras fosforila y, de esta manera, moviliza el primer nivel de las MAPKs 
compuesto por la famila de Raf (o MAPKKK), que a su vez fosforila a MEK1/2 (o MAPKK) y 
éstas a ERK1/2 (o MAPK). Esta cascada de fosforilaciones consecutivas termina en la 
activación de numerosos factores de transcripción implicados en procesos celulares tan vitales 
como la inflamación, mecanismos de reparación, crecimiento, proliferación, migración celular y 
angiogénesis.20 
Por esta razón el desarrollo de inhibidores de la interacción entre el receptor HER2 y la 
proteína adaptadora Grb2 podría constituir una nueva terapia para el tratamiento del cáncer,21 
sobre todo de aquellos tipos caracterizados por una elevada expresión de HER2. Así, se ha 
descrito que aproximadamente el 30% de los tumores de mama sobreexpresan HER2, 
condición que también se presenta en otros tipos de neoplasias (tales como ovario, pulmón, 
páncreas, colon, esófago, endometrio, cuello uterino o glándulas salivales).22 
1.1. Inhibidores de la interacción HER2-Grb2 
El desarrollo de compuestos capaces de inhibir la interacción entre el receptor HER2 y la 
proteína adaptadora Grb2 es un área de investigación que ha recibido una enorme atención en 
los últimos años. Esto se ha visto favorecido por la determinación de la estructura 
tridimensional de diferentes dominios SH2, en particular, del de la proteína Grb2.  
Grb2 es una proteína de 25 KDa compuesta por un dominio SH2 rodeado por dos 
dominios SH3 (Figura 4).23 El dominio SH3 se une específicamente a regiones ricas en 
                                                     
20 Chang, F.; Steelman, L. S.; Lee, J. T.; Shelton, J. G.; Navalonic, P. M.; Blalock, W. L.; Franklin, R. A.; McCubrey, J. 
A. Leukemia 2003, 17, 1263-1293. 
21 (a) Schubbert, S.; Shannon, K.; Bollag, G. Nat. Rev. Cancer 2007, 7, 295-308. (b) Lee-Hoeflich, S. T.; Crocker, L.; 
Yao, E.; Pham, T.; Munroe, X.; Hoeflich, K. P.; Sliwkowski, M. X.; Stern, H. M. Cancer Res. 2008, 68, 5878-5887. (c) 
Baselga, J. Ann. Oncol. 2010, 21, Suppl. 7:vii36-40. 
22 (a) Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Science 1987, 235, 177-182. (b) 
Holbro, T.; Hynes, N. E. Annu. Rev. Pharmacol. Toxicol. 2004, 44, 195-217. (c) Higgins, M. J.; Baselga, J. J. Clin. 
Invest. 2011, 121, 3797-3803. 
23 Maignan, S.; Guilloteau, J. P.; Fromage, N.; Arnoux, B.; Becquart, J.; Ducruix, A. Science 1995, 268, 291-293.  
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prolina,24 mientras que el dominio SH2 de Grb2 reconoce secuencias peptídicas específicas 
que contengan pTyr (Glu-pTyr-Ile-Asn-Gln)25 en el receptor con actividad tirosina quinasa. En 
1996 se elucidó mediante resonancia magnética nuclear (RMN) heteronuclear multidimensional 
la estructura tridimensional (3D) del dominio SH2 de Grb2, similar a la de otros dominios SH2.26 
 
Figura 4. Estructura de rayos X de la proteína Grb2 humana obtenida a una resolución de 3,1 Ǻ (Código 
PDB: 1gri). 
En general, los dominios SH2 poseen dos regiones de reconocimiento principales, la 
primera de ellas dedicada al anclaje de la pTyr, y la segunda especializada en el 
reconocimiento de la secuencia que rodea al resto de pTyr. La elucidación estructural del 
complejo dominio SH2 de Grb2-ligando tanto mediante cristalografía de rayos X27 como RMN28 
indica que el plegamiento óptimo del ligando en este dominio es en forma de U, a diferencia de 
lo descrito para otros dominios SH2 de otras proteínas donde el péptido que porta el residuo de 
pTyr se encuentra en una conformación extendida. Tras un extenso barrido estructural capaz 
de cubrir ambas regiones, han sido compuestos peptídicos con afinidad por el dominio SH2 de 
Grb2 los inhibidores más potentes descritos hasta la fecha. Sin embargo, es también posible 
encontrar algunos ejemplos aislados de pequeñas moléculas orgánicas capaces de unirse al 
dominio SH2 de Grb2 aunque con menor afinidad.  
                                                     
24 Véase cita 17a. 
25 Rahuel, J.; García-Echeverría, C.; Furet, P.; Strauss, A.; Caravatti, G.; Fretz, H.; Schoepfer, J.; Gay, B. J. Mol. Biol. 
1998, 279, 1013-1022. 
26 Thornton, K. H.; Mueller, W. T.; McConnell, P.; Zhu, G.; Saltiel, A. R.; Thanabal, V. Biochemistry 1996, 35, 11852-
11864. 
27 Rahuel, J.; Gay, B.; Erdmann, D.; Strauss, A.; García-Echeverría, C.; Furet, P.; Caravatti, G.; Fretz, H.; Schoepfer, J.; 
Grütter, M. G. Nat. Struct. Biol. 1996, 3, 586-589. 
28 Ogura, K.; Tsuchiya, S.; Terasawa, H.; Yuzawa, S.; Hatanaka, H.; Mandiyan, V.; Schlessinger, J.; Inagaki, F. J. Mol. 
Biol. 1999, 289, 439-445. 
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Los inhibidores peptídicos se pueden definir como tri- y tetrapéptidos de cadena 
abierta,29,30,31,32 (Figura 5), derivados tensionados (con restricción conformacional local)33 y 
macrociclos (con restricción conformacional global) de mayor peso molecular34,35,36,37 (Figura 6), 
























CI50 = 22 nM
a
(3-amino)-Z-pTyr-Ac6c-Asn-NH2 






















































CI50 = 11 nM  
Figura 5. Inhibidores peptídicos de cadena abierta. 
                                                     
29 Fretz, H.; Furet, P.; García-Echeverría, C.; Schoepfer, J.; Rahuel, J. Curr. Pharm. Des. 2000, 6, 1777-1796. 
30 García-Echeverría, C.; Furet, P.; Gay, B.; Fretz, H.; Rahuel, J.; Schoepfer, J.; Caravatti, G. J. Med. Chem. 1998, 41, 
1741-1744. 
31 Furet, P.; García-Echeverría, C.; Gay, B.; Schoepfer, J.; Zeller, M.; Rahuel, J. J. Med. Chem. 1999, 42, 2358-2363. 
32 Véase cita 29. 
33 (a) Liu, D. G.; Wang, X. Z.; Gao, Y.; Li, B.; Yang, D.; Burke, T. R. Jr. Tetrahedron 2002, 58, 10423–10428. (b) Oishi, 
S.; Kang, S. U.; Liu, H.; Zhang, M.; Yang, D.; Deschamps, J. R.; Burke, T. R. Jr. Tetrahedron 2004, 60, 2971-2977. 
34 Song, Y. L.; Roller, P. P.; Long, Y. Q. Bioorg. Med. Chem. Lett. 2004, 14, 3205-3208. 
35 Li, P.; Zhang, M.; Long, Y. Q.; Peach, M. L.; Liu, H.; Yang, D.; Nicklaus, M.; Roller, P. P. Bioorg. Med. Chem. Lett. 
2003, 13, 2173-2177. 
36 Shi, Z. D.; Lee, K.; Wei, C. Q.; Roberts, L. R.; Worthy, K. M.; Fisher, R. J.; Burke, T. R. Jr. J. Med. Chem. 2004, 47, 
788-791. 
37 Jian, S.; Liao, C.; Bindu, L.; Yin, B.; Worthy, K. W.; Fisher, R. J.; Burke, T. R. Jr.; Nicklaus, M. C.; Roller, P. P. Bioorg. 
Med. Chem. Lett. 2009, 19, 2693-2698. 












































































































































CI50 = 5,5 μM CI50  > 10 μM
CI50 = 2,4 nM CI50 = 20 μM
CI50 = 2 nM CI50 = 0,4 μM  
Figura 6. Inhibidores con restricción conformacional local (a, b) y macrocíclicos (c-f). 
Dentro de las moléculas pequeñas se encuentran tanto inhibidores que aún contienen el 
residuo de pTyr38 como compuestos en los que se ha eliminado totalmente39,40,41 (Figura 7). 
                                                     
38 Schoepfer, J.; Gay, B.; Caravatti, G.; García-Echeverría, C.; Fretz, H.; Rahuel, J.; Furet, P. Bioorg. Med. Chem. Lett. 
1998, 8, 2865-2870. 
39 Caravatti, G.; Rahuel, J.; Gay, B.; Furet, P. Bioorg. Med. Chem. Lett. 1999, 9, 1973-1978. 
40 Harris, G. D.; Nguyen, A.; App, H.; Hirth, P.; McMahon, G.; Tang, C. Org. Lett. 1999, 1, 431-433. 
41 Nam, J. Y.; Kim, H. K.; Kwon, J. Y.; Han, M. Y.; Son, K. H.; Lee, U. C.; Choi, J. D.; Kwon, B. M. J. Nat. Prod. 2000, 
63, 1303-1305. 




































CI50 = 7,2 μM
CI50 = 4,3 μM CI50 = 25,9 μM
CI50 = 1,2 μM
 
Figura 7. Inhibidor no peptídico en el que aún se conserva el residuo de pTyr (a) y estructuras no 
relacionadas (b-d). 
 
De lo expuesto resulta evidente que el bloqueo de la interacción HER2-Grb2 mediante el 
empleo de ligandos del dominio SH2 de Grb2 representa una prometedora estrategia de 
terapia dirigida contra el cáncer.  
Sin embargo, esta aproximación terapéutica aún no ha podido ser validada, ya que la 
mayoría de ligandos disponibles capaces de unirse eficientemente al dominio SH2 de Grb2 son 
de naturaleza peptídica y con limitaciones de biodisponibilidad, lo que ha dificultado su 
desarrollo farmacéutico. Por lo tanto, la identificación de pequeñas moléculas se presenta 
como una opción muy interesante dentro de este campo. En este sentido, en nuestro grupo de 
investigación hemos comenzado un proyecto dirigido al desarrollo de compuestos de carácter 
no peptídico capaces de unirse al dominio SH2 de Grb2 y bloquear su vía de señalización.  
 




























   
 2. Objetivos 
El objetivo principal de este proyecto es el desarrollo de moléculas pequeñas de 
naturaleza no peptídica con afinidad por el dominio Grb2-SH2. La consecución de este objetivo 
implica las siguientes etapas:  
1. Diseño de compuestos empleando como punto de partida la estructura cristalográfica del 































2. Síntesis y determinación de la afinidad de los compuestos sintetizados por el dominio SH2 
de Grb2.  
3. Proceso de optimización.  
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 3. Resultados y Discusión 
3.1. Diseño de compuestos con afinidad por el dominio SH2 de Grb2 
Empleando como punto de partida la estructura cristalográfica del dominio SH2 de Grb2 
unido al pentapéptido de alta afinidad 2-Abz-Glu-pTyr-Ile-Asn-Gln-NH242 se diseñaron dos 
series de compuestos que mantienen todas las interacciones clave de dicho pentapéptido con 


























































































































































Figura 8. Diseño de las estructuras generales I y II. 
                                                     
42 Véase cita 25. 
43 Orcajo-Rincón, Á. L.; Ortega-Gutiérrez, S.; Serrano, P.; Torrecillas, I. R.; Wüthrich, K.; Campillo, M.; Pardo, L.; Viso, 
A.; Benhamú, B.; López-Rodríguez, M. L. J. Med. Chem. 2011, 54, 1096-1100. 
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Las Figuras 9 y 10 muestran los modelos computacionales obtenidos para algunos de 
los compuestos representativos de dichas series: 
 
a        b 
           
Figura 9. Modelos computacionales del complejo formado por el compuesto (S)-1k, perteneciente a la 
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a 
           
b 
           
c 
          
 
Figura 10. Modelos computacionales de los complejos formados por el dominio SH2 de Grb2 con el 
compuesto 3a (panel a), el compuesto 2f (panel b) y el compuesto 18 (panel c). Las imágenes muestran 
el dominio SH2 completo (paneles izquierdos) así como las correspondientes secciones ampliadas con 
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3.2. Síntesis de los compuestos de las series I-II y determinación de su 
afinidad por Grb2-SH2 
La síntesis de los compuestos de las diferentes series 1a-j (serie I), 2a-i, 3a-c y 18 (serie 
II), así como la determinación de su afinidad por el dominio Grb2-SH2 se llevó a cabo de forma 






















Reactivos: (a) (i) NMM, tBuMe2SiCl, CH3CN, ta; (ii) 1H-tetrazol, iPr2NP(OBn)2, ta; (iii) tBuOOH ac., -20 ºC; (b) EDC, 
HOBt, CH2Cl2, R-NH2, ta; (c) H2/Pd(C)/etanol, ta.
W = MeCO, PhCO, 
        n-PrCO (4)
5a: W = MeCO
5b: W = n-PrCO
5c: W = PhCO
6a-d: W = MeCO
6e-g: W = n-PrCO










1a-d: W = MeCO
1e-g: W = n-PrCO
1h-j:  W = PhCO





















7a: n = 2
Δ
n n n n
7b: n = 1  
Esquema 2. Síntesis de las aminas 7a,b. 




Reactivos: (a) Br(CH2)nCOOEt, K2CO3, éter corona, acetona, 60 ºC; (b) H2/Pd(C), etanol, ta; (c) R-NH2, AlMe3, 
tolueno, 120 ºC; (d) (i) 1H-tetrazol, iPr2NP(OBn)2, 25 ºC; (ii) tBuOOH ac., -20 ºC.
11a: n = 3, X = Bn
11b: n = 4, X = Bn
12a: n = 3, X = H
12b: n = 4, X = H
R =
13a-h: n = 3






















15a-h: n = 3, X = Bn
16a-c: n = 4, X = Bn
2a-i: n = 3, X = H





2a,3a 2b 2c 2d 2e 2f, 3b 2g 2h, 3c 2i
 




Reactivos: (a) NC(CH2)P(O)(OC2H5)2, K2CO3 ac. 6 M, ta; (b) H2 /Ni-Ra, etanol, ta.
17
 














Reactivos: (a) 4-OH-C6H4-CH2COOH, HCl 6 M, Δ; (b) (i) 1H-tetrazol, iPr2NP(OBn)2, 25 ºC; (ii) tBuOOH ac., ta; 
(c) H2/Pd(C), etanol, ta.
(c) 20: Y = NO2, X = Bn




Esquema 5. Síntesis del compuesto 18. 
La evaluación biológica de todos los compuestos sintetizados requirió la puesta a punto 
de un ensayo tipo ELISA. Los valores obtenidos para los compuestos de la serie I se recogen 
en la Tabla 1, destacando el derivado 1a que, con un valor de CI50 = 190 ± 25 μM, es el que 
presenta mayor afinidad por el dominio SH2 de Grb2. Ninguno de los compuestos de la serie II 
mostró afinidad por la proteína (CI50 > 1 mM). 
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Compuesto W Espaciador Grupo T. CI50 (μM)a,b 
1a Me-CO- -(CH2)3- N NH
O
190±25 














1e nPr-CO- -(CH2)3- N NH
O
314±5 








1h Ph-CO- -(CH2)3- N NH
O
Inactivoc 









a Los ensayos de unión competitivos entre el dominio SH2 de Grb2 expresado como proteína de fusión a GST y el 
fosfopéptido biotina-Ahx-PSpYVNVQN fueron llevados a cabo tal como se detalla en la Parte Experimental 
(Experimental Section de la versión en lengua inglesa) de esta memoria. Las curvas dosis-respuesta fueron generadas 
empleando el programa Prisma. Los datos se expresan como la media±EE de al menos dos experimentos 
independientes realizados por duplicado. b Para el compuesto 1224-130, cedido por el Prof. T. R. Burke y usado como 
control en el test ELISA, los valores de CI50 obtenidos en nuestro laboratorio se corresponden con el descrito 
previamente.44 c Los compuestos inactivos desplazan menos del 10% del fosfopéptido a la máxima concentración 
empleada (5 mM).  
                                                     
44 Wei, C.-Q.; Li, B.; Guo, R.; Yang, D.; Burke, T. R. Jr. Bioorg. Med. Chem. Lett. 2002, 12, 2781-2784. 
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Puesto que la síntesis empleada para los derivados de la serie I (Esquema 1) conlleva 
un cierto grado de racemización (Figuras 11 y 12), se puso a punto una ruta para acceder a los 
enantiómeros de 1a, el compuesto que hasta el momento había mostrado la mayor afinidad 
(CI50 = 190 µM, Tabla 1). Así, se sintetizaron los derivados enantiopuros (R)- y (S)-1k 
(Esquema 6) y el racémico (R,S)-1k (en este caso empleando condiciones análogas a las 
indicadas en el Esquema 1, pero partiendo de N-acetiltirosina racémica) y se determinó la 




































































Figura 11. Evaluación del grado de racemización asociado a la síntesis de los compuestos 1a-j. 
 
 
Figura 12. Espectro de 1H-RMN de la mezcla diastereomérica resultante de la condensación del ácido 






















(R,S) grupo metilo 





















Reactivos: (a) (i) NMM, tBuMe2SiCl, CH3CN, ta; (ii) 1H-tetrazol, iPr2NP(OBn)2, ta; (iii) tBuOOH ac., -20 ºC; (b) 
EDC, HOBt, CH2Cl2, 7a, ta; (c) piperidina, CH3CN, 0 ºC; (ii) iPr2NEt, Ac2O, DMF, ta; (d) H2/Pd(C), etanol, ta.
L o D 8a,b
(b)


















10a,b: R1 = Ac
(d)
R = N NH
O
 
Esquema 6. Síntesis de los derivados enantiopuros (R)- y (S)-1k. 











Compuesto W Espaciador Grupo T. CI50 (μM)a,b 
1a 








a-c Para una explicación detallada véase nota al pie de la Tabla 1. 
Estos resultados permitieron seleccionar el compuesto (S)-1k como hit inicial para su 
optimización. 
3.3. Optimización del hit (S)-1k  
Con el fin de optimizar el compuesto (S)-1k, se determinó en primer lugar, de forma 
experimental, los aminoácidos del dominio Grb2-SH2 con los que (S)-1k interacciona. Para ello 
se llevaron a cabo experimentos de RMN (Heteronuclear Single Quantum Coherence, HSQC) 
empleando proteína marcada con 15N (Figuras 13 y 14). 
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Figura 13. Espectro 2D [15N,1H]-HSQC del dominio Grb2-SH2 en ausencia (azul) y en presencia de (S)-1k 
(rojo) (relación molar compuesto:proteína 1:1). 
 
Figura 14. Espectro 2D [15N,1H]-HSQC del dominio Grb2-SH2 en ausencia (azul) y en presencia de N-
acetilfosfotirosina (rojo) (relación molar compuesto:proteína 2:1). 
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Figura 15. Modificación de los desplazamientos químicos combinados 1H–15N (Δδav) del dominio Grb2-
SH2 frente a su secuencia primaria de aminoácidos. Δδav es el promedio ponderado de las diferencias en 
desplazamiento químico de 1H y 15N, Δδ = {0.5[Δδ (1HN)2 + (0.2Δδ (15N))2]}1/2, determinado a partir de la 
comparación de los dos espectros [15N,1H]-HSQC superpuestos en la Figura 13. 
El gráfico de la Figura 15 indica los residuos con los que (S)-1k interacciona, es decir, 
aquéllos cuyo desplazamiento químico se modifica en presencia del compuesto [zona I (Arg67); 
zonas II y III (Arg86, Ser88 y Ser96); zona IV (His107 y Lys109); y zona V (Trp121)]. Estos 
resultados validan claramente el diseño realizado. 
Teniendo en cuenta estos resultados, parece razonable suponer que la moderada 
actividad de (S)-1k (CI50 = 174±22 μM; Tabla 2) podría ser debida al alto grado de libertad 
conformacional asociado a su espaciador metilénico, por lo que la introducción de restricciones 
conformacionales en esta parte de la molécula quizá permitiría aumentar la afinidad. Con este 
objetivo, se diseñó un nuevo compuesto, (S)-1l, en cuyo espaciador se incorporó un anillo de 
ciclohexilo como elemento restrictivo (Figura 16).  
 
a         b 
           
Figura 16. a. Modelo computacional del complejo formado por el compuesto (S)-1l y el dominio SH2 de 
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La síntesis del compuesto (S)-1l (Esquema 7) hizo necesaria la obtención previa de la 












Reactivos: (a) (i) NMM, tBuMe2SiCl, CH3CN, ta; (ii) 1H-tetrazol, iPr2NP(OBn)2, ta; (iii) tBuOOH ac., -20 ºC; (b) 






















10c: R1 = Ac
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R = N NH
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Reactivos: (a) Tamiz molecular 4 
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, NaCNBH3, metanol, AcOH, 35 ºC; (b)  H2, Pd(OH)2(C), metanol, ta; (c) CDI, 






























Esquema 8. Síntesis de 1-[2-(1-aminociclohexil)etil]tetrahidropirimidin-2(1H)-ona (21). 
El compuesto (S)-1l mostró una afinidad por el dominio Grb2-SH2 aproximadamente tres 
veces mayor que el hit inicial (S)-1k (CI50 [(S)-1k] = 174 μM, CI50 [(S)-1l] = 56 μM). 
Este resultado muestra como la aplicación iterativa de modelos computacionales y RMN 
ha permitido la optimización de un hit inicial ((S)-1k) y la identificación de (S)-1l como un nuevo 
ligando del dominio Grb2-SH2. Sin embargo, con el fin de confirmar el interés de (S)-1l como 
candidato susceptible de desarrollo futuro, es vital conocer cuál es su potencial biológico. Para 
ello se consideraron dos aspectos fundamentales:  
a) Determinar si el compuesto muestra actividad antitumoral en sistemas celulares 
debido al bloqueo de la interacción HER2-Grb2. 
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b) Estudiar si el compuesto (S)-1l afecta la vía de las MAPKs tal y como se esperaría de 
una molécula capaz de bloquear las vías de transducción mitogénicas dependientes de Grb2. 
3.4. Perfil in vitro de (S)-1l  
Con el fin de establecer si (S)-1l es un compuesto con actividad en sistemas celulares, 
se determinó su citotoxicidad en células de cáncer de mama con sobreexpresión de HER2 
(MCF7-HER2+). Si (S)-1l es capaz de bloquear el crecimiento de estas células tumorales 
debido a su capacidad para inhibir la interacción ente HER2 y Grb2, este compuesto deberá 
resultar citotóxico en éstas pero no así en células no tumorales (como por ejemplo fibroblastos) 
o células tumorales que no expresen niveles apreciables de HER2 (como por ejemplo MCF7-
HER2- o MDA-231). Por tanto se estudió la capacidad de (S)-1l para inhibir la proliferación de 
estas cuatro líneas celulares. Los resultados obtenidos indican que efectivamente (S)-1l es 
citotóxico en las células MCF7-HER2+, pero no en fibroblastos (Figura 17) ni en células MCF7-
HER2- ni en MDA-231 (Figura 18a). 
Asimismo se confirmó mediante experimentos de inmunoprecipitación que (S)-1l es 
capaz de bloquear la interacción entre HER2 y la proteína adaptadora Grb2 (Figura 18b). 
 
 
Figura 17. a. Inhibición de la proliferación celular de (R)-1k, (S)-1k y (S)-1l en fibroblastos N1 a 
concentraciones de 50 μM (blanco) y 100 μM (gris claro), y en células de carcinoma mamario humano 
MCF7-HER2+ a concentraciones de 50 μM (gris oscuro) y 100 μM (negro). Los resultados representan la 
media ± EE de al menos dos experimentos llevados a cabo por triplicado.* p < 0.01 vs control. 
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 a         b  
 
Figura 18. a. Inhibición de la proliferación celular de (S)-1l en células de carcinoma mamario humano con 
muy baja expresión de HER2 (MDA-231 y MCF7-HER2-) a concentraciones de 50 μM (gris) y 100 μM 
(negro). b. Inhibición de la interacción HER2-Grb2 por (S)-1l. Las células MCF7-HER2+ fueron tratadas 
con (S)-1l o vehículo como en (a), lavadas y lisadas. Se inmunoprecipitó HER2 y los niveles de HER2 y 
Grb2 se determinaron mediante anticuerpos específicos (western blot). 
Por tanto, en conjunto, todos estos resultados confirman que (S)-1l puede considerarse 
como un nuevo esqueleto estructural en el desarrollo de moléculas pequeñas capaces de 
bloquear la interacción entre HER2 y Grb2, considerada actualmente como uno de los pasos 
críticos en la vía de señalización oncogénica de este receptor.  
Una vez comprobada la actividad de (S)-1l en sistemas celulares, a continuación nos 
propusimos desarrollar una plataforma proteómica que permitiera identificar las rutas de 
señalización celular afectadas por este compuesto.  
3.5. Desarrollo de una plataforma proteómica para la identificación de 
rutas de señalización celular 
Esta estrategia consiste en la identificación y/o cuantificación de proteínas con el fin de 
establecer cuáles se expresan de forma diferencial debido a la administración de un 
compuesto. Considerando que un inhibidor de la interacción HER2-Grb2 deberá afectar a 
proteínas relacionadas con funciones de proliferación y diferenciación celular, tales como 
quinasas, proteínas asociadas, factores de transcripción, etc., decidimos desarrollar una 
plataforma basada en el empleo de tres nucleótidos (m7GTP, ATP y AMPc) soportados en fase 
sólida. Estos nucleótidos se unen a multitud de proteínas que regulan las vías de señalización y 
que deberían ser afectadas por la administración de un inhibidor de la interacción HER2-Grb2. 
Así, por ejemplo, el ATP es el nucleótido al que se unen todas las quinasas, necesario para 
transferir el grupo fosfato de éste a la proteína sustrato.  
Por tanto, se emplearon m7GTP, ATP y AMPc soportados en fase sólida con el fin de 
aislar por precipitación aquellas proteínas capaces de interaccionar con ellos y así separarlas 
del resto del proteoma objeto de estudio. Una vez aisladas, estas proteínas son digeridas con 
tripsina e identificadas mediante espectrometría de masas en tándem (EM/EM) (Figura 19). 
Esta metodología permitirá establecer de forma inequívoca qué proteínas y qué vías, 
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relacionadas con estos nucleótidos, se afectan por la administración de un inhibidor de la 




Figura 19. Representación esquemática de la estrategia de purificación por afinidad (PA) -EM basada en 
nucleótidos de interés. a. Fase de pre-lavado. b. Captura de proteínas diana. c. Elución de los complejos 
proteicos de interés. d. Separación por SDS-PAGE de las proteínas capturadas y aislamiento de las 
bandas de interés. e. Digestión con tripsina. f. Análisis tándem de EM. g. Resultados de MASCOT. 
Los listados de las proteínas más relevantes halladas en los experimentos con m7GTP, 
ATP y AMPc se resumen en las Tablas 3, 4 y 5, respectivamente.  
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Tabla 3. Listado de las proteínas más relevantes asociadas a los experimentos con m7GTP.  
No. Acc. a Nombre de la Proteína Código del Gen
P60842 Eukaryotic translation initiation factor 4A-I EIF4A1 
P06730 Eukaryotic translation initiation factor 4E EIF4E 
P68104 Eukaryotic translation elongation factor-1-alpha EEF1A1 
P24534 Eukaryotic translation elongation factor-1-beta EEF1B2 
38522 Eukaryotic translation elongation factor-1-delta EEF1D 
P13639 Eukaryotic translation elongation factor-2 EEF2 
P62249 40S ribosomal protein S16 RPS16 
189306 Nucleolin NCL 
P22626-2 Heterogenous nuclear ribonucleoproteins A2-B1 HNRNPA2-B1 
P16930 Fumarylacetoacetase FAH 
P00326 Alcohol dehydrogenase 1C ADH1C 
157834561 Aldehyde reductase (chain A) AKR1A1 
1065362 GDP-complexed human ADP-ribosylation factor (chain B) ARF1 
1403050 Phosphoenolpyruvate carboxykinase (GTP) PCK2 
P43490 Nicotinamide phosphoribosyltransferase PBEF1 
Q9BYF0 Aldehyde oxidase AOX1 
179987 Chlordecone reductase AKR1C4 
IPI00219953.5 Cytidylate kinase CMPK 
P78417 Glutathione transferase omega-1 GSTO1 
P99024 Tubulin beta-5 chain Tubb5 
P10809 60 kDa heat shock protein HSPD1 
a Los números de acceso (No. Acc.) listados en esta tabla son los empleados por la base de datos UniProt 
(http://www.uniprot.org). 
Tabla 4. Listado de las proteínas más relevantes asociadas a los experimentos con ATP. 
No. Acc. a Nombre de la Proteína Código del Gen
20149621 Dihydroxyacetone kinase 2 DAK 
P54819 Adenylate kinase isoenzyme 2, mitochondrial AK2 
O00764 Pyridoxal kinase PDXK 
6491737 N-Acetylglucosamine kinase NAGK 
Q9H479 Fructosamine-3-kinase FN3K 
P05165 Propionyl-CoA carboxylase (chain A) PCCA 
3860238 4-Hydroxyphenylpyruvate dioxygenase HPD 
P38117 Electron transfer flavoprotein subunit beta ETFB 
12804999 3-Hydroxybutyrate dehydrogenase, type 2 BDH2 
P68133 Actin, alpha skeletal muscle ACTA1 
1336765 Glucose phosphate isomerase GPI 
a Los números de acceso (No. Acc.) listados en esta tabla son los empleados por la base de datos UniProt 
(http://www.uniprot.org). 
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Tabla 5. Listado de las proteínas más relevantes asociadas a los experimentos con AMPc. 
No. Acc. a Nombre de la Proteína Código del Gen 
P10644 cAMP-dependent protein kinase type I-alpha regulatory subunit 
PRKAR1A 
P13861 cAMP-dependent protein kinase type II-alpha regulatory subunit 
PRKAR2A 
915392 Fatty acid synthase FASN 
P07741 Adenine phosphoribosyltransferase APRT 
1093492 4-aminobutyrate aminotransferase GABA 
Q06278 Aldehyde oxidase AOX1 
3860238 4-hydroxyphenylpyruvate-dioxygenase HPD 
226527 Nucleoside diphosphate kinase NDK 
P26038 Moesin MSN 
178027 Alpha-actin ACTA2 
37492 Alpha-tubulin TUBA1A 
338695 Beta-tubulin TUBB 
a Los números de acceso (No. Acc.) listados en esta tabla son los empleados por la base de datos UniProt 
(http://www.uniprot.org). 
La clasificación de las proteínas identificadas se realizó con la ayuda de un paquete 
software especializado (ProteinCenter©, Proxeon Bioinformatics A/S) de acuerdo a los criterios 
definidos por el Consorcio Gene Ontology (GO)45 y, en particular, considerando los dominios 
“Función Molecular” y “Proceso Biológico” para su clasificación. Los resultados de este proceso 
aplicado a las proteínas asociadas a m7GTP, ATP y AMPc se ilustran en las Figuras 20, 21 y 
22, respectivamente. 
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 4. Conclusiones 
1. Basándonos en la estructura cristalográfica del dominio SH2 de Grb2 en complejo con el 
ligando pentapeptídico de alta afinidad 2-Abz-Glu-pTyr-Ile-Asn-Gln-NH2, se han diseñado y 
sintetizado dos series de compuestos de naturaleza no peptídica que mantienen todas (serie I) 
o algunas (serie II) de las interacciones con el dominio SH2 de Grb2. 
 
2. Con el fin de determinar la capacidad de los compuestos sintetizados para unirse al 
dominio SH2 de Grb2, se ha puesto a punto un ensayo competitivo tipo ELISA. De todos los 
compuestos estudiados, el derivado (S)-1k de la serie I mostró el valor más elevado de 
afinidad (CI50 = 174 μM). El hecho de que ninguno de los derivados de la serie II presentara 
una capacidad significativa para unirse a Grb2-SH2 indica que las interacciones eliminadas 
(Arg67 e His107) son clave para el reconocimiento de este dominio. 
 
3. El modo de unión de (S)-1k a Grb2-SH2 ha sido validado experimentalmente empleando 
estudios de RMN (HSQC). Basándonos en esta información se ha llevado a cabo la 
optimización de (S)-1k mediante la introducción de restricciones conformacionales en su 
estructura, lo que permitió la obtención del derivado (S)-1l. Éste, con un valor CI50 de 56 μM, 






























4. El compuesto (S)-1l fue además estudiado in vitro en sistemas celulares, incluyendo 
células de carcinoma mamario MCF7-HER2 positivas (MCF7-HER2+) y negativas (MCF7-
HER2-), así como en fibloblastos N1 de células no tumorales. Los resultados obtenidos 
mostraron que (S)-1l inhibe selectivamente la proliferación de las células MCF7-HER2+ (CI50 = 
100 μM), sin afectar de forma significativa al resto. Estos resultados confirman que (S)-1l 
interfiere específicamente con la vía de señalización de HER2, disminuyendo 
significativamente la interacción entre HER2 y Grb2, efecto demostrado mediante 
experimentos de inmunoprecipitación. 
 
5. Considerando el atractivo perfil de actividad de (S)-1l y el interés que supone identificar las 
vías de señalización a las que afecta, se diseñó y validó una plataforma proteómica basada en 
diferentes nucleótidos. Actualmente dicha plataforma se está empleando en células de 
carcinoma mamario HER2+ tratadas con (S)-1l con el fin de determinar exactamente las vías 
de señalización afectadas por este compuesto.  
  
